


Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives

María Escobar-Salom[†], Gabriel Torrens[†], Elena Jordana-Lluch, Antonio Oliver and Carlos Juan* 

Department of Microbiology, University Hospital Son Espases-Health Research Institute of the Balearic Islands (IdISBa), Carretera de Valldemossa 79, Palma, Balearic Islands, 07010, Spain

ABSTRACT

Mammalian innate immunity employs several humoral ‘weapons’ that target the bacterial envelope. The threats posed by the multidrug-resistant ‘ESKAPE’ Gram-negative pathogens (*Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.) are forcing researchers to explore new therapeutic options, including the use of these immune elements. Here we review bacterial envelope-targeting (peptidoglycan and/or membrane-targeting) proteins/peptides of the mammalian immune system that are most likely to have therapeutic applications. Firstly we discuss their general features and protective activity against ESKAPE Gram-negatives in the host. We then gather, integrate, and discuss recent research on experimental therapeutics harnessing their bactericidal power, based on their exogenous administration and also on the discovery of bacterial and/or host targets that improve the performance of this endogenous immunity, as a novel therapeutic concept. We identify weak points and knowledge gaps in current research in this field and suggest areas for future work to obtain successful envelope-targeting therapeutic options to tackle the challenge of antimicrobial resistance.

Key words: multidrug-resistant Gram-negatives, ESKAPE pathogens, bacterial envelope, cell wall, peptidoglycan, bacterial membranes, mammalian humoral innate immunity, lysozyme, peptidoglycan recognition proteins, cationic antimicrobial peptides

CONTENTS

I. Introduction	1006
II. Bacterial envelope-targeting mammalian humoral innate immunity: general features and natural protective activity	1007
(1) Peptidoglycan-targeting proteins	1007
(a) Lysozyme	1007
(b) Peptidoglycan recognition proteins (PGLYRPS)	1008
(2) Membrane disturbance-based immune components	1011
(a) Cationic antimicrobial peptides	1011
(i) Defensins	1011
(ii) Histatins	1014
(iii) Cathelicidins	1014

* Address for correspondence (Tel: +34 871 20 52 34; E-mail: carlos.juan@ssib.es)

[†]These authors contributed equally to this work.

(iv) Lactoferrin-derived peptides	1015
(b) Antimicrobial proteins	1015
(i) Bactericidal/permeability increasing protein (BPI)	1015
(ii) Group IIA secretory phospholipase A2 (GIIA SPLA2)	1016
(iii) Surfactant-associated proteins	1016
III. Bacterial envelope-targeting mammalian humoral innate immunity: therapeutic potential	1017
(1) Bacterial resistance: a non-negligible threat for treatments based on envelope-targeting immune proteins/peptides	1017
(2) <i>IN VITRO</i> activity, experimental treatments and animal models	1018
(a) Peptidoglycan-targeting proteins	1018
(b) Membrane disturbance-based immune weapons	1019
(i) Defensins	1019
(ii) Histatins	1019
(iii) Cathelicidins	1019
(iv) Lactoferrin-derived peptides	1021
(v) Bactericidal/permeability increasing protein (BPI)	1021
(vi) Group IIA secretory phospholipase A2 (GIIA-SPLA2)	1022
(vii) Surfactant-associated proteins	1022
(3) Bacterial envelope-targeting immunity-based treatments under clinical trials	1022
(4) Bacterial targets leading to increased susceptibility to envelope-targeting immune components	1023
(a) Peptidoglycan-targeting proteins	1023
(b) Bacterial membranes interaction-based immune components	1024
(5) Host-related targets that improve the performance of bacterial envelope-targeting immune components	1025
IV. Resources yet to be exploited: novel human antimicrobial peptides targeting the gram-negative envelope	1025
V. Conclusions	1026
VI. Acknowledgements and author contributions	1027
VII. References	1027

I. INTRODUCTION

New therapeutic solutions are urgently needed to counter the clinical–epidemiological threat posed by the ‘ESKAPE’ Gram-negative species [*Klebsiella pneumoniae* (KP), *Acinetobacter baumannii* (AB), *Pseudomonas aeruginosa* (PA), and *Enterobacter* species (ES)] which have high levels of virulence, intra-hospital dissemination, morbi-mortality and antibiotic resistance (Mulani *et al.*, 2019; Tacconelli & Pezzani, 2019). As our therapeutic arsenal is becoming obsolete and the release of new antibiotics is increasingly rare (Provenzano *et al.*, 2020), the design of successful therapies must be approached from all perspectives, including learning from our own immune system (Theuretzbacher *et al.*, 2020). The design of treatments mimicking the modes of action of the immune system against infection is an old idea, but has only been partially exploited, with many research lines discontinued for a variety of reasons (Zelechowska, Agier & Brzezińska-Błaszczak, 2016; Kumar, Kizhakkedathu & Straus, 2018). However, given our current need for new therapeutic options, recent research has resumed several of these projects. In addition, novel approaches involving natural immune defences, linked to scientific–technical advances such as the development of artificially modified proteins/peptides, nanoparticles, etc., and to recently discovered immune components, now together provide a large body of encouraging evidence (Sola *et al.*, 2020; Theuretzbacher *et al.*, 2020; Upert *et al.*, 2021). In this review we gather

and discuss these advances, specifically regarding bacterial envelope-targeting humoral innate immunity.

The cell wall (comprising *sensu stricto* the outer membrane, periplasm, and peptidoglycan) of Gram-negative bacteria is the structure most exposed to the host’s innate immunity and therefore, this weapon–target interplay is an obvious source of therapeutic potential (Mishra *et al.*, 2017). However, although many of the immune components reviewed herein are believed to target the cell wall (outer membrane and/or peptidoglycan), at least some of these proteins/peptides may also target the bacterial inner membrane and hence, the more inclusive concept of ‘bacterial envelope’-targeting immunity is used herein (the ‘bacterial envelope’ includes the inner and outer membranes as well as the peptidoglycans) (Silhavy, Kahne & Walker, 2010). The humoral ‘weapons’ referred to here generally act by disturbing bacterial membranes and/or peptidoglycan through a variety of mechanisms, causing loss of the permeability barrier, cytosolic content, osmotic balance and resistance to osmotic pressure, leading to cell lysis. Moreover, several bacterial envelope-targeting peptides/proteins also display immunomodulatory features that may enhance their therapeutic potential. Among these, the capacity for lipopolysaccharide (LPS) neutralization (i.e. anti-endotoxin activity) is of particular interest because of its anti-inflammatory and septic-shock-preventive effects (Mishra *et al.*, 2017; Pachón-Ibáñez *et al.*, 2017; Theuretzbacher *et al.*, 2020).

Here we review mammalian Gram-negative envelope-targeting immune components that display the greatest antimicrobial therapeutic potential, including anti-biofilm applications. Although the complement system could fit into this definition because of its membrane perforation-mediated mode of action, given the complexity of its activation/regulation pathways and its cascade nature, we do not include it herein. Moreover, to our knowledge there is no research on compounds mimicking the complement membrane-attack complex as a therapeutic treatment.

Following our discussion of the general features and activity in the host of the main bacterial envelope-targeting innate humoral components, we review recent research regarding experimental therapeutics harnessing this immunomodulatory and especially bacteriolytic potential. We review studies based on exogenous administration (including artificially modified derivatives and combinations with antibiotics) but also the discovery of bacterial/host targets that enhance the performance of our endogenous immunity. We discuss the knowledge gaps, obstacles to overcome and avenues for further development to enable these treatments to advance towards clinical practice. We specifically focus this review on data regarding the ESKAPE Gram-negative pathogens, for which the development of new therapeutic treatments is most urgent. This review is intended to be a resource for researchers investigating bacterial envelope-targeting immunity and for those working in the fields of antimicrobial resistance and the development of new therapies, with the goal of defeating one of the greatest health threats of the 21st century: antibiotic resistance.

II. BACTERIAL ENVELOPE-TARGETING MAMMALIAN HUMORAL INNATE IMMUNITY: GENERAL FEATURES AND NATURAL PROTECTIVE ACTIVITY

Bacterial envelope-targeting immunity could be classified according to the predominant target (peptidoglycan *versus* membranes), but the presence of immune elements with simultaneous modes of action on both makes this classification complex (Raheem & Straus, 2019). In fact, although these immune elements interact, at least initially, with the bacterial envelopes as part of their mechanism of action, the concept that this interaction always leads to permeabilization and cell lysis is no longer valid. Moreover, some of these immune elements act in parallel on cytoplasmic targets and/or by disturbing cell division (Graf & Wilson, 2019; Raheem & Straus, 2019). We do not include in this review a discussion of immune elements that act exclusively against cytosolic targets (Cardoso *et al.*, 2019), those that act exclusively against Gram-positive species, nor artificially synthesized compounds that attack bacterial envelopes. A general overview of the elements included in this review is provided in Fig. 1.

(1) Peptidoglycan-targeting proteins

(a) Lysozyme

Although three major types of lysozymes have been described in the animal kingdom (c-type, g-type, and i-type), this review focuses on the conventional (c-type) form, predominant in mammals and considered the archetypical variant (Callewaert & Michiels, 2010). c-type lysozymes (see Table 1) are produced by several tissues and leukocytes that release the protein into body fluids (Callewaert & Michiels, 2010). c-type lysozymes display a globular structure (*ca.* 140 amino acids in length) with a long cleft accommodating the active site. Their classically attributed mechanism of action is peptidoglycan enzymatic disruption (Fig. 2): cleavage of the β -(1,4)-glycosidic bond between N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) of the peptidoglycan's sugar chains, disturbing its structure and causing osmotic lysis (Juan *et al.*, 2018; Torrens *et al.*, 2020). Some authors propose instead that this muramidase enzymatic activity functions in the clearance of free peptidoglycan fragments to exert anti-inflammatory effects [i.e. avoiding their detection by certain pathogen-associated pattern recognition receptors (PRRs)], hence arguing against a significant antimicrobial action. Lysozyme bactericidal capacity then was suggested to be driven by membrane permeabilization, achieved through a positively charged helix-loop-helix motif (amino acids 87–115 in the human protein). This region enables the establishment of electrostatic interactions, allowing c-type lysozyme to cross the external bacterial membrane *via* self-promoted uptake and the formation of channels (Ibrahim, Thomas & Pellegrini, 2001; Ganz *et al.*, 2003; Nash *et al.*, 2006; Ragland & Criss, 2017; Juan *et al.*, 2018; Torrens *et al.*, 2020). This remains controversial however, since some studies suggest that this self-translocation allows lysozyme to reach the Gram-negative peptidoglycan, enabling its enzymatic breakdown. This activity would obviously be enhanced in the presence of immune elements that act as outer membrane permeabilizers, as happens *in vivo* (Ellison & Giehl, 1991; Callewaert & Michiels, 2010; Heesterbeek *et al.*, 2021).

Regardless of its mode of action, this protein provides an efficient early defence against ESKAPE Gram-negatives; lysozyme gene deletion and/or protein depletion was clearly related to increased severity of PA infection, and transgenic mice with higher expression levels of lysozyme in their airways exhibited milder infection-derived parameters (mortality, systemic dissemination and bacterial load) (Akinbi *et al.*, 2000; Markart *et al.*, 2004a; Cole *et al.*, 2005). Similar results were observed even with a muramidase activity-deficient lysozyme variant against KP (Markart *et al.*, 2004b; Nash *et al.*, 2006). It is important to note that lysozyme has additional functions besides its bactericidal effects. Its involvement in processes such as wound healing, immune modulation, inflammatory regulation and angiogenesis highlight this protein as a potential target for interventions to ameliorate the outcomes of infection, such as avoiding excessive inflammation that can be detrimental to the patient in




Fig. 1. Overview of the major bacterial envelope-targeting components of the mammalian innate humoral immune system, and of the artificial derivative murepavadin, and the specific bacterial structures/processes that they attack. Numbers within circles represent different targets and/or mechanisms of action: (1) disturbance of outer and inner membranes; (2) lysozyme-driven self-translocation and membrane permeabilization; (3) lysozyme muramidase activity; (4) cleavage site for PGLYRP2 enzymatic (amidase) activity; (5) binding of BPI, SP-A, and SP-D to LPS and participation in membrane disturbance; (6) sensing of outer membrane-bound PGLYRPs (monomers or dimers) by the two-component CpxA sensor system and signal transduction towards the cytosolic effector CpxR, leading to overactivation, multiple stressors, and thereby to cell suicide; (7) antimicrobial peptides and CpxAR overactivation-driven alteration of cytoplasmic processes such as nucleic acid synthesis, protein synthesis, protein folding, energy metabolism, and cytosolic steps of peptidoglycan synthesis; (8) although they are CAMPs, the particular mode of action of specific defensins (HNP-1 and hBD-3) is shown: blockade of lipid II-mediated incorporation of new building units into peptidoglycan; (9) enzymatic degradation of membrane phospholipids by GIIA sPLA2; (10) murepavadin specifically binds PA LptD membrane protein and thereby blocks LPS component translocation and outer envelope biogenesis. Abbreviations: BPI, bactericidal permeability increasing protein; CAMPs, cationic antimicrobial peptides; GIIA sPLA2, Group IIA secretory phospholipase A2; hBD-3, human β -defensin 3; HNP-1, human neutrophil peptide 1; LPS, lipopolysaccharide; NAG, N-acetylglucosamine; NAM, N-acetylmuramic acid; PGLYRP, peptidoglycan recognition protein; PGN, peptidoglycan; SP-A/-D, surfactant-associated protein A/D.

some contexts (Ganz *et al.*, 2003; Markart *et al.*, 2004b; Ragland & Criss, 2017).

(b) Peptidoglycan recognition proteins (PGLYRPs)

Four PGLYRPs (see Table 1) have been described in mammals: PGLYRP1, 2, 3, and 4, formerly named PGLYRP-S, -L, -I α , and -I β , respectively (Torrens *et al.*, 2020). Although these proteins were initially named after their capacity for peptidoglycan binding *in vitro* and their role as peptidoglycan recognition receptors, they display additional domains to

bind other molecules such as LPS. Later, PGLYRPs were shown not only to be PRRs but also to display antibacterial activity through different modes of action (Dziarski & Gupta, 2018). The largest variant is PGLYRP2, with an approximate length of 550–650 amino acids depending on the species, and which is mainly produced in the liver and enters the serum as a monomer (Wolf & Underhill, 2018). This protein displays amidase activity, i.e. cleavage of the bonds between N-acetylmuramic acid and the stem peptides (Fig. 2) (Torrens *et al.*, 2020). The role of this activity is controversial. Some authors argue that causes only minor

Table 1. Overview of mammalian peptidoglycan-targeting innate humoral immune proteins and their therapeutic potential. See main text for additional references

Immune element	Main features and examples/variants	Mode of action	Activity (<i>in vitro/in vivo</i>) against ESKAPE Gram-negatives	Artificially derived variants, research lines, therapeutic potential
Lysozyme (c-type)	Ca. 140 aa. Produced in the skin, liver, granulocytes and monocytes and secreted into fluids. Highly concentrated in milk and tears. Production inducible upon multiple trauma or infection. Displays important immunomodulatory properties.	(i) Muramidase activity: cleavage of β -(1,4)-glycosidic bonds between NAM and NAG. (ii) Membrane-disrupting capacity, linked to its cationic helix-loop-helix motif establishing electrostatic interactions with external membrane, self-promoted uptake, and formation of channels through cytoplasmic membrane.	Variable (usually mild, with the exception of AB) <i>in vitro</i> activity against ESKAPE Gram-negatives unless certain adjuvants (polymyxins, docosahexanoic acid) are added. Different murine models of infection show encouraging results in terms of bacterial burden and reduction of inflammatory variables. High anti-biofilm activity against KP, poor against PA if not combined with cephalosporins (Eladawy <i>et al.</i> , 2020).	Modified versions created to avoid electrostatic sequestration (e.g. 2-3-7), and conjugate/nanoparticle formulations (e.g. LYZOX) to protect against proteolysis. Artificially designed variants to circumvent bacterial lysozyme inhibitors (Dostal <i>et al.</i> , 2015). Bacterial targets leading to increased susceptibility: PA PGN recycling, BamB and FabY; AB capsule. Boosting the expression of host lysozyme could increase antimicrobial activity and avoid harmful over-inflammation.
Peptidoglycan recognition protein 2 (PGLYRP2)	Ca. 90 kDa. Constitutively produced by the liver and released into blood as a monomer. Inducible in certain epithelia.	N-acetylmuramoyl-L-alanine amidase activity: breaks down PGN by cleaving stem peptide-NAM bonds.	Modest <i>in vitro</i> activity against PA. Addition of a permeabilizer increases activity up to 100-fold, more so in mutants with impaired PGN recycling. No data for other ESKAPE Gram-negatives.	Depending on the pathogen and context exerts a protective effect. In other cases, it triggers an inflammatory excess that is harmful to the host.
PGLYRP1, 3, and 4	PGLYRP1 (ca. 20 kDa.) secreted by granulocytes as monomer or homodimer. PGLYRP3/4 (both ca. 45 kDa) are secreted by skin/mucous epithelia as monomer, homodimer, or heterodimer.	Binding to LPS and outer membrane causing over-activation of the stress-sensing two-component CpxAR system. This induces the cessation of nucleic acid, protein, and PGN synthesis, leading to cell suicide.	Same as PGLYRP2.	Participation in microbiome homeostasis and inflammatory regulation. PGLYRP1-null mice display enhanced severity compared to wild-type animals in PA keratitis model.

aa, amino acid; ESKAPE, *Klebsiella pneumoniae* (KP), *Acinetobacter baumannii* (AB), *Pseudomonas aeruginosa* (PA) and *Enterobacter* species (ES); LPS, lipopolysaccharide; NAG, N-acetyl glucosamine; NAM, N-acetyl muramic acid; PGN, peptidoglycan.

impacts to intact peptidoglycan sacculi and thus would function to degrade free fragments, hence exerting a scavenger anti-inflammatory function [theoretically reducing stimulation of nucleotide-binding oligomerization domain-like receptors (NOD)] (Boneca, 2009). Others propose that it exerts bactericidal activity through peptidoglycan disruption, mainly against Gram-positives (Gelius *et al.*, 2003; Lee *et al.*, 2012; Bobrovsky *et al.*, 2016). Its large size likely hinders penetration through the external Gram-negative envelope, and thus its

lytic activity is probably modest in the absence of a permeabilizer (Torrens *et al.*, 2017; Torrens *et al.*, 2020). Therefore, PGLYRP2 has been described as largely dispensable in terms of mammalian protection against Gram-negative infection (Xu, Wang & Locksley, 2004).

PGLYRP1 (ca. 200 amino acids), 3, and 4 (ca. 350–400 amino acids) do not show an enzymatic mode of action, nor do they interact directly with peptidoglycan when challenged with live Gram-negative bacteria, which appears




Fig. 2. Mechanism of action (cleavage sites) of two peptidoglycan-lytic mammalian immune proteins, lysozyme and peptidoglycan recognition protein 2 (PGLYRP2). The Gram-negative peptidoglycan, also known as murein sacculus, is composed of glycan chains (consisting of repeated NAG–NAM units) connected to other such chains through crosslinked stem peptides bound to the NAM units. Lysozyme (purple scissors, muramidase activity) cleaves the β -(1,4)-glycosidic bond between the NAM and NAG molecules, whereas PGLYRP2 (blue scissors, amidase activity) cleaves the bonds between NAM and L-Ala in the peptide chains. Abbreviations: Ala, alanine; Glu, glutamic acid; M-DAP, meso-di-amino-pimelic acid; NAG, N-acetylglucosamine; NAM, N-acetylmuramic acid.

paradoxical. Instead, they seemingly bind to LPS and the outer membrane, where they stimulate the bacterial two component-system CpxAR, described to respond to envelope stress caused by changes in pH, composition, presence of misfolded proteins and β -lactams (Dziarski & Gupta, 2018; Masi, Pinet & Pagès, 2020). Over-activation of this system causes simultaneous and synergistic oxidative, thiol, and metal stresses, leading to bacterial suicide associated with the blockade of synthesis of nucleic acids, proteins, and peptidoglycan building units (Dziarski, Kashyap & Gupta, 2012; Kashyap *et al.*, 2014; Dziarski & Gupta, 2018) (Fig. 1). Interestingly, some authors proposed that PGLYRP2 may also drive CpxAR over-activation in certain species (Bobrovsky *et al.*, 2016). Whereas PGLYRP1 is mainly produced by granulocytes, PGLYRP3 and PGLYRP4 are principally secreted in skin and mucosal epithelia. These three variants can be found as monomers or disulfide-linked homodimers, although the formation of PGLYRP3:PGLYRP4 heterodimers is also common (Torrens *et al.*, 2020). PGLYRPs have other roles in addition to bacterial killing, such as participation in homeostasis of the microbiome and regulation of inflammation (Royet,

Gupta & Dziarski, 2011; Dziarski *et al.*, 2012). This topic is very complex especially for PGLYRP2 which, depending on the pathogen and/or context, can either exert a protective anti-inflammatory effect (Saha *et al.*, 2010; Lee *et al.*, 2012) or trigger a harmful inflammatory excess (Boneca, 2009; Saha *et al.*, 2009; Gowda *et al.*, 2015).

Regarding the direct bactericidal capacity of PGLYRPs against ESKAPE pathogens *in vivo*, the available data refer only to murine models of PA keratitis. In these studies, the only protein shown to be significantly defensive against PA was PGLYRP1, since KO mice displayed enhanced infection severity. Whereas PGLYRP3 and PGLYRP4 displayed a minor protective role, PGLYRP2 was shown paradoxically to contribute to a poor clinical outcome, triggering an excessive inflammatory response and curbing the expression of other antimicrobial peptides (Ghosh *et al.*, 2009; Gowda *et al.*, 2015). There is an apparent lack of research assessing the natural activity of these proteins against KP, AB or ES, a gap in our knowledge worthy of filling to ascertain the therapeutic potential of these proteins against these species.

(2) Membrane disturbance-based immune components

In this section, we consider bacterial envelope-targeting immune components that, regardless of additional modes of action, at least initially interact with and disturb the bacterial membranes. We divide them into peptides (<100 amino acids) and proteins (>100 amino acids, usually with complex and/or oligomeric structures and enzymatic activity) (Haney, Straus & Hancock, 2019), with their main features listed in Tables 2 and 3, respectively.

(a) Cationic antimicrobial peptides

Although mammals display an important array of anionic antimicrobial peptides (Harris, Dennison & Phoenix, 2009), they seemingly do not work through bacterial envelope-targeting mechanisms and therefore are not discussed here. Conversely, the antimicrobial peptides that target bacterial envelopes generally have a strong positive charge, and are generically termed cationic antimicrobial peptides (CAMPs). Although other names for these humoral components, such as ‘innate immune peptides’, could be appropriate due to their immunomodulatory roles beyond direct antimicrobial action, we here retain ‘CAMP’ due to its widespread use (together with ‘host defence peptide’) in recent decades. CAMPs usually display an amphiphilic structure, which enables them to be soluble in aqueous solutions, facilitating their defensive functions (Boparai & Sharma, 2019). Although they can be classified in several ways, here we refer to their predominant structure: α -helical, β -sheet, loop, or those with no regular secondary structure (known as ‘extended’ or ‘flexible’) (Kumar *et al.*, 2018; Amerikova *et al.*, 2019). Regardless of structure, a general mode of action can be attributed to CAMPs: due to their positive charge, they establish electrostatic interactions with the negatively charged outer membrane moieties such as LPS or the head-groups of the lipid bilayer (Krishnakumari *et al.*, 2020). These interactions disturb the structure of the external envelope, enabling CAMP penetration into the periplasm where it can also affect the inner membrane, finally leading to indiscriminate permeabilization and lysis. Three classic models explain this process (Fig. 3): (i) carpet, (ii) barrel-stave pore, and (iii) toroidal pore, although other variations have recently been described (see recent reviews by Kumar *et al.* (2018) and Lee, Hall & Aguilar (2016)). Table 2 provides a general overview of the main mammalian bacterial envelope-targeting CAMP groups: defensins, histatins, cathelicidins, and lactoferrin-derived peptides.

(i) *Defensins*. The extensive group of defensins show a molecular mass of *ca.* 3.5–4.5 kDa, a β -sheet structure, and the typical presence of three disulfide bridges between six cysteine residues. The exact location of these bridges enables their classification into three sub-classes: α , β , and θ (Amerikova *et al.*, 2019). Representatives of α and β defensins are found in different mammals, whereas θ defensins are only produced by certain primate species (Krishnakumari *et al.*, 2003; Pasupuleti, Schmidtchen & Malmsten, 2012; Amerikova *et al.*, 2019). In humans, we find six variants of α

defensins: four of these are known as human neutrophil peptides 1–4 (HNPs; produced as active and processed mature peptides by these leukocytes), and the other two (HNP-5 and HNP-6) are mainly produced in the intestinal Paneth cells (stored as immature propeptides and sometimes known as cryptidins) and female genital epithelia (Pasupuleti *et al.*, 2012; Amerikova *et al.*, 2019). Closely related to these CAMPs but displaying five cysteines with a distinctive spacing pattern as opposed to the canonical α defensin six-cysteine motif, rattusin (isolated from rat intestines) shows strong *in vitro* activity against Gram-negatives, including antibiotic-resistant strains, but further research is needed (Min *et al.*, 2017). The human array of β defensins (hBDs) is even broader: over 30 variants have been described, although only hBD-1 to -4 have been deeply characterized (Amerikova *et al.*, 2019). β defensins usually show inducible expression and are almost ubiquitous, being found in urogenital epithelia, mouth mucosa, respiratory tract, skin, testicles, stomach, neutrophils, etc. (Bals *et al.*, 1999a; Sang *et al.*, 2005; Amerikova *et al.*, 2019).

Within the group of defensins, besides a general membrane permeabilization-based mode of action, some variants attack other related targets in parallel, such as blocking a specific step of peptidoglycan metabolism (Amerikova *et al.*, 2019; Malin & De Leeuw, 2019). In this last role, one key intermediary for peptidoglycan construction is lipid II (undecaprenyl-pyrophosphoryl-N-acetyl-muramic acid-pentapeptide-N-acetyl-glucosamine), which enables the incorporation of new building units (NAG-NAM pentapeptides) into the murein sacculus (Malin & De Leeuw, 2019). Once translocated to the periplasmic side of the cytosolic membrane, both HNP-1 and hBD-3 have been shown to bind to lipid II, sequestering it from further reactions and therefore blocking the incorporation of new material into the nascent peptidoglycan, which drastically weakens the resistance of the cell wall to osmotic pressure, causing lysis (Fig. 1). These defensins were initially reported to act preferentially on Gram-positives, but they also retain activity against Gram-negatives because of their permeabilization capacity that enables their entry into the periplasm (Oppedijk, Martin & Breukink, 2016; Grein, Schneider & Sahl, 2019). Meanwhile, hBD-5 has been shown to translocate into the bacterial cytoplasm and accumulate in the surroundings of cell poles, interfering with cellular division (Chileveru *et al.*, 2015).

Some defensins have been shown to be essential for natural protection against ESKAPE Gram-negatives in animal and/or *ex vivo* models. For instance, the thrombocyte-secreted hBD-3 participates in the response against KP in the context of infected wounds (Tohidnezhad *et al.*, 2011). A very important protection capacity against PA has been demonstrated for murine β defensins (mBD) 3 and 4 (homologs of hBD-2 and -3 respectively) in the cornea (Huang *et al.*, 2007a; Augustin *et al.*, 2011). Conversely, mBD1 seems expendable for protection against PA keratitis (Wu *et al.*, 2009). Similarly, an antibacterial role of hBD-2 on the ocular surface has been questioned, since its activity is affected by high NaCl concentrations such as those in tears (Huang *et al.*, 2007b). Defensins contribute notably to natural protection against ESKAPE Gram-negatives in the lung

Table 2. Overview of mammalian bacterial membrane-targeting innate humoral immune peptides (<100 amino acids) and their therapeutic potential. See main text for references

Immune element	Main features and examples/variants	Mode of action	Activity (<i>in vitro/in vivo</i>) against ESKAPE Gram-negatives	Artificially derived variants, research lines, and therapeutic potential
Defensins	Ca. 3.5–4.5 kDa. Ubiquitous inducible expression. Three subclasses; α , β , and θ . In humans: six variants of α -defensins (HNP-1 to 6), and over 30 β -defensins (hBD-1 to -5 are the best studied).	Bacterial membrane permeabilization. HNP-1 and hBD-3 also block the incorporation of new material into PGN. hBD-5 targets cell division.	Notable <i>in vitro</i> anti-ESKAPE Gram-negative activity (including biofilms). Several murine models of infection with varied outcomes. Synergistic effects with ciprofloxacin, lysozyme, and erythromycin.	Modified (shorter, chimeric, dimeric) versions provide better access to targets and resistance to proteolysis (e.g. BAS00127538 and 6jc48-1). Bioengineered skin replacements for burn infections. hBD-1-loaded cotton gauzes for wound KP infection.
Histatins	Two human variants (20–40 amino acids): Hst1 and Hst3. They provide shorter derivatives (Hst2, Hst4–Hst12) after digestion with oral proteases. Also found in certain primates.	Mitochondrial targeting. Membrane disruption as a specific mechanism against AB and PA.	Notable <i>in vitro</i> activity against ESKAPE Gram-negatives (including biofilms), except KP. Synergy with β -lactams.	Hst5 derivatives with increased resistance against degradation in CF sputum and antipseudomonal efficacy. Safe in clinical trials for the treatment of oral candidiasis.
Cathelicidins	Mainly stored in neutrophils. Fewer than 50 amino acids. Main variants/homologues: LL-37, CRAMP, PR-39, protegrins, indolicidin, bactenecins, and MAPs.	Membrane disruption. Some variants attack cytosolic targets. Significant immunomodulatory activity.	Variable <i>in vitro</i> activity depending on the cathelicidin/pathogen. Variable synergy with conventional antibiotics and anti-biofilm capacity. Several animal infection models with various administration routes and outcomes (Chennupati <i>et al.</i> , 2009).	Artificially modified variants with improved activity: LL-37 derivatives (KS-30, KR-20, KR-12, LLKKK, GKE, P60.4, SAAP-148, 17BIPHE2DP7); Bac5(1-23), Bac5(1-25); omiganan, isegaganan, and murepavadin (these latter three under clinical trials). Formulations for abiotic surface coating, immobilization on nanoparticles or magnetic beads.
Lactoferrin-derived peptides	Lactoferricin: 25–50 residues depending on the species), obtained mostly through digestion by host pepsin. LF1-11: obtained through artificial proteolysis of human lactoferrin (amino acids 1–11, which form the first cationic domain of the protein). Lactoferrampin: obtained through artificial proteolysis of human lactoferrin (amino acids 268–284).	LPS binding and bacterial membrane disruption. LF1-11 additionally targets mitochondria.	Lactoferricin: mild anti-ESKAPE-activity (including anti-biofilm and synergy with antibiotics). No bacterial burden reduction in murine PA keratitis. LF1-11: notable activity against KP and AB, and synergy with antibiotics. Successful in murine models. Lactoferrampin: mild antipseudomonal power <i>in vitro</i> .	Shorter/computationally designed Lactoferricin variants with increased permeabilization power. Acylated analogues with higher synergistic, LPS-neutralizing and antipseudomonal activities. Immobilization on surfaces for the design of anti-colonization strategies on catheters or implants (Chen <i>et al.</i> , 2017). Lactoferricin–lactoferrampin chimera: strong activity against planktonic PA and biofilms, also displaying virulence-attenuating effects (Xu <i>et al.</i> , 2010).

CF, cystic fibrosis; CRAMP, cathelin-related antimicrobial peptide; ESKAPE, *Klebsiella pneumoniae* (KP), *Acinetobacter baumannii* (AB), *Pseudomonas aeruginosa* (PA) and *Enterobacter* species (ES); LPS, lipopolysaccharide; MAPs, myeloid antimicrobial peptides; PR-39, proline-arginine-rich-39.

(Porro *et al.*, 2001) and when their levels decrease below certain thresholds, the risk of infection increases. This has been reproduced in a murine model of PA infection of burnt skin (Kawasaki *et al.*, 2015), but is also visible in patients with chronic

respiratory pathologies such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), in which conditions such as an abnormally acidic pH impair the activity of defensins, favouring infection (Taggart *et al.*, 2003; Dalcin &

Table 3. Overview of mammalian bacterial membrane-targeting innate humoral immune proteins (>100 amino acids) and their therapeutic potential. See main text for references

Immune element	Main features and examples/variants	Mode of action	Activity (<i>in vitro/in vivo</i>) against ESKAPE Gram-negatives	Artificially derived variants, research lines and therapeutic potential
Bactericidal/permeability increasing protein (BPI) and related proteins	<i>Ca.</i> 60 kDa. The cationic N-terminal fragment harbours antimicrobial properties. Mainly found within neutrophil granules, although its expression is inducible elsewhere. Other members of the BPI superfamily with antibacterial activity include: SPLUNC1 and BPIFA2 (both <i>ca.</i> 25 kDa and secreted in nasal/oral cavities)	Binding to LPS through electrostatic interactions and penetration into inner membrane, leading to its disturbance and dissipation of electrochemical gradients. Several roles beyond bacterial killing: anti-endotoxin, anti-angiogenesis, chemotaxis, and opsonization.	Therapeutic approaches with fragments of human BPI: rBPI-23 (first 199 amino acids), rBPI-21 (first 193 amino acids with Cys132Ala substitution), rBPI (10–193) (lacks the first nine rBPI-21 amino acids), showed enhanced activity <i>in vitro</i> . Different animal models provided encouraging results in terms of bacterial burden and inflammation reduction. Additive (not synergistic) effects with antibiotics.	Synthetic BPI derivatives: Asp190Ala substitution in murine BPI5. Betapep 33mers: betapep-25 (and shorter derivatives, with LD ₅₀ at nM ranges against PA). Subcutaneous administration of SC-4 improved survival in murine PA intraperitoneal infection model. SPLUNC1-derivative α4-short (24 residues, increased positive charge): important anti-KP/AB/PA activity (including biofilms), and encouraging results in a murine model of PA respiratory infection. GL13NH2, GL14K, and D-GL13K (141–153 residues from BPIFA2 with different modifications): notable antipseudomonal power (including biofilms), and efficacy in murine models of septic shock, PA burn wound infection, and <i>G. mellonella</i> .
Group IIA secretory phospholipase 2 (GIIA sPLA2)	<i>Ca.</i> 14 kDa. Constitutively expressed in the surroundings of infection gates: Paneth cells, prostate epithelial cells, lacrimal glands, etc. Inducible expression elsewhere. Metabolizes endogenous phospholipids to enable the synthesis of pro-inflammatory eicosanoids.	Enzymatic hydrolysis of bacterial membrane phospholipids.	Notable antipseudomonal power not affected by high protein or salt concentrations. Different animal models showed the potential of this weapon as an exogenous administered option (not tested against ESKAPE Gram-negatives).	Transgenic mice over-expressing human sPLA2-IIA are resistant to infection by different pathogens (not ESKAPE Gram-negatives), which suggests that increasing the expression of this protein could be a valid therapeutic/prophylactic measure.
Surfactant-associated proteins (SP-A and SP-D)	<i>Ca.</i> 25 and 37 kDa, respectively. Mainly produced by bronchiolar exocrine cells and type II pneumocytes, and other locations such as the eye. SP-A: hexamer of <i>ca.</i> 600 kDa. SP-D: tetramer of <i>ca.</i> 500 kDa. Different associations (multimers, trimers, dimers, monomers) may also appear.	Membrane permeabilization relying on binding to LPS sugar moieties. Work as opsonins leading to enhanced phagocytosis and superoxidative burst.	Pivotal role in the defence of the cornea against PA infection. Exogenous administration (or artificial induction of expression) significantly enhanced survival of mice/rats with lung KP/PA infection, respectively.	SP-A4: not directly bactericidal, but its administration in a murine model of infection caused a significant decrease in bacterial burden, inflammation, oedema, and tissue damage, linked to immunomodulatory and opsono-phagocytosis-enhancing capacities.

BPIFA2, BPI fold containing family A member 2; ESKAPE, *Klebsiella pneumoniae* (KP), *Acinetobacter baumannii* (AB), *Pseudomonas aeruginosa* (PA) and *Enterobacter* species (ES); LD₅₀, lethal dose 50; LPS, lipopolysaccharide; SPLUNC1, short palate, lung, and nasal epithelium clone 1.




Fig. 3. The three main mechanistic models for the membrane disturbance-based activity of cationic antimicrobial peptides (CAMPs). (A) In the ‘carpet model’, CAMPs do not form a defined channel across the lipid bilayers but adhere to them in parallel, causing a detergent-like effect leading to the formation of micelles and membrane disintegration. Indolicidin and LL-37 both work through this mode of action. Some authors have proposed that this ‘carpet’ formation is also an essential step to trigger toroidal pore formation. (B) In the ‘toroidal pore’ model, CAMPs insert perpendicularly into the lipid bilayer and disrupt the regular segregation of polar (hydrophilic head-groups) and non-polar (hydrophobic hydrocarbon cores) segments of lipids, alternately exposing them in order to enable interaction with different sections of the CAMP. This leads to local curvature of the lipid bilayer, with the pores partially formed by the CAMP but also partially by the polar head-groups. No vertebrate CAMPs seem to act through this model. (C) In the ‘barrel-stave pore’ model, CAMPs are again inserted perpendicularly, but here their hydrophobic region only interacts with the membrane hydrocarbon core for self-assembly, thus not disorganizing the polar/non-polar distribution.

Ulanova, 2013; Alaiwa *et al.*, 2014; Arnason *et al.*, 2017). This has been demonstrated by a notable attenuation of hBD-2 production caused by certain contaminants on respiratory epithelia (Chen *et al.*, 2018b). The artificial overexpression of rat β -defensin 2 in rodent airways has been found to enhance natural protection against PA infection (Hu *et al.*, 2010; Shen *et al.*, 2014). Similar results have recently been obtained by using lentiviral vectors in mice to increase expression of hBD-2 and hBD-3, i.e. the mice showed ameliorated survival after skin flap infection by PA introduced through catheters (Casal *et al.*, 2019). Likewise, the overexpression of β -defensin 2 in rats improved the outcome of PA lung infection, demonstrating the important protection exerted by these CAMPs *in vivo* (Shen *et al.*, 2017). As recently demonstrated for diverse HNPs (Zheng *et al.*, 2018), besides their obviously beneficial bactericidal activity (McHugh *et al.*, 2019), defensins show pro-inflammatory properties which, depending on their levels and context of infection, can lead to excessive and harmful consequences for the host. Therefore, defensins have been suggested as a target for future personalized therapies (Crimi *et al.*, 2020).

(ii) *Histatins*. Another interesting group of bacterial envelope-targeting CAMPs is histatins, which were originally discovered in human saliva, although they are also produced by certain primates. Histatins are *ca.* 20–40 amino acids long

and display an extended structure with a high proportion of histidines (Oppenheim *et al.*, 1988). There are two human variants (Hst1 and Hst3) that provide shorter derivatives (Hst2 and Hst4–Hst12) after digestion by oral proteases (Pasupuleti *et al.*, 2012). Interestingly, histatins seem to display different bactericidal mechanisms depending on the bacteria. For instance, Hst5-mediated killing of PA and AB appears to be exclusively linked to membrane permeabilization, whereas *Enterobacter cloacae* elimination requires mitochondrial targeting, therefore affecting energy metabolism (Du *et al.*, 2017). The scarcity of recent studies characterizing the natural protective activity of these CAMPs against ESKAPE pathogens is striking.

(iii) *Cathelicidins*. Peptides belonging to this large group are mainly stored in neutrophils and are formed by the enzymatic cleavage of the C-terminus of protein precursors showing homology with a porcine cysteine protease inhibitor called cathelin (Kościuczuk *et al.*, 2012; Haney *et al.*, 2019). Cathelicidins are highly heterogeneous and representatives are known that belong to any of the three predominant structures (α -helical, β -sheet and extended), many of them with notable membrane-permeabilizing activities (Travis *et al.*, 2000; Kumar *et al.*, 2018). Examples include the human LL-37 (Dürr, Sudheendra & Ramamoorthy, 2006), known to

act synergistically with other innate immune system components such as neuropeptides (Ohta *et al.*, 2011); cathelin-related antimicrobial peptide (CRAMP) in rats and mice (Kovach *et al.*, 2012); cationic antimicrobial protein 18 (CAP-18) in rabbits (Larrick *et al.*, 1994); porcine antibacterial peptides (PMAPs) (Scheenstra *et al.*, 2019), prophenins (PFs) (Wang *et al.*, 2004), protegrins (PGs) (Lazaridis, He & Prieto, 2013), salivary pig E (SP-E) (Ciociola *et al.*, 2018), tritrypticin, and proline-arginine-rich 39 (PR-39) in pigs (Mishra *et al.*, 2018); bovine myeloid antimicrobial peptides (BMAPs) and indolicidin in cattle (Mishra *et al.*, 2018); ChMAPs in goats (Pantelev *et al.*, 2018); SMAPs in sheep (Brogden *et al.*, 2001); bacterenecins (a group that includes proline-rich Bac5 and Bac7 peptides, for instance) in several ruminants (Shamova *et al.*, 2016); an extraordinary diversity in marsupials (Peel *et al.*, 2016); etc. Since an exhaustive description of all of these would be excessive, only those used for experimental therapeutics are reviewed in Sections III.2 and III.3. As explained above, some immune components are known to interfere with certain intracellular processes in parallel to their envelope-targeting activity and similar examples can be found within cathelicidins: indolicidin, which inhibits DNA synthesis; the proline-rich Bac5/Bac7 peptides that inhibit protein synthesis by binding to ribosomes; and PR-39 which blocks both processes (Cardoso *et al.*, 2019).

(iv) *Lactoferrin-derived peptides.* Another example of a protein precursor that can produce different CAMPs depending on the proteolytic process is lactoferrin, which is a secreted globular glycoprotein (≈ 80 kDa) with an iron sequestration-based (non-cell wall lytic) antimicrobial activity (Cutone *et al.*, 2019; Gruden & Poklar Ulrich, 2021). Besides the two bacterial envelope-targeting peptides obtained from lactoferrin by artificial digestion (LF1-11 and lactoferrampin, see Section III.2*b.iv*), the loop-structured lactoferricin is naturally released mainly through proteolysis by host pepsin (Bellamy *et al.*, 1992; Van Der Kraan *et al.*, 2004; Bruni *et al.*, 2016; Amerikova *et al.*, 2019). Human lactoferricin is a single chain corresponding to residues 1–49 of whole lactoferrin [including two-disulfide bridges (Hunter *et al.*, 2005)] or residues 17–41 with an inner disulfide bridge in the case of bovine lactoferricin (Gifford, Hunter & Vogel, 2005). Human lactoferricin has also been proposed to comprise lactoferrin residues 1–47, separated into two chains linked through a disulfide bond (Bellamy *et al.*, 1992; Wakabayashi, Takase & Tomita, 2005). The capacity of lactoferricin for LPS binding and membrane alteration lies in a well-defined 11-amino acid amphipathic α -helical region (Gifford *et al.*, 2005; Wakabayashi *et al.*, 2005; Bruni *et al.*, 2016), but its translocation to reach cytosolic targets has also been proposed (Haukland *et al.*, 2001). Given this evidence, although the power of lactoferricin cannot easily be differentiated from that of lactoferrin *in vivo*, it is likely that lactoferricin also contributes to natural protection in the host (Gruden & Poklar Ulrich, 2021).

Apart from the abovementioned works for defensins, there is a notable scarcity of publications assessing the natural protective activity of the bacterial envelope-targeting CAMPs

listed in this section, particularly against ESKAPE Gram-negatives. The few examples that can be cited include the artificially induced expression of LL-37 in rodent lungs, which enhanced natural protection against PA infection (Bals *et al.*, 1999b), and the well-documented defensive role of CRAMP in the rodent cornea and lung (Huang *et al.*, 2007c; Kovach *et al.*, 2012; Wang *et al.*, 2013). Finally, the so-called keratin-derived antimicrobial peptides (KDAMPs) have been shown to be essential for protection of the cornea against PA infection (Tam *et al.*, 2012). These 13- to 26-amino acid long glycine-rich peptides derived from the C-terminus of human cytokeratin 6A (a fibrous protein contributing to the cytoskeleton of epithelial cells) seemingly exert their antibacterial activity through initial interference with bacterial adherence to the ocular surface but also by direct membrane permeabilization, but no further therapy-oriented research has been published (Tam *et al.*, 2012).

(b) *Antimicrobial proteins*

Mammals display a wide array of membrane-targeting antimicrobial proteins, but only representatives with activity against at least some of the ESKAPE Gram-negatives, and/or publications regarding their therapeutic potential are discussed here (Table 3, Fig. 1): Bactericidal/permeability increasing protein (BPI) and related proteins, Group IIA secretory Phospholipase A 2 (GIIA sPLA2), and the surfactant-associated proteins SP-A and SP-D, which have been reviewed recently not only in terms of their antimicrobial power but also for other interesting immunomodulatory features and implications (Floros *et al.*, 2021; Letsiou, Htwe & Dudek, 2021; Theprungsirikul, Skopelja-Gardner & Rigby, 2021). Some antimicrobial proteins are not addressed here, either because they have poor (or untested) activity against ESKAPE Gram-negative pathogens [for example, human skin chemerin (Banas *et al.*, 2013)], or because there is uncertainty about their mechanistic action. This is the case for certain C-terminal fragments derived from flaggrin-2, a pleiotropic protein involved in the maintenance of the skin barrier function, which shows high activity against PA apparently not mediated by membrane permeabilization (Hansmann, Schröder & Gerstel, 2015). Another example is psoriasin, which has a well-known membrane permeabilizer activity involved in skin defence, but has not been approached for therapeutic exploitation against ESKAPE Gram-negatives (Michalek *et al.*, 2009).

(i) *Bactericidal/permeability increasing protein (BPI).* The multifunctional cationic BPI has several roles beyond bacterial killing, including LPS neutralization, anti-angiogenesis, chemotaxis, opsonization, etc. (Balakrishnan *et al.*, 2013). This protein has a molecular weight of *ca.* 60 kDa and has two functional domains: the N-terminal harbours antimicrobial properties, whereas the C-terminal region is responsible for its other activities. BPI is found mainly within neutrophil granules, although it is also produced by monocytes or eosinophils. Expression of BPI is highly inducible at least in mice, through the interaction of different toll-like receptors (TLRs)

with their agonists (Eckert *et al.*, 2006). The bactericidal activity of BPI is restricted to Gram-negatives and is initially mediated by electrostatic interactions with the lipid A moiety of LPS, which enables the penetration of BPI into the periplasm, reaching the inner membrane in a time-dependent fashion and leading to its disturbance, dissipation of electrochemical gradients and death (Fig. 1) (Mannion, Weiss & Elsbach, 1990). BPI has been shown to act synergistically with other CAMPs but the murine protein seems to be incapable of inhibiting PA growth by itself (Wittmann *et al.*, 2008). Although BPI was classically considered a bactericidal protein, its superfamily has additional representatives with non-negligible antimicrobial potential: the bovine salivary proteins BSP30a and BSP30b, which display some degree of antipseudomonal activity (Haigh *et al.*, 2008); the human parotid secretory protein (PSP or BPIFA2), from which synthetic derivatives displaying direct bactericidal activity have been obtained [see Section III.2b.v (Abdolhosseini *et al.*, 2012)]; and the short palate, lung, and nasal epithelium clone 1 (SPLUNC1). Some studies proposed that SPLUNC1 acts as a permeability-increasing agent in Gram-negatives together with other roles such as an immunomodulator or chemoattractant (Balakrishnan *et al.*, 2013; Sayeed *et al.*, 2013; Wei *et al.*, 2016). SPLUNC1 exerts an important natural protective role *in vivo*, since mice in which this protein was deleted showed an increased severity of infection by KP or PA. Similarly, individuals with decreased levels or an impaired performance of this protein are at increased risk of PA infection (Tsou *et al.*, 2013; Nichols *et al.*, 2015; Moore *et al.*, 2019). The mechanisms involved are likely multi-factorial, including anti-biofilm and inflammatory regulation properties, and are not only based on the direct bacteriolytic power of SPLUNC1 (Liu *et al.*, 2013a, b). Likewise, BPI exerts an essential protection *in vivo*; its malfunction dramatically increases susceptibility to infections, as for example in CF patients. In fact, chronic infection by PA is a hallmark of these individuals, whose increased susceptibility to PA colonization is explained, at least in part, by the well-documented expression of anti-BPI autoantibodies that dramatically impair its activity in the lung (Carlsson *et al.*, 2011).

(ii) *Group IIA secretory phospholipase A2 (GIIA sPLA2)*.

Within the phospholipase A2 (PLA2) superfamily, secretory PLA2 (sPLA2) enzymes are the largest family, with 10–12 different variants depending on the species. Members of the sPLA2 family display quite specific tissue and cellular distributions, as well as particular enzymatic behaviours (Murakami *et al.*, 2015). Nevertheless, some common traits can be found, such as a low molecular weight and a shared activity in the degradation of phospholipids. The goal of this degradation is variable: production of inflammatory mediators, membrane remodelling, breakdown of food lipids or the destruction of microbes. GIIA sPLA2 clearly stands out in terms of antibacterial activity. GIIA sPLA2 has a molecular weight of *ca.* 14 kDa and its expression is induced during inflammatory processes linked to infection, in response to the stimulation of certain host PRRs by microbial ligands.

Consequently, GIIA sPLA2 levels are correlated with the severity of inflammation (Wu *et al.*, 2010; Pernet *et al.*, 2014; Dore & Boilard, 2019). For this reason, GIIA sPLA2 is often known as an inflammatory sPLA2, related to its capacity to generate inflammatory intermediaries: once synthesized in the cytosol, GIIA sPLA2 degrades some intracellular phospholipids, and then is released outside the cell, exerting this degradation over phospholipids from extracellular vesicles. The arachidonic acid derived from this activity is used for the synthesis of pro-inflammatory eicosanoids, which enable the amplification of inflammation and drive the recruitment of additional immune components (Nevalainen, Graham & Scott, 2008; Murakami *et al.*, 2015; Dore & Boilard, 2019). In accordance with this protective role, GIIA sPLA2 is constitutively expressed in the surroundings of potential infection sites, *i.e.* intestinal Paneth cells, prostate epithelial cells and lacrimal gland cells. Its expression also can be induced in other sites such as vascular endothelium, hepatocytes, platelets, etc., but GIIA sPLA2 is not released by neutrophils (Dore & Boilard, 2019).

The bactericidal capacity of GIIA sPLA2 relies on the enzymatic hydrolysis of phospholipids in bacterial membranes, whose high content of phosphatidylglycerol and phosphatidylethanolamine make them excellent substrates for this enzyme (Fig. 1). GIIA sPLA2 is bactericidal only against Gram-positives at physiological concentrations, and hence it requires the collaboration of additional immune elements that disturb LPS, such as BPI or complement, to enable access to Gram-negative membranes (Nevalainen *et al.*, 2008; Murakami *et al.*, 2015; Heesterbeek *et al.*, 2021). The concentrations of GIIA sPLA2 required to kill Gram-negative bacteria are not attainable *in vivo*, although these have been shown to be bactericidal for PA *in vitro* (Dubouix *et al.*, 2003; Nevalainen *et al.*, 2008). Obviously, not all pathogens will exhibit the same level of susceptibility to GIIA sPLA2. PA infection has been shown to alter the expression of GIIA sPLA2 in the lungs of CF patients, increasing its levels by 2.5-fold compared with healthy individuals. This increased concentration is sufficient to kill *Staphylococcus aureus*, another typical colonizer of CF patients, but does not kill PA. These facts have been interpreted as a strategy of PA to eliminate competitors, and may be one of the reasons why PA is more associated with CF in patients during adulthood, whereas *S. aureus* is most prevalent in younger individuals. These phenomena have been related to the PA exotoxin S (ExoS), which is responsible for the promotion of GIIA sPLA2 expression through different pathways (Pernet *et al.*, 2014; Dore & Boilard, 2019). These data suggest an important role of GIIA sPLA2 in natural protection against infection and, indeed, overproduction of human GIIA sPLA2 in transgenic mice was demonstrated to protect against various pathogens in different models (Wu *et al.*, 2010).

(iii) *Surfactant-associated proteins*. Pulmonary surfactant is a lipid–protein complex whose classically attributed function is to decrease the surface tension of the air–water interface of alveoli, avoiding their collapse during exhalation and being essential for correct pulmonary function. Other roles

have been attributed to its protein fraction, including immunomodulation and direct microbicidal action (Han & Mallampalli, 2015). The proteins that take part in these functions are known as surfactant-associated proteins. They are produced by bronchiolar exocrine cells and type II pneumocytes, and their classical representatives are SP-A, SP-B, SP-C, and SP-D. SP-B and SP-C (but also the recently discovered SP-G and SP-H) are hydrophobic proteins without significant antimicrobial capacity and therefore, we do not discuss them further here, although some immunomodulatory functions related to LPS-binding have been attributed to them (Ketko & Donn, 2014; Han & Mallampalli, 2015).

Structurally, SP-A and SP-D usually appear as oligomeric complexes: SP-A is a hexamer in which the different subunits associate to form a *ca.* 600 kDa macromolecule, whereas human SP-D is assembled into a *ca.* 500 kDa tetrameric structure. However, different associations, i.e. multimers, trimers, dimers, and monomers are also known (Nayak *et al.*, 2012). SP-A and SP-D are hydrophilic collectins capable of binding to sugars on the microorganisms' surfaces through their C-terminal lectin domains, thus working as opsonins. This results in the aggregation of pathogens, enhanced phagocytosis and induction of superoxidative bursts by phagocytes, which together enable increased bacterial killing (Han & Mallampalli, 2015; Vieira, Kung & Bhatti, 2017). Once SP-A and SP-D are bound to their microbial ligands, they interact through their collagen-like N-terminal end, with certain surface receptors [cluster of designation 14 (CD14), toll-like receptor 4 (TLR4), etc.] on different immunocytes in order to initiate and/or regulate inflammatory and clearance responses (Jakel *et al.*, 2013). Therefore, SP-A and SP-D are often considered as soluble PRRs. They also bind to different humoral proteins (such as the complement C1q or immunoglobulins), exerting an additional aggregative role on pre-opsonized pathogens and other regulatory functions (Nayak *et al.*, 2012; Jakel *et al.*, 2013).

Regarding their direct bactericidal capacity, SP-A and SP-D display strong membrane permeability-increasing activity mainly related to LPS binding, although several additional ligands have been suggested (Kuzmenko *et al.*, 2005; Jakel *et al.*, 2013). For instance, SP-A also binds to capsular polysaccharides of *Klebsiella* species, which could contribute to permeabilization (Nayak *et al.*, 2012). SP-A seems to bind strongly to rough-type LPS (variants lacking the O-antigen usually found in pathogenic bacteria) and lipid A, but not to complete LPS (Kuzmenko, Wu & McCormack, 2006). By contrast, SP-D apparently binds to both rough LPS and smooth LPS containing mannose-rich O-polysaccharides. SP-A-mediated permeabilization involves the formation of calcium-mediated three-dimensional lipid-protein aggregates that extract lipids from their correct location within bacterial membranes, thus disrupting their natural structure (Cañadas *et al.*, 2008). SP-A and SP-D are highly susceptible to oxidative stress, and therefore pathological conditions that enhance the formation of reactive oxygen species such as CF, functionally impair these proteins. This may contribute to the enhanced susceptibility of CF

patients to PA infection, demonstrating the natural anti-infective role that these proteins play (Kuzmenko *et al.*, 2005; Starosta & Griese, 2006). Other data also support these two proteins as being essential for defence against infection: animal models in which they were deleted showed increased severity of lung infection by PA or KP (LeVine *et al.*, 1998; Giannoni *et al.*, 2006; Mikerov *et al.*, 2008; Ali *et al.*, 2010; Du *et al.*, 2018; Thorenoor *et al.*, 2018). SP-A and SP-D also are secreted in locations other than the lung and apparently play an important role in defence of the cornea against PA infection as shown in different animal and cell-culture models (Mun *et al.*, 2009; Alarcon *et al.*, 2011; Nayak *et al.*, 2012; Vieira *et al.*, 2017).

III. BACTERIAL ENVELOPE-TARGETING MAMMALIAN HUMORAL INNATE IMMUNITY: THERAPEUTIC POTENTIAL

In this section we address the most relevant and recent work investigating the therapeutic potential of mammalian bacterial envelope-targeting immunity, not only studies on 'conventional' treatments based on the external administration of a bactericidal compound, but also *in vitro* activity studies, animal models, and clinical trials. We additionally provide insights into new concepts based on host/bacterial targets that could increase the performance of bacterial envelope-targeting immunity and/or reduce the resistance of pathogens to these approaches, as a necessary perspective for the future development of such treatments (Bergman *et al.*, 2020). To avoid saturation with numerical data, only the most relevant values of minimum inhibitory concentrations (MICs), survival percentages and related parameters are provided below.

(1) Bacterial resistance: a non-negligible threat for treatments based on envelope-targeting immune proteins/peptides

An initial question is the potential for the development of bacterial resistance against bacterial envelope-targeting treatments, which could be a serious threat. However, one strength that has been classically attributed to such an approach is the unlikely development of resistance. The main reason for this is that many of the immune components targeting the envelope work through non-specific modes of action, making it less likely that there will be selection for bacterial resistance mechanisms (Dziarski & Gupta, 2018; Lewies, Du Plessis & Wentzel, 2019). Whereas classic antibiotics usually have one specific target and mechanism (enabling the selection of single mutations conferring resistance), envelope-targeting immune components often interact with different ligands, with parallel and relatively unspecific effects on bacterial envelopes. Therefore, the acquisition of resistance would require the simultaneous selection of different adaptations, which is less likely to occur.

Since these immune components target highly conserved essential structures, the possible selection of viable mutants with alterations in these structures is limited (Lewies *et al.*, 2019). Selection of resistance is even less likely if the immune-based treatment is combined with a classic antibiotic, a strategy followed in several studies, as described below [Sections III.2a and III.2b.iv (Zharkova *et al.*, 2019)]. Another advantage of envelope-targeting immunity in comparison with antibiotics is that bacteria seemingly have not developed mechanisms/platforms for the dissemination of genes conferring resistance to these immune elements (Kintses *et al.*, 2019), contrary to the situation for the horizontal transfer of β -lactamases for example, which can take place through integrons, transposons, and/or plasmids (Juan *et al.*, 2017). The minimal potential for environmental dissemination of free and active immune compounds (given their low stability outside the organism), in contrast with antibiotics (usually found at sub-lethal concentrations in the environment), is another factor that may limit the selection of mutations and the appearance/transmission of resistance genes against bacterial envelope-targeting immune elements (Lazzaro, Zasloff & Rolff, 2020).

One circumstance that suggests caution when considering bacterial envelope-targeting immunity as therapeutic option is the identification of cross-resistance phenomena between certain antibiotic treatments and exogenously administered CAMPs, potentially affecting the effectiveness of endogenous CAMPs (Kádár *et al.*, 2015; Fleitas & Franco, 2016). Such cross-resistance episodes often involve polymyxins and CAMPs, perhaps understandably given their biochemical and mechanistic similarities (Kádár *et al.*, 2015; Fleitas & Franco, 2016; Crémieux *et al.*, 2019). It is also of interest that a dramatically increased susceptibility to lysozyme appearing in tandem with colistin resistance mediated by LPS loss in AB has been reported, as well as an increase in KP or PA susceptibility to CAMPs after avibactam/quinolone treatments (Campos, Morey & Bengoechea, 2006; Ulloa *et al.*, 2019; Kamoshida *et al.*, 2020). A lack of association between antibiotic *versus* defensin bacterial resistance has also been suggested, indicating the complexity of this topic (Supp *et al.*, 2009). The aforementioned cross-resistance phenomena may be caused by point mutations in different genes related to LPS and/or synthesis of other surface structures (Napier *et al.*, 2013), but they are also intimately related to the induction of adaptive resistance phenotypes. These latter are transitory states with no mutational basis, usually mediated by regulatory networks including two-component systems such as CprRS, which are ultimately activated by the presence of CAMPs (Fernández *et al.*, 2012). Interestingly, these metabolic regulatory networks have also been shown to facilitate bacterial adaptation by regulating the expression of virulence factors, which could be a negative implication of using some CAMPs as therapies. This threat could be even greater if we consider that mutations in the abovementioned two-component systems themselves could be selected to

increase resistance to CAMPs (Llobet *et al.*, 2011; Limoli *et al.*, 2014; Rodríguez-Rojas *et al.*, 2015). Therefore, while the therapeutic potential of bacterial envelope-targeting immunity is encouraging, unwanted problems may arise if they are used without control or foresight (Kádár *et al.*, 2015; Fleitas & Franco, 2016; Crémieux *et al.*, 2019; Lazzaro *et al.*, 2020; Vitale *et al.*, 2020). Among these, we include recently reported phenomena of non-classical antagonism in combined treatments of lysozyme with certain CAMPs against PA, a worrying development that deserves detailed investigation (Blumenthal *et al.*, 2021). Therefore, specific strategies to prevent/block such phenomena and potential mechanisms of cross-resistance/adaptation must be studied in parallel with the development of envelope-targeting immunity-based therapies (Shang *et al.*, 2020).

(2) *In vitro* activity, experimental treatments and animal models

(a) Peptidoglycan-targeting proteins

Several studies have analysed the *in vitro* activity of lysozyme against different ESKAPE Gram-negatives, generally showing modest effectiveness ranges (Torrens *et al.*, 2020). However, powerful activity against AB (MIC 1.2 μ M), potentiated through polymyxin B, has been reported (Zharkova *et al.*, 2019). From *in vivo* assays, the early instillation of human lysozyme into the lungs of PA-infected mice has been shown to significantly reduce bacterial load (by *ca.* 1 log unit compared to controls) (Epaud *et al.*, 2019). Milder results had been obtained previously with aerosolized lysozyme in hamster models of PA respiratory infection, with this difference probably due to differences in timing, dosage, and administration route. However, a significant decrease in inflammation parameters and a significant synergy with tobramycin was observed (Bhavsar *et al.*, 2011, 2010). Initiatives to improve the performance of aerosolized lysozyme and increase its effectiveness have been published (Ferrati *et al.*, 2018; Nieto-Orellana *et al.*, 2018). Modified variants of lysozyme with a reduced positive charge to avoid electrostatic sequestration by various mucus polyanions, including DNA, mucin, and alginate (all of which are typically increased in CF patients), have been developed, with encouraging results in murine respiratory infection models (Teneback *et al.*, 2013; Griswold *et al.*, 2014). In a search for greater stability, solubility, and reusability, synthetic conjugates or nanoparticles have been developed, demonstrating improved activity against PA and AB (Liu *et al.*, 2013c; Saito *et al.*, 2019). This is particularly interesting for lysozyme immobilized in chitosan nanoparticles through ionic gelation, which is very active against KP, with MICs around 10 mg/l and significant bactericidal capacity (a 2 log unit decrease in viable bacteria in 120 min) (Wu *et al.*, 2017a; Wang *et al.*, 2020). Although lysozyme barely inhibits PA biofilm formation, application against KP seems exploitable, since concentrations of 5 mg/l

completely eradicated 24 h-old biofilms (Sheffield *et al.*, 2012; Hukić *et al.*, 2018).

(b) *Membrane disturbance-based immune weapons*

(i) *Defensins*. Several studies have analysed the *in vitro* activity of defensins against AB, KP, or PA, mostly using hBD-2/-3, and providing data that suggest significant bactericidal power [e.g. a MIC of 5 mg/l for hBD-1 against KP (Sahly *et al.*, 2006; Huang *et al.*, 2007b; Maisetta *et al.*, 2008; Routsias *et al.*, 2010; Gomes *et al.*, 2015)]. Some defensins, such as hBD-2, also have interesting anti-biofilm potential, as tested using classical *in vitro* assays but also in novel electrochemical catheters (designed to avoid infections linked to these devices), in which the defensin is administered synergistically together with nitric oxide (NO), with reports of a 5 log unit reduction in viable cells from 7-day-old biofilms (Ren *et al.*, 2016; Parducho *et al.*, 2020). The natural dimerization of human α -defensin 5 has been demonstrated under certain conditions, enhancing its protease resistance and activity against AB (Wommack *et al.*, 2014). Different variants from species including monkeys (θ -defensins), rats, dogs, and even a defensin-like peptide from platypus have been tested for antimicrobial activity *in vitro*, with notable results against PA or KP although with similar performance to human variants (Sang *et al.*, 2005; Torres *et al.*, 2014; Gomes *et al.*, 2015; Tai *et al.*, 2015; Beringer *et al.*, 2016).

The search for artificially modified defensin derivatives with improved properties is ongoing. Defensin-related peptide 1 (Defr1), a 34-amino-acid fragment with only five of the canonical six cysteine residues, works as a covalent dimer with enhanced bactericidal power (Taylor *et al.*, 2009); some simplified hBD-3 or HNP-1 scaffolds show increased anti-ESKAPE activity (Hoover *et al.*, 2003; Varney *et al.*, 2013; Chauhan *et al.*, 2016; Nigro *et al.*, 2017); some synthetic peptides corresponding to the carboxy-terminal segment of bovine β -defensin-2 retained interesting antibacterial activity (Krishnakumari *et al.*, 2003); the β -hairpin loop of the 33-amino-acid α -defensin rabbit neutrophil peptide 2 (NP-2) exhibits high antipseudomonal power (Thennarasu & Nagaraj, 1999); a Cys2-4 bond-containing 32 residue derivative of HNP-5, with non-cationic/non-hydrophobic residues replaced by positively charged arginine (denominated HD5d5), showed enhanced activity against AB (Wang *et al.*, 2018); the fragment of the first 11 N-terminus residues obtained by tryptic digestion of HNP-4 (denominated HNP-4₁₋₁₁) outperformed the original peptide and showed activity enhanced by acetylation/amidation (Ehmann *et al.*, 2020); certain chimeric/oligomeric variants with specific amino acid substitutions displayed significant activity against PA, etc. (Zhou *et al.*, 2011; Corrales-Garcia *et al.*, 2013; Scudiero *et al.*, 2015, 2013).

Fewer studies have assessed the administration of defensins as a treatment *in vivo*. Interestingly, injection of HNP-1 was found to cause a notable (*ca.* 2 log units) leukocyte-dependent KP burden reduction in the peritoneum and thigh in murine models (Welling *et al.*, 1998). Nebulized monkey θ -defensins

provided significant inflammation and PA load reductions in rodent models of chronic respiratory infection (Beringer *et al.*, 2016; Bensman *et al.*, 2017). Finally, the artificially induced over-expression of different defensins in rodent lungs and in skin infection models provided encouraging results, as did the incorporation of hBD-1 into cotton gauzes to treat KP-infected wounds (Hu *et al.*, 2010; Gibson *et al.*, 2012; Park *et al.*, 2014; Shen *et al.*, 2014; Gomes *et al.*, 2015).

(ii) *Histatins*. Research has focused on Hst5, which shows powerful *in vitro* activity especially against PA, with over 99.9% of bacteria killed after 1 h incubation with 30 μ M Hst5 in solution (Du *et al.*, 2017). By contrast, KP has been shown to remain mostly resistant to this peptide, likely owing to its capsule (Du *et al.*, 2017). The Hst5-derivative Dhvar-5, a synthetic analog based on residues 11–24, showed potent anti-PA and anti-AB activity and encouraging anti-biofilm potential for the development of preventative coatings against implant-associated infections (Barbosa *et al.*, 2019). The P-113D derivative (Hst5 residues 4–15) showed increased stability against proteases (Cirioni *et al.*, 2004), leading to 100% planktonic PA death after 10 min of exposure to $\times 2$ MIC, an activity that was amplifiable through synergy with β -lactams (Giacometti *et al.*, 2005). Interestingly, P-113D was also shown to clear PA sepsis successfully in rats, with an activity comparable to that of imipenem/polymyxin B (Cirioni *et al.*, 2004). Unfortunately, these encouraging results with histatin derivatives have not been translated into ongoing research lines.

(iii) *Cathelicidins*. The human cathelicidin LL-37 has been the subject of intensive research [reviewed by Duplantier & van Hoek (2013) and Wang *et al.* (2019)]. This peptide comes from the proteinase 3-mediated cleavage of the inactive human precursor protein hCAP18 (human cationic antimicrobial protein 18, 170 amino acids). LL-37 is the accepted name for the mature CAMP derived from the last 37 residues of the hCAP18 C-terminus and is widely expressed in different tissues but mainly produced by neutrophils. It is believed to act through the carpet model (see Fig. 3), but the existence of intracytosolic targets has not been completely ruled out (Rozek, Friedrich & Hancock, 2000; Kumar *et al.*, 2018). The existence of a second cathelicidin, FALL-39, similarly derived from the proteolysis of hCAP18, but displaying two additional residues at the beginning of the peptide, was accepted some years ago; it is considered analogous to porcine PR-39, but has been little studied to date (Kuroda *et al.*, 2015). There are mixed results regarding the *in vitro* activity of LL-37, ranging from mild antipseudomonal activity (Pompilio *et al.*, 2011; Min *et al.*, 2012; Wang *et al.*, 2012; Chen *et al.*, 2018a) to high effectiveness against AB, with active concentrations below 4 μ M, and a comparatively higher bactericidal efficiency than either hBD-3 or Hst5 (Lin *et al.*, 2015b; Jaśkiewicz *et al.*, 2019). Variable results regarding its anti-biofilm capacity are also reported (Overhage *et al.*, 2008; Dean, Bishop & Van Hoek, 2011; Dosler & Karaaslan, 2014; Gomes *et al.*, 2015; Jaśkiewicz *et al.*, 2019). Shorter LL-37-derived fragments such as FK-16 display similar activity to LL-37 and synergy with

conventional antibiotics against KP, AB, and PA, but their performance against ES is poor (Feng *et al.*, 2013; Lin *et al.*, 2015a; Rajasekaran, Kim & Shin, 2017; Mishra & Wang, 2017b; Geitani *et al.*, 2019; Mohammed *et al.*, 2019). Other artificially modified versions of LL-37 with cationicity and/or hydrophobicity changes outperform the original peptide regarding anti-ESKAPE Gram-negative activity *in vitro* (Table 2) (Wang *et al.*, 2014; Kim, Rajasekaran & Shin, 2017; Mishra & Wang, 2017a; De Breij *et al.*, 2018; Gunasekera *et al.*, 2020, 2018). The anti-biofilm action of LL-37 immobilized onto poly-hydroxyethylmethacrylate or of FK-16 on titanium surfaces suggests their potential for the development of anti-infective coatings (Mishra & Wang, 2017b; Su *et al.*, 2019).

In vivo and *ex vivo* data show that the LL-37 D-enantiomer increased the survival (from 10 to 60–70%) of PA-infected *Galleria mellonella* larvae (a typical invertebrate infection model) compared to ciprofloxacin, clearly outperforming the original peptide (Dean *et al.*, 2011; Duplantier & van Hoek, 2013). The use of LL-37 in wound dressings/ointments resulted in significant KP, AB, and PA load reductions in cell culture, *ex vivo* and in murine skin models (De Breij *et al.*, 2018; Su *et al.*, 2019). The artificial expression of LL-37 in rodents or in bioengineered skin provided greater AB and PA load reductions compared to exogenous administration in burn infections (Bals *et al.*, 1999b; Thomas-Virinig *et al.*, 2009; Thomas-Virinig & Allen-Hoffmann, 2012; Zhou *et al.*, 2020). The administration of LL-37 successfully helped to clear PA sepsis and lung infection in mice, although the proposed therapeutic mediator was neutrophil recruitment rather than direct bacteriolysis (Cirioni *et al.*, 2008; Beaumont *et al.*, 2014). Finally, CAP18_{106–142} peptide (also known as CAP7, a fragment of 37 residues from rabbit CAP18 protein, homologous to LL-37) and some derivatives have shown *in vitro* antipseudomonal activity exceeding that of LL-37 (Travis *et al.*, 2000; Brogden *et al.*, 2001; Saiman *et al.*, 2001), but unfortunately they failed *in vivo* likely because of high susceptibility to proteolysis (Sawa *et al.*, 1998). Attempts to circumvent this limitation, and to increase its concentration through microgel/carboxylate anions have not yet been tested *in vivo* (Qin *et al.*, 2015; Nordström *et al.*, 2018).

The membrane-permeabilizing 13-amino-acid long bovine peptide indolicidin is believed additionally to inhibit DNA replication (Bera *et al.*, 2015), contributing to its notable anti-PA, anti-KP, and to a lesser extent anti-AB, activities (Giacometti *et al.*, 2000; Overhage *et al.*, 2008). Recently, it has been shown that this cathelicidin and its derivatives (called ‘Indopts’) are interesting in terms of their better synergy with antibiotics, compared to over 20 other CAMPs tested in ≈ 400 combinations (Ruden *et al.*, 2019). Proline-rich bactericins are cathelicidins present in ruminant neutrophils, with those from goats and sheep displaying the strongest activity against Gram-negatives (Shamova *et al.*, 2009). Their effectiveness against PA seems limited (Runti *et al.*, 2017; Mardirossian *et al.*, 2019), but for AB and KP lower MICs are reported (Mardirossian *et al.*, 2018;

Dolzani *et al.*, 2019). The bovine bactericin dodecapeptide (Bac2A) and certain derivatives (DP7 and DP-7C) showed better antipseudomonal activity (Wu & Hancock, 1999; Hilpert *et al.*, 2006) and synergy with antibiotics (Wu *et al.*, 2017b). When used in a zebrafish model, DP-7C caused drastic reductions in PA loads linked to boosted monocyte recruitment (Zhang *et al.*, 2018). Very recently, several cetacean proline-rich antimicrobial peptides (cePrAMPs), which display high similarity to bovine Bac7 but nuances regarding their mechanisms of action (some inhibited protein synthesis without membrane disturbance, while others were very membrane-active), have shown significant bactericidal activity against ESKAPE Gram-negatives, with MICs $\leq 4 \mu\text{M}$ for PA (Sola *et al.*, 2020).

Another extensively studied group of cathelicidins is the myeloid antimicrobial peptides (MAPs), a generic denomination for various ruminant cathelicidins such as BMAPs (bovine), ChMAPs (caprine), and SMAPs (sheep). Of these, BMAP-27/-28 showed interesting antipseudomonal activity (including the prevention of/disruption of biofilms) with MICs $\approx 1 \mu\text{M}$ (Pompilio *et al.*, 2011, 2012). Unfortunately, MAPs generally display poor selectivity between bacterial and eukaryotic membranes (Lee *et al.*, 2011; Guo, Xun & Han, 2018), but BMAP-18 (a synthetic N-terminal 18-residue amphipathic peptide obtained from BMAP-27) showed low eukaryotic cytotoxicity due to its different mode of action: formation of well-defined channels as opposed to massive membrane perturbation (Lee *et al.*, 2011). Sadly, BMAPs failed *in vivo*, likely because of susceptibility to proteolysis and/or sequestration by tissues (Mardirossian *et al.*, 2016, 2017). Ovine MAPs, especially SMAP-29 and its derivatives ovispirins, displayed increased activity against PA and KP compared to LL-37 or Bac7, although their anti-biofilm power was low (Pompilio *et al.*, 2011). Interestingly, although CF sputum notably inhibits SMAP-29 activity *in vitro*, SMAP-29 successfully prevented endotoxin-induced mortality in rat models of septic shock (Travis *et al.*, 2000; Brogden *et al.*, 2001; Saiman *et al.*, 2001; Giacometti *et al.*, 2004; Pompilio *et al.*, 2012).

The porcine cathelicidins protegrins (usually 16–18 amino acids long) act through a barrel-stave pore mechanism (see Fig. 3) (Lazaridis *et al.*, 2013), although some synthetic peptidomimetics (e.g. murepavadin, see Section III.3) act through interference with membrane biogenesis (Shankaramma *et al.*, 2003; Srinivas *et al.*, 2010; Zerbe, Moehle & Robinson, 2017; Andolina *et al.*, 2018; Martin-Loeches, Dale & Torres, 2018). The protegrin PG-1 exhibited interesting MICs against several PA strains (up to 4 mg/l) (Steinstraesser *et al.*, 2001; Albrecht *et al.*, 2002), and notable *in vitro* activity of PG-1 against AB and strong synergy with colistin has also been reported (Steinstraesser *et al.*, 2001; Morroni *et al.*, 2019). PG-1 has been tested in porcine/murine wound infection models, where its inoculation/topical application produced a 4 log unit reduction in PA loads. This effectiveness, likely at least partially dependent on immunomodulatory effects, was very variable depending on the timing of administration: when PG-1 was inoculated

together with bacteria, a 10000-fold decrease in bacterial counts was observed but when the administration was 120 h post-infection, the reduction was only 10-fold. These results indicate the importance of early administration for a successful clinical outcome (Ceccarelli *et al.*, 2001; Steinstraesser *et al.*, 2001; Morroni *et al.*, 2019). Another porcine cathelicidin, tritrpticin, displayed the same MIC₉₀ as colistin (8 mg/l) against several clinical strains of PA and good synergy with β -lactams, in a very encouraging research line that awaits further study (Cirioni *et al.*, 2006). Some tritrpticin derivatives with enhanced permeabilization capacity have been developed, but not tested on ESKAPE Gram-negatives to date (Arias *et al.*, 2016, 2018). Finally, some interesting cathelicidins with excellent anti-AB and anti-PA activity, e.g. WAM-1, have been found in marsupials (Wang *et al.*, 2011b; Spencer *et al.*, 2018).

(iv) *Lactoferrin-derived peptides*. The *in vitro* potential of lactoferrin-derived peptides have been widely investigated (Gifford *et al.*, 2005; Théolier *et al.*, 2014; Bruni *et al.*, 2016; Vega-Bautista *et al.*, 2019; Gruden & Poklar Ulrich, 2021). LF1-11 (an artificially obtained peptide corresponding to the initial 11 amino acids of human lactoferrin) showed strong activity, reducing the KP load by *ca.* 3 log units was observed in a murine thigh infection model (Nibbering *et al.*, 2001). Different synergistic combinations suggest that LF1-11 causes a sensitizing effect on KP especially to hydrophobic antibiotics, which are usually ineffective against it (Morici *et al.*, 2017). In another murine thigh infection model, a *ca.* 3 log unit reduction in AB count was also reported (Dijkshoorn *et al.*, 2004). Administration of LF1-11 is well tolerated in healthy individuals (van der Velden *et al.*, 2009), which enhances its possible use in clinical applications as a bactericidal/immunomodulatory agent, potentially improving AB infection outcomes as shown in mice (Dai *et al.*, 2018).

Lactoferricin is formed by digestion through proteases produced by the host (mainly pepsin) but likely also by microbes at infection sites (Gifford *et al.*, 2005; Théolier *et al.*, 2014; Bruni *et al.*, 2016). The bovine variant displays the strongest antimicrobial power *in vitro* among mammals (Bellamy *et al.*, 1992; Wakabayashi *et al.*, 2005), whereas some derivatives (undcapeptides, based on lactoferricin amino acids 17–27, especially undeca-9) have been found to outperform the original peptide, but not to avoid the appearance of resistant mutants *in vitro* (Strøm, Rekdal & Svendsen, 2002). The fragment between residues 17 and 30 exhibits strong activity, outperforming that of the whole protein (PA MICs: 3 versus 414 mg/l) (Van Der Kraan *et al.*, 2004). The use of bovine lactoferricin in a murine keratitis model was demonstrated to cause a significant decrease in inflammation, but barely reduced PA burden (Oo *et al.*, 2010). Other derivatives (linear, palindromic, branched, polymeric, etc.) based on bovine lactoferricin have been shown to outperform it only slightly in terms of MICs for KP or PA (Huertas *et al.*, 2017; Vega Chaparro *et al.*, 2018). Conversely, some derivatives such as C12LF11 (also known as lauryl-LF11), a N-terminally acylated analogue of LF11 (which corresponds to amino acids 21–31 of human lactoferricin), clearly

outperformed the original molecule *in vitro* (PA MICs 10-fold lower) (Andrä *et al.*, 2005; Hunter *et al.*, 2005; Zweytick *et al.*, 2006). Other LF11 variants such as P-22 showed excellent synergies with antibiotics at subinhibitory concentrations, and were stable against well-known PA resistance mechanisms (Sánchez-Gómez *et al.*, 2015), although their cytotoxicity towards eukaryotic cells has not been solved (Harm *et al.*, 2019).

Finally, some studies have analysed the *in vitro* activity of multiple CAMPs in parallel, providing a useful comparison. Xie *et al.* (2020) reported that BMAP-27 was the strongest cathelicidin (PA, KP, and AB MICs below 2 μ M) and that a combined treatment with LL-37 provided a 2.5 log unit PA load reduction in a murine lung infection model. Other single/combined treatments were recently tested (Zharkova *et al.*, 2019), and showed the CAMPs with the highest activity against AB, KP, and PA to be HNP-1, HNP-4, and PG-1 (MICs below 2 μ M). The most synergistic combinations were polymyxin B plus hBD-2, and gentamicin plus hBD-3 or PG-1 against AB; and amikacin/erythromycin plus PG-1 or ChBac3.4 (a 26-amino-acid long proline-rich cathelicidin identified in goat leukocytes) against KP and PA (Zharkova *et al.*, 2019).

(v) *Bactericidal/permeability increasing protein (BPI)*. Although the whole BPI protein is bactericidal, some shorter fragments with increased activity against ESKAPE Gram-negatives have received research interest (Domingues, Santos & Castanho, 2012; Domingues *et al.*, 2014) (Table 3). Among these, rBPI-21 (comprising the first 193 amino acids of BPI and displaying a Cys132Ala substitution) was the most stable and functional in a murine systemic PA infection model, increasing survival up to 10-fold (Ammons, Kohn & Kung, 1994). The use of rBPI-21 against KP or *E. cloacae* cells in blood/plasma suggested a leukocyte-independent activity, and therefore a direct permeabilization was proposed, although no synergy with antibiotics was seen (Levy *et al.*, 2000). A \approx 2 log unit reduction in multidrug-resistant PA and AB viable cells was shown *in vitro* after 1 h with achievable doses of rBPI-21, although KP remained mostly resistant (Weitz *et al.*, 2013). The Asp190Ala variant of BPI5 (murine BPI fold containing family B, member 5; also known as Bpifb5 or Lplunc5) showed a significant increase in LPS-binding capacity and in *in vitro* antipseudomonal power (Wu *et al.*, 2016). Some synthetic constructs combining fragments of chemokines and functional residues of the BPI β -sheet have shown interesting results: Betapep-25 and its shorter dodecapeptide, SC-4, showed a lethal dose 50 (LD₅₀) at nanomolar range for PA (Lockwood *et al.*, 2004; Dings, Haseman & Mayo, 2008; Dings *et al.*, 2013). Interestingly, SC-4 also improved survival in mice intraperitoneally infected with PA from 9 to 45% (60% in combination with piperacillin-tazobactam) (Dings *et al.*, 2013).

Another BPI superfamily member, SPLUNC1 displays neutrophil chemoattractant activity and inhibits PA growth (Sayeed *et al.*, 2013), properties residing in its 30-residue α -helix called α 4 (Walton *et al.*, 2016). Its α 4 short derivative has shown even better characteristics, including: PA biofilm

preventive and disrupting activity, MICs against multidrug-resistant KP, AB, and PA between 2 and 4 μM , and a 2 log unit decrease in PA burden in murine respiratory infection models (Jiang *et al.*, 2019). GL13K (a fragment including residues 141–153 of BPIFA2, with specific lysine residues replacing the original amino acids and an increased positive charge) displayed direct antipseudomonal activity *in vitro* and reduced mortality (from 85 to 30%) in a murine model of LPS-induced shock (Gorr *et al.*, 2008; Abdolhosseini *et al.*, 2012). A combination of GL13K with tobramycin provided an excellent anti-PA biofilm activity. This was further improved by the D amino-acid version (DGL13K), which was found to be more resistant to proteases (Hirt & Gorr, 2013). DGL13K has been shown to kill PA efficiently in both *G. mellonella* and murine burn wound infection models (Gorr, Flory & Schumacher, 2019).

(vi) *Group IIA secretory phospholipase A2 (GIIA-sPLA2)*. Although GIIA-sPLA2 displays non-negligible activity *in vitro*, it needs the collaboration of permeabilizers to enable its access to the bacterial inner membrane in order to kill Gram-negatives *in vivo* (Dubouix *et al.*, 2003; Nevalainen *et al.*, 2008; Pernet *et al.*, 2014; Dore & Boilard, 2019). Data regarding its potential therapeutic applications are still scarce, with additional research needed. Nevertheless, the available results are encouraging: GIIA-sPLA2 (probably largely through its pro-inflammatory properties) has been shown significantly to increase protection against respiratory infection (not tested to date for ESKAPE Gram-negatives) when exogenously administered/artificially over-expressed in transgenic mice (Wu *et al.*, 2010).

(vii) *Surfactant-associated proteins*. Although SPs do not show synergy with antibiotics (Ferrara, Dos Santos & Lupi, 2001), exogenous administration of human SP-A has been found to increase mouse survival after lung KP infection, from 40% to almost 100% (Thorenoor *et al.*, 2018). Similar results were obtained after the induction of SP-D expression in a rat model of PA respiratory infection (Thacker *et al.*, 2014). The 20-amino-acid fragment derived from the TLR4-interacting region of SP-A (SP-A4) is not directly bactericidal but, when tested in a murine model of respiratory infection, efficiently reduced PA burden, inflammation and tissue damage, suggesting that their action involves opsonization and immunomodulation (Awasthi *et al.*, 2019).

(3) Bacterial envelope-targeting immunity-based treatments under clinical trials

Some envelope-targeting treatments potentially effective against multidrug-resistant Gram-negatives are under clinical trials. Despite preliminary encouraging results against ESKAPE Gram-negatives, most trials [e.g. the BPI derivatives XMP-629 and Neuprex (Koo & Seo, 2019; Mercer *et al.*, 2020) and the histatin-5-derived peptide P-113 (Cheng *et al.*, 2018)] have not involved these pathogens. A 28-residue peptide with antipseudomonal and immunomodulatory activities derived from the human hormone ghrelin, is in phase II trials for the treatment of inflammation in CF

patients (Min *et al.*, 2012). The antipseudomonal and immunomodulatory kininogen-derived peptide, DPK-060 (at 0.5 μM eradicated 10^6 PA cells/ml in 2 h) has finished phase II trials for the treatment of otitis/dermatitis (Butler, Blaskovich & Cooper, 2013; Koo & Seo, 2019; Mercer *et al.*, 2020). For LL-37 and human LF1-11, proposed as treatments for chronic leg ulcer and KP infections, respectively, phase II trials have not been completed (van der Does *et al.*, 2012; Koo & Seo, 2019; Mercer *et al.*, 2020). The bovine indolicidin-derived 12-amino-acid peptide, omiganan (formerly MBI226), shows considerable *in vitro* activity against AB, KP, and PA (Sader *et al.*, 2004; Melo, Dugourd & Castanho, 2006; Melo & Castanho, 2007), although low success against biofilms (Jaśkiewicz *et al.*, 2019). *E. cloacae* load was reduced by 3 log units after topical application of omiganan 1% gel in a pig skin colonization model (Rubinchik *et al.*, 2009). Sadly, although phase II–III trials for skin antiseptic and for acne/dermatitis treatment are ongoing, application against ESKAPE Gram-negatives seems far off (Isaacson, 2003; Septimus & Schweizer, 2016; Koo & Seo, 2019; Mercer *et al.*, 2020).

The 17-amino-acid PG-1 analog, iseganan (also known as IB-367), developed for the treatment of oral mucositis/stomatitis and ventilator associated pneumonia (VAP) prevention, initially displayed very interesting antipseudomonal activity *in vitro*: when tested against exponentially growing PA, a reduction in viability similar to that of polymyxin B was reported (IB 367, 1999; Mosca *et al.*, 2000; Bogucka *et al.*, 2004). In a rat model of chronic respiratory infection, iseganan reduced PA load ≈ 1000 -fold (Fricker, 2002), and it displayed a strong anti-endotoxic capacity useful for the treatment of septic shock, and potent activity against KP (MIC ≈ 5 mg/l) and AB (MIC 2 mg/l) (Chen *et al.*, 2000; Giles *et al.*, 2002; Giacometti *et al.*, 2003a,b; Bogucka *et al.*, 2004). A MIC₉₀ of 16 mg/l was later reported for a larger collection of AB, KP, and PA strains, and a reduction of ca. 3 log units in PA load was achieved through topical iseganan in murine wound infections. Synergistic treatment with colistin/imipenem reduced bacterial counts by 3 additional log units (Simonetti *et al.*, 2014). Nevertheless, iseganan in oral solution as a VAP prophylaxis was found to provide no improvement compared to non-treated patients (Kollef *et al.*, 2006; Muscedere *et al.*, 2008; Li *et al.*, 2013; Messika, La Combe & Ricard, 2018). Topical/mouthwash use of iseganan for mucositis/stomatitis treatment has shown contradictory results in phase III trials (Hashemi *et al.*, 2015; Saunders *et al.*, 2015), either showing no reduction in risk or clinical symptoms (Giles *et al.*, 2004; Trotti *et al.*, 2004) or reducing stomatitis-associated symptoms and oral microbial load, suggesting its applicability as a prophylaxis (although not against ESKAPE Gram-negatives specifically) (Giles *et al.*, 2004; Elad *et al.*, 2012).

The bacterial envelope-targeting peptides closest to clinical application are probably the protegrin analogs murepavadin (formerly POL7080) and its derivative POL7001. Murepavadin is a 14-amino-acid cyclized analog peptidomimetic obtained from PG-1 through the introduction of beta-

hairpin domains. Both murepavadin and POL7001 are derived from L27-11, which was not a valid therapeutic option because of high susceptibility to proteolysis in human serum (Cigana *et al.*, 2016; Romano *et al.*, 2019). These cyclized compounds display specific anti-PA activity through binding and inhibition of the LPS transport protein LptD, therefore blocking outer envelope biogenesis (Srinivas *et al.*, 2010; Andolina *et al.*, 2018). Although their initial MICs were extremely low (0.06 mg/l), the appearance of resistant mutants (MICs >32 mg/l for murepavadin and 8 mg/l for POL7001) has been reported, selected through non-inactivating mutations in *lptD* with low frequency ($\leq 1 \times 10^{-10}$) (Romano *et al.*, 2019). It also has been shown that PA can acquire resistance to murepavadin and POL7001 through non-inactivating mutations in the two-component sensor gene *pmrB*, which involves cross resistance to colistin and PG-1 mediated by LPS modifications. These mutants display much lower resistance levels (MICs up to 1.6 mg/l) than those with altered LptD (Srinivas *et al.*, 2010; Romano *et al.*, 2019).

Regardless of these resistance-related drawbacks, a study with 1219 PA clinical isolates provided a murepavadin MIC₉₀ of 0.12 mg/l, whereas a parallel study, performed using 785 extensively drug resistant isolates (non-susceptible to at least one agent in all but two or fewer antimicrobial categories), found a MIC₉₀ of 0.25 mg/l (eightfold higher activity than colistin) (Sader *et al.*, 2018a,b). In another study, murepavadin activity against CF patient-proceeding PA strains was shown to be weaker (MIC₉₀: 2 mg/l), with a higher MIC₉₀ (8 mg/l) for small colony variants (slow-growing isolates usually selected during CF, characterized by their excellent adaptation to this niche) (Ekkelenkamp *et al.*, 2020). Analyses of pharmacokinetic/pharmacodynamic (PK/PD) parameters in mice indicate that the concentration–time curve for the drug's unbound fraction was better correlated with murepavadin efficacy (Melchers *et al.*, 2019). Six phase I (POL7080-001, NP29332, NP29333, NP29334, POL7080-005, and POL7080-009) and four phase II trials (POL7080-002, POL7080-003, NCT03582007, and NCT03409679) have been completed for murepavadin, with different goals (Dembowsky *et al.*, 2012; Martin-Loeches *et al.*, 2018; Poulakou *et al.*, 2018; Wach, Dembowsky & Dale, 2018; Horcajada *et al.*, 2019). In patients with VAP, intravenous murepavadin treatment achieved clinical cure in 10 out of 12 participants (Armaganidis, Zakyntinos & Mandragos, 2017), but in individuals with impaired renal function, murepavadin clearance was significantly reduced (Dale *et al.*, 2018; Poulakou *et al.*, 2018). Additionally, pivotal phase III studies, POL7080-002, POL7080-003, NCT03582007, and NCT03409679 have been discontinued because of high rates of kidney failure (Polyphor, 2019; Ekkelenkamp *et al.*, 2020; Jabbour, Sharara & Kanj, 2020; Matos De Opitz & Sass, 2020). Although this nephrotoxicity is a disappointment, the development of inhalation-based formulations to avoid this drawback is ongoing, supported by recent *in vivo* models (Bernardini *et al.*, 2019; Polyphor, 2019; Tümmler, 2019; Ekkelenkamp *et al.*, 2020; Jabbour *et al.*, 2020; Provenzani

et al., 2020). Less information is available for POL7001, although *in vitro* activity comparable to murepavadin and therapeutic efficacy in murine models of PA respiratory infection has been demonstrated (Srinivas *et al.*, 2010; Cigana *et al.*, 2016; Romano *et al.*, 2019). Finally, although quite far from the original molecule, some murepavadin-derived compounds (chimeric constructs linked to the peptide macrocycle of polymyxins) have recently been developed and shown to target LPS and the bacterial BamA protein (required for the correct insertion of β -barrel proteins into the outer membrane of Gram-negatives). The *in vitro* activity of some of these membrane biogenesis-targeting constructs (the most successful are compound 3 and 4) is excellent against all ESKAPE Gram-negatives (MICs well below 1 mg/l). Some of these compounds, which also display low eukaryotic toxicity, low propensity for resistance development, satisfactory pharmacokinetics and efficacy in murine infection models, are currently in pre-clinical toxicology studies, and envisaged as very promising (Luther *et al.*, 2019; McLaughlin & Van Der Donk, 2020).

(4) Bacterial targets leading to increased susceptibility to envelope-targeting immune components

In this section we discuss the main recently discovered bacterial targets that can lead to sensitization against mammalian envelope-targeting immunity, potentially useful for the development of future anti-virulence therapies (Bergman *et al.*, 2020; Duperthuy, 2020; Rezzoagli *et al.*, 2020). Advances have been made in the identification of bacterial targets leading to a blockade of the capacity for resistance development to these experimental treatments, for example for the chimeric compounds 3 and 4 mentioned above (Luther *et al.*, 2019; Vitale *et al.*, 2020). A set of 13 genes, many of which are involved in LPS modification, have been identified as drivers of PA resistance to these chimeric compounds, and therefore, disabling these genes would allow us to enhance the chances of therapeutic success (Shang *et al.*, 2020; Vitale *et al.*, 2020).

(a) Peptidoglycan-targeting proteins

Although bacterial muramidase inhibitors (Ivy and MliC/PliC families) are essential for lysozyme resistance in certain Gram-negatives (Callewaert *et al.*, 2012; Zielke *et al.*, 2018; Torrens *et al.*, 2020), knowledge concerning the ESKAPE representatives is scarce. In PA, the protection exerted by these inhibitors seems expendable (Torrens *et al.*, 2017), and although in KP they may be an advantage for infection, their presence is not uniform in clinical strains (Fialkina *et al.*, 2014). Although basic local alignment search tool (BLAST) or other similar tools show that both AB and ES have these inhibitors encoded in their genomes, no studies to date have analysed their therapeutic potential.

The AB capsule provides outstanding protection against lysozyme: a defective mutant is 137-fold more susceptible than the wild-type (Tipton *et al.*, 2018). PA-secreted

rhamnolipid seemingly participates in a complex strategy contributing to lysozyme degradation by host proteases and PA elastase (Andersen *et al.*, 2017). BamB and FabY proteins have also been shown to be essential for PA protection (*in vitro* and in a murine model); their inactivation likely causes cell envelope perturbation leading to increased lysozyme influx (Lee *et al.*, 2017). Peptidoglycan recycling blockade (through *nagZ* or *ampG* deletion) has been demonstrated to raise PA susceptibility to host immune components targeting this structure (including lysozyme and PGLYRPs), after they overcome the permeability barrier in the presence of subinhibitory levels of colistin. The inactivation of Mpl ligase, involved in β -lactam resistance and peptidoglycan recycling, also sensitized PA to lysozyme (Torrens *et al.*, 2017, 2019a). These findings were corroborated *in vivo*: peptidoglycan recycling-defective mutants showed attenuated virulence (increased mouse survival and decreased PA load), whereas subtherapeutic colistin cleared systemic infection by these mutants, likely through synergy with the endogenous peptidoglycan-targeting immunity (Torrens *et al.*, 2019b).

(b) Bacterial membranes interaction-based immune components

There are many strategies by which bacteria resist the action of membrane-targeting immune components, mainly relying on their surface structures. Among these, LPS modification, usually of transient nature, is one of the most important (Guilhelmelli *et al.*, 2013; Nuri, Shprung & Shai, 2015; Abdi, Mirkalantari & Amirmozafari, 2019; Duperthuy, 2020). For example, the attachment of aminoarabinose to lipid A contributes to PA resistance against hBD-2 and PG-1, and also to KP survival (Moskowitz, Ernst & Miller, 2004; Cheng, Chen & Peng, 2010; Lam *et al.*, 2011; Abdi *et al.*, 2019). Lipid A hepta-acylation (mediated by Lpx acyltransferases) enables AB resistance to certain CAMPs (Boll *et al.*, 2015) and LpxO-dependent hydroxylation protects against hBD-3 (Bartholomew *et al.*, 2019). Lipid A acylation (mediated by LpxM) also protects KP, especially against defensins (Clements *et al.*, 2007). LpxL2 acyltransferase also has been shown to participate in KP lipid A acylation, which is necessary for survival in *G. mellonella* (Mills *et al.*, 2017). These modifications are generally governed by two-component systems responding to stress (e.g. PmrAB, PhoPQ), and therefore could represent therapeutic targets (Moskowitz *et al.*, 2004; Gooderham & Hancock, 2009; Beceiro *et al.*, 2011; Bhagirath *et al.*, 2019).

In KP the capsule plays a prominent role in protection against host defences: the majority of clinical strains express a pronounced capsule causing the characteristic mucoid phenotype. This anionic polysaccharide provides a physical barrier against envelope-targeting elements, but also works through the release of fragments that act as decoys (Campos *et al.*, 2004; Llobet, Tomás & Bengochea, 2008). Capsule-defective mutants display increased susceptibility to defensins, lactoferrin-derived CAMPs, and Hst5 (Campos *et al.*, 2004; Llobet *et al.*, 2008; Du *et al.*, 2017). The KP capsule additionally masks certain epitopes to avoid

their detection and reduce the host's expression of antimicrobial peptides and inflammatory mediators (Moranta *et al.*, 2010). Therefore, any participant in capsule production (e.g. the *cps* operon, *dsbC*, *wzm/t*, *ycgE*, etc.) can be seen as a potential anti-KP target (Wyres *et al.*, 2016).

Other surface-related protective strategies include the MprF protein-mediated addition of positively charged L-alanine to membranes, causing repulsion of CAMPs (Klein *et al.*, 2009; Abdi *et al.*, 2019), and the regulator PsrA, which promotes the expression of genes involved in PA membrane impermeability and derived resistance against indolicidin (Gooderham *et al.*, 2008; Abdi *et al.*, 2019). Type IV pili and their correct glycosylation have been shown to contribute to resistance to SPs, likely because these structures contribute to PA membrane integrity (Tan *et al.*, 2015). Also linked to correct envelope structure, *pch* and *ptsP* have been described to participate in PA resistance to SP-A (Zhang *et al.*, 2005). KP OmpA is essential for protection against HNP-1 (Llobet *et al.*, 2009), whereas its AB homolog is key for resistance to LL-37 (Lin *et al.*, 2015b). Finally, KP peptidoglycan-associated and murein lipoproteins are needed for serum resistance and full virulence, likely because they contribute to cell wall integrity (Hsieh *et al.*, 2013).

Biofilm formation is another strategy that protects bacteria against host defences. PA biofilm, mainly made up of alginate, is a paradigmatic example of how this extracellular element acts as a physical barrier to the diffusion of immune mediators/antibiotics (Thi, Wibowo & Rehm, 2020). Alginate induces conformational changes in CAMPs similar to those occurring when they insert into membranes, thereby preventing them from interacting with the PA surface. Alginate also induces aggregation of CAMPs, hampering their diffusion (Chan, Burrows & Deber, 2005; Benincasa *et al.*, 2009; Foschiatti *et al.*, 2009; Guilhelmelli *et al.*, 2013). Thus, any participant in the complex pathways responsible for alginate production (and other polymers produced by PA) and biofilm formation is a potential antipseudomonal target (Thi *et al.*, 2020).

Production of proteases is another strategy studied in detail in PA: LasB degrades LL-37 in human wounds (Schmidtchen *et al.*, 2002), as well as SP-A/-D (Alcorn & Wright, 2004; Kuang *et al.*, 2011b). These proteins are also degraded by PA protease IV, which impairs pulmonary surfactant function (Malloy *et al.*, 2005). Interestingly, PA flagellum-defective mutants produce an insufficient quantity of exoproteases to degrade SP-A, leading to their increased clearance in mouse lungs. This defective protease production apparently also renders PA unable to degrade lysozyme (Kuang *et al.*, 2011a). The other ESKAPE Gram-negatives are not known to produce this type of proteases (Lindsay, Oates & Bourdillon, 2017), a topic worthy to investigate further to unveil potential bacterial weak points. Some studies showed the production of proteases by AB that lead to immunoglobulin A (IgA) degradation (Diebel *et al.*, 2009), suggesting that AB and other ESKAPE Gram-negatives may produce mediators that contribute to the inactivation of envelope-targeting immunity.

Finally, unlike AB, ES, or PA (Rieg *et al.*, 2009), in which there is little extrusion of immune compounds, efflux enables KP resistance against certain CAMPs. More specifically, the AcrAB-TolC system contributes to resistance against HNP-1, hBD-1, and hBD-2, with the expression of this pump essential for full virulence in a murine model (Padilla *et al.*, 2010; Veleba *et al.*, 2012). The well-known role of efflux pumps in antibiotic resistance adds interest to their use as anti-virulence targets, which would not only boost the power of CAMPs, but also enable the re-use of classic antibiotics. In this regard, it has been proposed that bacteria may display increased susceptibility to envelope-targeting immunity when they exert responses to antibiotic challenge (or *vice versa*). Besides the examples cited throughout this review, other studies have demonstrated clear synergy for quinolones plus hBD-1 or HNP-1 against KP and PA (Campos *et al.*, 2006), and enhanced PA susceptibility to ciprofloxacin promoted by HNP-3, likely because these CAMPs activate a massive ATP efflux reducing drug expulsion in exchange (Wang, Dong & Lou, 2011a). A similar pattern is seen for indolicidin derivatives, based on the fact that these peptides inhibit phosphotransferase/acetyltransferase activities, mechanisms on which aminoglycoside resistance strongly depends (Boehr *et al.*, 2003; Ruden *et al.*, 2019). Finally, avibactam treatment has been shown to sensitize KP against LL-37, probably because this β -lactamase inhibitor alters cell wall mechanics in this species (Ulloa *et al.*, 2019).

(5) Host-related targets that improve the performance of bacterial envelope-targeting immune components

Besides bacterial targets that could reduce pathogen resistance to envelope-targeting immunity, other host-related alternatives might improve its performance. In this regard, PA stimulates the production of host cathepsins B, L, and S, which are proteases affecting hBD-2/-3 (Taggart *et al.*, 2003). Besides acting in the direct degradation of host immune compounds, the PA proteases AprA, LasA, and LasB also affect certain host proteins such as decorin, an extracellular matrix constituent. Decorin degradation releases dermatan sulfate that binds to α -defensins, abrogating their bactericidal activity (Schmidtchen, Frick & Björck, 2001). Similarly, the degradation of heparan sulfate proteoglycans by LasA causes the release of free syndecan-1 that neutralizes several CAMPs (Park *et al.*, 2001). More recently, PA rhamnolipid has been shown to interfere with the host's protein kinase C pathways, leading to a decrease in hBD-2 and inflammatory mediator production (Dössel *et al.*, 2012). Therefore, any treatment interfering with these mechanisms could trigger increased bacterial envelope-targeting immune effectiveness, a field worthy of further development.

Other host elements may also be considered as direct therapeutic allies to improve immune performance. For instance, boosting the production of specific immune components such as β -defensin-2, which is below the normal range in COPD

patients (Arnason *et al.*, 2017), could help limit the spread of infection in this context but possibly also in other situations. Moreover, it may also be possible to harness the immunomodulatory power of other immune resources. For instance, PGLYRP2 has been shown to increase inflammation and reduce the expression of CAMPs during infection, thus silencing its expression could potentially improve the clinical outcome in specific cases (Gowda *et al.*, 2015). Conversely, lysozyme displays an anti-inflammatory capacity in certain contexts; therefore, increasing its expression could provide benefits to the host and in bactericidal activity (Ganz *et al.*, 2003). Minimizing the expression of certain host proteases/peptidases such as those discussed above could increase the half-life of endogenous or exogenously administered immune elements (Mardirossian *et al.*, 2016). Additionally, modulating some features in specific patient profiles could improve immune performance, for example: overproduction of cathepsins (mainly in CF and/or COPD) (Taggart *et al.*, 2003; Dalcin & Ulanova, 2013); docosahexaenoic acid levels below normal values in CF, which impairs lysozyme performance (Martinez *et al.*, 2009); expression of autoantibodies in CF, which bind to BPI and dramatically reduce its activity (Carlsson *et al.*, 2011); host expression of dipeptidyl peptidase I, shown to degrade SP-D, which in turn favours KP survival *in vivo* (Sutherland *et al.*, 2014); and modulation of oxidative stress in CF patients that dampens SP-A/-D natural defences (Kuzmenko *et al.*, 2005; Starosta & Griese, 2006). Finally, in a step closer to therapeutic applications, experimental treatments disabling the neutrophil elastase-mediated degradation of SPLUNC1 in the lungs have shown positive effects in alleviating PA infection severity in mice (Nichols *et al.*, 2015).

IV. RESOURCES YET TO BE EXPLOITED: NOVEL HUMAN ANTIMICROBIAL PEPTIDES TARGETING THE GRAM-NEGATIVE ENVELOPE

Some inconspicuous peptides (known as 'cryptides') released through the action of bacterial/host proteases have recently been identified within larger human non-immune proteins, often displaying membrane disruption-based antimicrobial activity (Pane *et al.*, 2017, 2016). Three cryptides have been found within pepsinogen A3 (PAP-A3, IMY25 and FLK22) that show activity against AB, KP, and PA (Pane *et al.*, 2018). PAP-A3 stood out in reducing the PA burden (by 4 log units) in a murine skin abscess model, whereas IMY25 showed the greatest antibiofilm capacity, likely because alginate does not significantly sequester it (Pane *et al.*, 2018). Human apolipoproteins are also a source of cryptides [e.g. r(P)ApoBL, r(P)ApoBS, etc.] that display non-negligible anti-inflammatory and anti-KP or anti-PA activities *in vitro* (Pane *et al.*, 2016; Zanfardino *et al.*, 2018; Gaglione *et al.*, 2020).

Some cryptides have been identified in coagulation-related proteins, e.g. GKY25, released from pro-thrombin/

thrombin and found in wounds (Van Der Plas *et al.*, 2016; Saravanan *et al.*, 2018). Although GKY25 displays limited bactericidal capacity, when tested in murine models of PA systemic infection or LPS-induced shock, large increases in survival were reported (from 0 to 60% and 0 to 90%, respectively) (Papareddy *et al.*, 2010a; Merza *et al.*, 2014), likely due to its capacity to modulate monocyte/macrophage responses and neutrophil rolling/migration (Hansen *et al.*, 2017; Lim *et al.*, 2017). Its shorter derivative, GKY20, whose carpet-like mechanism is well understood, shows similar features with reduced toxicity (Oliva *et al.*, 2019). The thrombin-derived fragment TCP96 molecules bind to each other to form aggregates with LPS, obviously with an anti-endotoxin role, and also with entire bacteria, boosting phagocytosis. This has been proved in murine models of subcutaneous infection and LPS challenge, in which PA load and inflammation were significantly decreased (Petrlova *et al.*, 2020). Some peptides derived from anti-thrombin III (e.g. FFF21) killed PA *in vitro* and reduced infection burden (by 5 log units) in a murine model of peritoneal infection, but oddly, did not increase mouse survival (Papareddy *et al.*, 2014). The heparin cofactor II-derived peptide KYE28 displays significant LPS-neutralizing capacity *in vitro/ex vivo*, reproduced in murine models of LPS-induced shock and sepsis, increasing mouse survival (by more than 70%) and reducing PA load (Kalle *et al.*, 2014).

Other cryptides with comparable activity to LL-37 have been identified, such as GVF27 (released from 11-hydroxysteroid dehydrogenase-1 β) (Bosso *et al.*, 2016); RQA21, corresponding to the C-terminus of extracellular superoxide dismutase (Pasupuleti *et al.*, 2009a); and MAN28, KKR20, and LVL20 [all released from the human cellular prion protein PrP(c)] (Pasupuleti *et al.*, 2009b). The *in vitro* antimicrobial power of the anti-endotoxin peptide YR26, derived from the cationic region of furin, is substantial, with MICs \approx 4 μ M for KP and PA (Sinha *et al.*, 2018).

Hornerin is one of the main protein components of epidermal cornified cell envelopes, and its derived peptides released by the action of skin proteases and generically known as cationic intrinsically disordered antimicrobial peptides (CIDAMPs) have exhibited excellent antipseudomonal activity, with MICs \approx 0.3 mg/l (Latendorf *et al.*, 2019). Their artificial derivatives obtained by palmitoylation display even greater anti-KP and anti-PA power, relying on a strong membrane-disruption capacity in addition to their constitutive ribosome-targeting activity (Latendorf *et al.*, 2019). The peptides GGL27 and EDC34, derived from the tissue factor pathway inhibitors TFPI-1 and TFP-2, share similar antipseudomonal activities *in vitro*, with some differences (Papareddy *et al.*, 2010b, 2012, 2013): GGL27 treatment barely increased mouse survival after PA systemic infection, whereas in a LPS-induced shock model, survival rose from 0 to 50% Papareddy *et al.*, 2010b). Conversely, EDC34 was incapable of neutralizing LPS-linked inflammation, but in a PA sepsis model increased mouse survival to 70% (Papareddy

et al., 2013). Activation of the complement cascade and immunoglobulin binding were proposed to contribute to this activity (Ali *et al.*, 2018).

V. CONCLUSIONS

- (1) There is a large body of research showing that mammalian bacterial envelope-targeting immunity has important therapeutic potential against ESKAPE Gram-negatives, notably yet to be explored/exploited, and with variable chances of success depending on pathogen species. It is noteworthy that much of the information published refers to PA, AB, and KP, but there is an important gap regarding our knowledge on ES that must be filled.
- (2) The large number of studies showing at least partially contradictory results regarding the *in vitro* activity of a given immune component and the discrepancies between *in vitro/in vivo* results in some cases, raise a number of unsolved questions that must be addressed to enable the successful development of therapies.
- (3) There is limited information on PK/PD parameters or resistance development dynamics regarding bacterial envelope-targeting immunity-based treatments. Such knowledge will be essential for designing robust therapeutic options. Proteolytic degradation, sequestration by host tissues, toxicity at high doses, and the need for a vehicle to allow suitably high concentrations at infection sites are also critical questions to be studied in more detail.
- (4) Although some encouraging results have been found *in vitro* and/or *in vivo* for certain treatments (histatin derivatives, tritrypticin, BPI and SPLUCN1 derivatives, KDAMPs, GIIA-sPLA2, etc.), many research lines related to these findings have been discontinued. To extend these studies is essential, as is the initiation of new clinical trials for the most promising treatments (e.g. iseganan or murepavadin and its derivatives).
- (5) Although preliminary *in vitro* and *in vivo* models showed promising results against ESKAPE Gram-negatives for some experimental treatments, their intended use in clinical trials is often reduced to mild infections and/or for other species. Research projects for their application against ESKAPE Gram-negatives and/or severe infections must be restored.
- (6) There are likely to be additional antimicrobial peptides discovered in other mammals or even in our own species, hidden in the sequences of larger proteins (cryptides) and whose anti-ESKAPE Gram-negatives potential must be studied.
- (7) Although less studied and therefore still far from entry into clinical practice, there are other potential targets in the biology of ESKAPE Gram-negatives and in the host that could be investigated with respect to

developing novel anti-virulence treatments, reducing pathogen resistance and improving the performance of our bacterial envelope-targeting immunity. This new concept for therapy development is a promising option that has been barely explored to date.

VI. ACKNOWLEDGEMENTS AND AUTHOR CONTRIBUTIONS

This work was supported by the Balearic Islands Government grants FPI/2206/2019 and FOLIUM17/04, the Spanish Network for Research in Infectious Diseases (RD16/0016/0004) and grants CPII17/00017, PI18/00681, PI18/00076 and PI21/00753 Instituto de Salud Carlos III (Spain), cofinanced by the European Regional Development Fund.

Author contributions: M. E.-S.: investigation (bibliography collection), writing (original draft preparation); G. T.: investigation (bibliography collection), writing (original draft preparation); E. J.-L.: investigation (bibliography collection), writing (original draft preparation); A.O.: funding acquisition, supervision, writing (review & editing); C.J.: conceptualization, funding acquisition, visualization, writing (original draft preparation, review & editing), supervision, validation.

VII. REFERENCES

- ABDI, M., MIRKALANTARI, S. & AMIRMOZAFARI, N. (2019). Bacterial resistance to antimicrobial peptides. *Journal of Peptide Science* **25**, e3210.
- ABDOLHOSSEINI, M., NANDULA, S. R., SONG, J., HIRT, H. & GORR, S. U. (2012). Lysine substitutions convert a bacterial-agglutinating peptide into a bactericidal peptide that retains anti-lipoplysaccharide activity and low hemolytic activity. *Peptides* **35**, 231–238.
- AKINBI, H. T., EPAUD, R., BHATT, H. & WEAVER, T. E. (2000). Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. *Journal of Immunology* **165**, 5760–5766.
- ALAIWA, M. H. A., REZNIKOV, L. R., GANSEMER, N. D., SHEETS, K. A., HORSWILL, A. R., STOLTZ, D. A., ZABNER, J. & WELSH, M. J. (2014). pH modulates the activity and synergism of the airway surface liquid antimicrobials β -defensin-3 and LL-37. *Proceedings of the National Academy of Sciences of the United States of America* **111**, 18703–18708.
- ALARCON, I., TAM, C., MUN, J. J., LE DUE, J., EVANS, D. J. & FLEISZIG, S. M. J. (2011). Factors impacting corneal epithelial barrier function against *Pseudomonas aeruginosa* traversal. *Investigative Ophthalmology & Visual Science* **52**, 1368–1377.
- ALBRECHT, M. T., WANG, W., SHAMOVA, O., LEHRER, R. I. & SCHILLER, N. L. (2002). Binding of protegrin-1 to *Pseudomonas aeruginosa* and *Burkholderia cepacia*. *Respiratory Research* **3**, 18.
- ALCORN, J. F. & WRIGHT, J. R. (2004). Degradation of pulmonary surfactant protein D by *Pseudomonas aeruginosa* elastase abrogates innate immune function. *Journal of Biological Chemistry* **279**, 30871–30879.
- ALI, M., UMSTEAD, T. M., HAQUE, R., MIKEROV, A. N., FREEMAN, W. M., FLOROS, J. & PHELPS, D. S. (2010). Differences in the BAL proteome after *Klebsiella pneumoniae* infection in wild type and SP-A^{-/-} mice. *Proteome Science* **8**, 34.
- ALI, M. N., KASETTY, G., ELVÉN, M., ALYAFEI, S., JOVIC, S., EGESTEN, A., HERWALD, H., SCHMIDTCHEN, A. & PAPAREDDY, P. (2018). TFPI-2 protects against gram-negative bacterial infection. *Frontiers in Immunology* **9**, 2072.
- AMERIKOVA, M., PENCHEVA EL-TIBI, I., MASLARSKA, V., BOZHANOV, S. & TACHKOV, K. (2019). Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents. *Biotechnology & Biotechnological Equipment* **33**, 671–682.
- AMMONS, W. S., KOHN, F. R. & KUNG, A. H. C. (1994). Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties. *Journal of Infectious Diseases* **170**, 1473–1482.
- ANDERSEN, K. K., VAD, B. S., SCAVENIUS, C., ENGHILD, J. J. & OTZEN, D. E. (2017). Human lysozyme peptidase resistance is perturbed by the anionic glycolipid biosurfactant rhamnolipid produced by the opportunistic pathogen *Pseudomonas aeruginosa*. *Biochemistry* **56**, 260–270.
- ANDOLINA, G., BENCZE, L. C., ZERBE, K., MÜLLER, M., STEINMANN, J., KOCHERLA, H., MONDAL, M., SOBEK, J., MOEHLE, K., MALOJČIĆ, G., WOLLSCHIED, B. & ROBINSON, J. A. (2018). A peptidomimetic antibiotic interacts with the periplasmic domain of LptD from *Pseudomonas aeruginosa*. *ACS Chemical Biology* **13**, 666–675.
- ANDRÁ, J., LOHNER, K., BLONDELLE, S. E., JERALA, R., MORIYON, I., KOCH, M. H. J., GARIDEL, P. & BRANDENBURG, K. (2005). Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide. *Biochemical Journal* **385**, 135–143.
- ARIAS, M., HOFFARTH, E. R., ISHIDA, H., ARAMINI, J. M. & VOGEL, H. J. (2016). Recombinant expression, antimicrobial activity and mechanism of action of tritrypticin analogs containing fluoro-tryptophan residues. *Biochimica et Biophysica Acta - Biomembranes* **1858**, 1012–1023.
- ARIAS, M., FIGA, K. B., HYNDMAN, M. E. & VOGEL, H. J. (2018). Improving the activity of trp-rich antimicrobial peptides by Arg/Lys substitutions and changing the length of cationic residues. *Biomolecules* **8**, 19.
- ARMAGANIDIS, A., ZAKYNTHINOS, S. & MANDRAGOS, C. (2017). *Efficacy of Murepavadin Coadministered with Standard of Care in a Phase 2 Study in Patients with Ventilator-Associated Pneumonia Due to Suspected or Documented Pseudomonas aeruginosa Infections, Poster A459*. Belgium, Brussels.
- ARNASON, J. W., MURPHY, J. C., KOOL, C., WIEHLER, S., TRAVES, S. L., SHELFON, C., MACLEJEWski, B., DUMONCEAUX, C. J., LEWENZA, W. S., PROUD, D. & LEIGH, R. (2017). Human β -defensin-2 production upon viral and bacterial coinfection is attenuated in COPD. *PLoS One* **12**, 1–19.
- AUGUSTIN, D. K., HEIMER, S. R., TAM, C., LI, W. Y., LE DUE, J. M., EVANS, D. J. & FLEISZIG, S. M. J. (2011). Role of defensins in corneal epithelial barrier function against *Pseudomonas aeruginosa* traversal. *Infection and Immunity* **79**, 595–605.
- AWASTHI, S., SINGH, B., RAMANI, V., XIE, J. & KOSANKE, S. (2019). TLR4-interacting SPA4 peptide improves host defense and alleviates tissue injury in a mouse model of *Pseudomonas aeruginosa* lung infection. *PLoS One* **14**, e0210979.
- BALAKRISHNAN, A., MARATHE, S. A., JOGLEKAR, M. & CHAKRAVORTY, D. (2013). Bactericidal/permeability increasing protein: a multifaceted protein with functions beyond LPS neutralization. *Innate Immunity* **19**, 339–347.
- BALS, R., WANG, X., MEEGALLA, R. L., WATTLER, S., WEINER, D. J., NEHLS, M. C. & WILSON, J. M. (1999a). Mouse β -defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. *Infection and Immunity* **67**, 3542–3547.
- BALS, R., WEINER, D. J., MOSCIONI, A. D., MEEGALLA, R. L. & WILSON, J. M. (1999b). Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. *Infection and Immunity* **67**, 6084–6089.
- BANAS, M., ZABIEGLO, K., KASETTY, G., KAPINSKA-MROWIECKA, M., BOROWCZYK, J., DRUKALA, J., MURZYN, K., ZABEL, B. A., BUTCHER, E. C., SCHROEDER, J. M., SCHMIDTCHEN, A. & CICHY, J. (2013). Chemerin is an antimicrobial agent in human epidermis. *PLoS One* **8**, e58709.
- BARBOSA, M., COSTA, F., MONTEIRO, C., DUARTE, F., MARTINS, M. C. L. & GOMES, P. (2019). Antimicrobial coatings prepared from Dhvar-5-click-grafted chitosan powders. *Acta Biomaterialia* **84**, 242–256.
- BARTHOLOMEW, T. L., KIDD, T. J., PESSOA, J. S., ÁLVAREZ, R. C. & BENGOCHEA, J. A. (2019). 2-hydroxylation of *Acinetobacter baumannii* lipid A contributes to virulence. *Infection and Immunity* **87**, e00066-19.
- BEAUMONT, P. E., MCHUGH, B., FINDLAY, E. G., MACKELLAR, A., MACKENZIE, K. J., GALLO, R. L., GOVAN, J. R. W., SIMPSON, A. J. & DAVIDSON, D. J. (2014). Cathelicidin host defence peptide augments clearance of pulmonary *Pseudomonas aeruginosa* infection by its influence on neutrophil function in vivo. *PLoS One* **9**, e99029.
- BECEIRO, A., LLOBET, E., ARANDA, J., BENGOCHEA, J. A., DOUMITH, M., HORNSEY, M., DHANJI, H., CHART, H., BOU, G., LIVERMORE, D. M. & WOODFORD, N. (2011). Phosphoethanolamine modification of lipid A in colistin-resistant variants of *Acinetobacter baumannii* mediated by the *pmrAB* two-component regulatory system. *Antimicrobial Agents and Chemotherapy* **55**, 3370–3379.
- BELLAMY, W., TAKASE, M., WAKABAYASHI, H., KAWASE, K. & TOMITA, M. (1992). Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. *Journal of Applied Bacteriology* **73**, 472–479.
- BENINCASA, M., MATTIUZZO, M., HERASIMENKA, Y., CESCUTTI, P., RIZZO, R. & GENNARO, R. (2009). Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens. *Journal of Peptide Science* **15**, 595–600.
- BENSMAN, T. J., JAYNE, J. G., SUN, M., KIMURA, E., MEINERT, J., WANG, J. C., SCHAAL, J. B., TRAN, D., RAO, A. P., AKBARI, O., SELSTED, M. E. & BERINGER, P. M. (2017). Efficacy of rhesus theta-defensin-1 in experimental

- models of *Pseudomonas aeruginosa* lung infection and inflammation. *Antimicrobial Agents and Chemotherapy* **61**, e00154–e00117.
- BERA, S., GHOSH, A., SHARMA, S., DEBNATH, T., GIRI, B. & BHUNIA, A. (2015). Probing the role of proline in the antimicrobial activity and lipopolysaccharide binding of indolicidin. *Journal of Colloid and Interface Science* **452**, 148–159.
- BERGMAN, P., RAQIB, R., REKHA, R. S., AGERBERTH, B. & GUDMUNDSSON, G. H. (2020). Host directed therapy against infection by boosting innate immunity. *Frontiers in Immunology* **11**, 1209.
- BERINGER, P. M., BENSMAN, T. J., HO, H., AGNELLO, M., DENOVEL, N., NGUYEN, A., WONG-BERINGER, A., SHE, R., TRAN, D. Q., MOSKOWITZ, S. M. & SELSTED, M. E. (2016). Rhesus O-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of *Pseudomonas aeruginosa*. *Journal of Antimicrobial Chemotherapy* **71**, 181–188.
- BERNARDINI, F., DALE, G. E., WACH, A. & OBRECHT, D. (2019). Pharmacokinetics and pharmacodynamics of murepavadin (POL7080) in neutropenic lung infection models when evaluated by aerosol administration. *Journal of Cystic Fibrosis* **18**, S2.
- BHAGIRATH, A. Y., LI, Y., PATIDAR, R., YEREX, K., MA, X., KUMAR, A. & DUAN, K. (2019). Two component regulatory systems and antibiotic resistance in gram-negative pathogens. *International Journal of Molecular Sciences* **20**, 1781.
- BHAVSAR, T., LIU, M., HARDEJ, D., LIU, X. & CANTOR, J. (2010). Aerosolized recombinant human lysozyme ameliorates *Pseudomonas aeruginosa*-induced pneumonia in hamsters. *Experimental Lung Research* **36**, 94–100.
- BHAVSAR, T., LIU, M., LIU, X. & CANTOR, J. (2011). Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of *Pseudomonas aeruginosa*-induced pneumonia. *Experimental Lung Research* **37**, 536–541.
- BLUMENTHAL, I., DAVIS, L. R., BERMAN, C. M. & GRISWOLD, K. E. (2021). Nonclassical antagonism between human lysozyme and AMPs against *Pseudomonas aeruginosa*. *FEBS Open Bio* **11**, 705–713.
- BOBROVSKY, P., MANUVERA, V., POLINA, N., PODGORNY, O., PRUSAKOV, K., GOVORUN, V. & LAZAREV, V. (2016). Recombinant human peptidoglycan recognition proteins reveal antichlamydial activity. *Infection and Immunity* **84**, 2124–2130.
- BOEHR, D. D., DRAKER, K. A., KOTEVA, K., BAINS, M., HANGCOCK, R. E. & WRIGHT, G. D. (2003). Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes. *Chemistry and Biology* **10**, 189–196.
- BOGUCKA, K., KRÓLICKA, A., KAMYSZ, W., OSSOWSKI, T., LUKASIAK, J. & LOJKOWSKA, E. (2004). Activities of synthetic peptides against human pathogenic bacteria. *Polish Journal of Microbiology* **53**, 41–44.
- BOLL, J. M., TUCKER, A. T., KLEIN, D. R., BELTRAN, A. M., BRODBELT, J. S., DAVIES, B. W. & TRENT, M. S. (2015). Reinforcing lipid acylation on the cell surface of *Acinetobacter baumannii* promotes cationic antimicrobial peptide resistance and desiccation survival. *MBio* **6**, e00478–e00415.
- BONECA, I. G. (2009). Mammalian PGRPs in the spotlight. *Cell Host and Microbe* **5**, 109–111.
- BOPARAI, J. K. & SHARMA, P. K. (2019). Mini review on antimicrobial peptides, sources, mechanism and recent applications. *Protein and Peptide Letters* **27**, 4–16.
- BOSSO, A., PIRONE, L., GAGLIONE, R., PANE, K., DEL GATTO, A., ZACCARO, L., DI GAETANO, S., DIANA, D., FATTORUSSO, R. & PEDONE, E. (2016). A new cryptic host defense peptide identified in human 11-hydroxysteroid dehydrogenase-1 β -like: from in silico identification to experimental evidence. *Biochimica et Biophysica Acta - General Subjects* **1861**, 2342.
- BROGDEN, K. A., KALFA, V. C., ACKERMANN, M. R., PALMQUIST, D. E., MCCRAY, J. & TACK, B. F. (2001). The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection. *Antimicrobial Agents and Chemotherapy* **45**, 331–334.
- BRUNI, N., CAPUCCHIO, M. T., BIASIBETTI, E., PESSIONE, E., CIRRINCIONE, S., GIRAUDO, L., CORONA, A. & DOSIO, F. (2016). Antimicrobial activity of lactoferrin-related peptides and applications in human and veterinary medicine. *Molecules* **21**, 752.
- BUTLER, M. S., BLASKOVICH, M. A. & COOPER, M. A. (2013). Antibiotics in the clinical pipeline in 2013. *The Journal of Antibiotics* **66**, 571–591.
- CALLEWAERT, L. & MICHELIS, C. W. (2010). Lysozymes in the animal kingdom. *Journal of Biosciences* **35**, 127–160.
- CALLEWAERT, L., VAN HERREWEGHE, J. M., VANDERKELEN, L., LEYSEN, S., VOET, A. & MICHELIS, C. W. (2012). Guards of the great wall: bacterial lysozyme inhibitors. *Trends in Microbiology* **20**, 501–510.
- CAMPOS, M. A., MOREY, P. & BENGOCHEA, J. A. (2006). Quinolones sensitize Gram-negative bacteria to antimicrobial peptides. *Antimicrobial Agents and Chemotherapy* **50**, 2361–2367.
- CAMPOS, M. A., VARGAS, M. A., REGUEIRO, V., LLOMPART, C. M., ALBERTÍ, S. & BENGOCHEA, J. A. (2004). Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. *Infection and Immunity* **72**, 7107–7114.
- CAÑADAS, O., GARCÍA-VERDUGO, I., KEOUGH, K. M. W. & CASALS, C. (2008). SP-A permeabilizes lipopolysaccharide membranes by forming protein aggregates that extract lipids from the membrane. *Biophysical Journal* **95**, 3287–3294.
- CARDOSO, M. H., MENEGUETTI, B. T., COSTA, B. O., BUCCINI, D. F., OSHIRO, K. G. N., PREZA, S. L. E., CARVALHO, C. M. E., MIGLIOLLO, L. & FRANCO, O. L. (2019). Non-lytic antibacterial peptides that translocate through bacterial membranes to act on intracellular targets. *International Journal of Molecular Sciences* **20**, 4877.
- CARLSSON, M., SHUKLA, S., PETERSSON, A. C., SEGELMARK, M. & HELLMARK, T. (2011). *Pseudomonas aeruginosa* in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease. *Journal of Cystic Fibrosis* **10**, 265–271.
- CASAL, D., IRIA, I., RAMALHO, J. S., ALVES, S., MOTA-SILVA, E., MASCARENHAS-LEMOS, L., PONTINHA, C., GUADALUPE-CABRAL, M., FERREIRA-SILVA, J., FERRAZ-OLIVEIRA, M., VASSILENKO, V., GOYRI-O'NEILL, J., PAIS, D. & VIDEIRA, P. A. (2019). BD-2 and BD-3 increase skin flap survival in a model of ischemia and *Pseudomonas aeruginosa* infection. *Scientific Reports* **9**, 1–19.
- CECCARELLI, A., COLE, A., PARK, A., TAHK, S., YOSHIOKA, D. & GANZ, T. (2001). Therapeutic effect of a pig-derived peptide antibiotic on porcine wound infections. *Comparative Medicine* **51**, 75–79.
- CHAN, C., BURROWS, L. L. & DEBER, C. M. (2005). Alginate as an auxiliary bacterial membrane: binding of membrane-active peptides by polysaccharides. *Journal of Peptide Research* **65**, 343–351.
- CHAUHAN, J., CARDINALE, S., FANG, L., HUANG, J., KWASNY, S. M., ROSS PENNINGTON, M., BASI, K., DITARGIANI, R., CAPACIO, B. R., MACKERELL, A. D., OPPERMAN, T. J., FLETCHER, S. & DE LEEUW, E. P. H. (2016). Towards development of small molecule lipid II inhibitors AS novel antibiotics. *PLoS One* **11**, e0164515.
- CHEN, H., WUBBOLTS, R. W., HAAGSMAN, H. P. & VELDHIJZEN, E. J. A. (2018a). Inhibition and eradication of *Pseudomonas aeruginosa* biofilms by host defence peptides. *Scientific Reports* **8**, 10446.
- CHEN, J., FALLA, T. J., LIU, H., HURST, M. A., FUJII, C. A., MOSCA, D. A., EMBREE, J. R., LOURY, D. J., RADEL, P. A., CHENG CHANG, C., GU, L. & FIDDES, J. C. (2000). Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. *Biopolymers* **55**, 88–98.
- CHEN, R., COLE, N., DUTTA, D., KUMAR, N. & WILLCOX, M. D. P. (2017). Antimicrobial activity of immobilized lactoferrin and lactoferricin. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* **105**, 2612–2617.
- CHEN, X., LIU, J., ZHOU, J., WANG, J., CHEN, C., SONG, Y. & PAN, J. (2018b). Urban particulate matter (PM) suppresses airway antibacterial defence. *Respiratory Research* **19**, 1–11.
- CHENG, H. Y., CHEN, Y. F. & PENG, H. L. (2010). Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in *Klebsiella pneumoniae* CG43. *Journal of Biomedical Science* **17**, 60.
- CHENG, K. T., WU, C. L., YIP, B. S., YU, H. Y., CHENG, H. T., CHIH, Y. H. & CHENG, J. W. (2018). High level expression and purification of the clinically active antimicrobial peptide P-113 in *Escherichia coli*. *Molecules* **23**, 800.
- CHENNUPATI, S. K., CHIU, A. G., TAMASHIRO, E., BANKS, C. A., COHEN, M. B., BLEIER, B. S., KOFONOW, J. M., TAM, E. & COHEN, N. A. (2009). Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm *Pseudomonas sinusitis*. *American Journal of Rhinology & Allergy* **23**, 46–51.
- CHILEVERU, H. R., LIM, S. A., CHAIRATANA, P., WOMMACK, A. J., CHIANG, I. L. & NOLAN, E. M. (2015). Visualizing attack of *Escherichia coli* by the antimicrobial peptide human defensin 5. *Biochemistry* **54**, 1767–1777.
- CIGANA, C., BERNARDINI, F., FACCHINI, M., ALCALÁ-FRANCO, B., RIVA, C., DE FINO, I., ROSSI, A., RANUCCI, S., MISSON, P., CHEVALIER, E., BRODMANN, M., SCHMITT, M., WACH, A., DALE, G. E., OBRECHT, D., et al. (2016). Efficacy of the novel antibiotic POL7001 in preclinical models of *Pseudomonas aeruginosa* pneumonia. *Antimicrobial Agents and Chemotherapy* **60**, 4991–5000.
- CIOCIOLA, T., GIOVATI, L., GIOVANNELLI, A., CONTI, S., CASTAGNOLA, M. & VITALI, A. (2018). The activity of a mammalian proline-rich peptide against gram-negative bacteria, including drug-resistant strains, relies on a nonmembranolytic mode of action. *Infection and Drug Resistance* **11**, 969–979.
- CIRIONI, O., GHISELLI, R., TOMASINSIG, L., ORLANDO, F., SILVESTRI, C., SKERLAVAJ, B., RIVA, A., ROCCHI, M., SABA, V., ZANETTI, M., SCALISE, G. & GIACOMETTI, A. (2008). Efficacy of LL-37 and granulocyte colony-stimulating factor in a neutropenic murine sepsis due to *Pseudomonas aeruginosa*. *Shock* **30**, 443–448.
- CIRIONI, O., GIACOMETTI, A., GHISELLI, R., ORLANDO, F., KAMYSZ, W., D'AMATO, G., MOCCHIGIANI, F., LUKASIAK, J., SILVESTRI, C., SABA, V. & SCALISE, G. (2004). Potential therapeutic role of histatin derivative P-113D in experimental rat models of *Pseudomonas aeruginosa* sepsis. *Journal of Infectious Diseases* **190**, 356–364.
- CIRIONI, O., GIACOMETTI, A., SILVESTRI, C., DELLA VITTORIA, A., LICCI, A., RIVA, A. & SCALISE, G. (2006). In vitro activities of tritriptin alone and in combination with other antimicrobial agents against *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* **50**, 3923–3925.

- CLEMENTS, A., TULL, D., JENNEY, A. W., FARN, J. L., KIM, S. H., BISHOP, R. E., MCPHEE, J. B., HANCOCK, R. E. W., HARTLAND, E. L., PEARSE, M. J., WIJBURG, O. L. C., JACKSON, D. C., MCCONVILLE, M. J. & STRUGNELL, R. A. (2007). Secondary acylation of *Klebsiella pneumoniae* lipopolysaccharide contributes to sensitivity to antibacterial peptides. *Journal of Biological Chemistry* **282**, 15569–15577.
- COLE, A. M., THAPA, D. R., GABAYAN, V., LIAO, H.-I., LIU, L. & GANZ, T. (2005). Decreased clearance of *Pseudomonas aeruginosa* from airways of mice deficient in lysozyme M. *Journal of Leukocyte Biology* **78**, 1081–1085.
- CORRALES-GARCIA, L., ORTIZ, E., CASTAÑEDA-DELGADO, J., RIVAS-SANTIAGO, B. & CORZO, G. (2013). Bacterial expression and antibiotic activities of recombinant variants of human β -defensins on pathogenic bacteria and *M. tuberculosis*. *Protein Expression and Purification* **89**, 33–43.
- CRÉMIEUX, A. C., DINH, A., NORDMANN, P., MOUTON, W., TATTEVIN, P., GHOUT, I., JAYOL, A., AIMER, O., GATIN, L., VERDIER, M. C., SALEH-MGHIR, A. & LAURENT, F. (2019). Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing *Klebsiella pneumoniae*. *Journal of Antimicrobial Chemotherapy* **74**, 2666–2675.
- CRIMI, E., BENINCASA, G., CIRRI, S., MUTESI, R., FAENZA, M. & NAPOLI, C. (2020). Clinical epigenetics and multidrug-resistant bacterial infections: host remodelling in critical illness. *Epigenetics* **15**, 1021–1034.
- CUTONE, A., LEPANTO, M. S., ROSA, L., SCOTTI, M. J., ROSSI, A., RANUCCI, S., DE FINO, I., BRAGONZI, A., VALENTI, P., MUSCI, G. & BERLUTTI, F. (2019). Aerosolized bovine lactoferrin counteracts infection, inflammation and iron dysbalance in a cystic fibrosis mouse model of *Pseudomonas aeruginosa* chronic lung infection. *International Journal of Molecular Sciences* **20**, 2128.
- DAI, M., PAN, P., LI, H., LIU, S., ZHANG, L., SONG, C., LI, Q., MAO, Z., LONG, Y., SU, X. & HU, C. (2018). The antimicrobial cathelicidin peptide hLF (1-11) attenuates alveolar macrophage pyroptosis induced by *Acinetobacter baumannii* in vivo. *Experimental Cell Research* **364**, 95–103.
- DALCIN, D. & ULANOVA, M. (2013). The role of human beta-defensin-2 in *Pseudomonas aeruginosa* pulmonary infection in cystic fibrosis patients. *Infectious Diseases and Therapy* **2**, 159–166.
- DALE, G. E., HALABI, A., PETERSEN-SYLLA, M., WACH, A. & ZWINGELSTEIN, C. (2018). Pharmacokinetics, tolerability, and safety of murepavadin, a novel antipseudomonal antibiotic, in subjects with mild, moderate, or severe renal function impairment. *Antimicrobial Agents and Chemotherapy* **62**, e00490-18.
- DE BREIJ, A., RIOOL, M., CORDFUNKE, R. A., MALANOVIC, N., DE BOER, L., KONING, R. I., RAVENSBERGEN, E., FRANKEN, M., VAN DER HEIJDE, T., BOEKEMA, B. K., KWAKMAN, P. H. S., KAMP, N., EL GHALBZOURI, A., LOHNER, K., ZAAAT, S. A. J., et al. (2018). The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. *Science Translational Medicine* **10**, eaan4044.
- DEAN, S. N., BISHOP, B. M. & VAN HOEK, M. L. (2011). Susceptibility of *Pseudomonas aeruginosa* biofilm to alpha-helical peptides: D-enantiomer of LL-37. *Frontiers in Microbiology* **2**, 128.
- DEMBOWSKY, K., WILBRAHAM, D., OGRABEK, A., ARGEN, J., WACH, A. & DALE, G. (2012). Phase I (multiple ascending dose) study with the novel *Pseudomonas aeruginosa* antibiotic POL7080 in healthy volunteers. Presented in the European Congress of Clinical Microbiology and Infectious Diseases 2012;P1421 London, United Kingdom.
- DIEBEL, L. N., LITERATI, D. M., AMIN, P. B. & DIGLIO, C. A. (2009). Cleavage of slgA by gram negative respiratory pathogens enhance neutrophil inflammatory potential. *Journal of Trauma: Injury, Infection, and Critical Care* **66**, 1336–1342.
- DIJKSHOORN, L., BROUWER, C. P. J. M., BOGAARDS, S. J. P., NEMEC, A., VAN DEN BROEK, P. J. & NIBBERING, P. H. (2004). The synthetic n-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy* **48**, 4919–4921.
- DINGS, R. P. M., HASEMAN, J. R., LESLIE, D. B., LUONG, M., DUNN, D. L. & MAYO, K. H. (2013). Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with *Pseudomonas aeruginosa*. *Biochimica et Biophysica Acta* **1830**, 3454–3457.
- DINGS, R. P. M., HASEMAN, J. R. & MAYO, K. H. (2008). Probing structure-activity relationships in bactericidal peptide β pep-25. *Biochemical Journal* **414**, 143–150.
- DOLZANI, L., MILAN, A., SCOCCHI, M., LAGATOLLA, C., BRESSAN, R. & BENINCASA, M. (2019). Sub-MIC effects of a proline-rich antibacterial peptide on clinical isolates of *Acinetobacter baumannii*. *Journal of Medical Microbiology* **68**, 1253–1265.
- DOMINGUES, M., SANTOS, N. & CASTANHO, M. (2012). Antimicrobial peptide rBPI21: a translational overview from bench to clinical studies. *Current Protein & Peptide Science* **13**, 611–619.
- DOMINGUES, M. M., SILVA, P. M., FRANQUELIM, H. G., CARVALHO, F. A., CASTANHO, M. A. R. B. & SANTOS, N. C. (2014). Antimicrobial protein rBPI21-induced surface changes on gram-negative and gram-positive bacteria. *Nanomedicine: Nanotechnology, Biology and Medicine* **10**, 543–551.
- DORE, E. & BOILARD, E. (2019). Roles of secreted phospholipase A 2 group IIA in inflammation and host defense. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids* **1864**, 789–802.
- DOSLER, S. & KARASLAN, E. (2014). Inhibition and destruction of *Pseudomonas aeruginosa* biofilms by antibiotics and antimicrobial peptides. *Peptides* **62**, 32–37.
- DÖSSEL, J., MEYER-HOFFERT, U., SCHRÖDER, J. M. & GERSTEL, U. (2012). *Pseudomonas aeruginosa*-derived rhamnolipids subvert the host innate immune response through manipulation of the human beta-defensin-2 expression. *Cellular Microbiology* **14**, 1364–1375.
- DOSTAL, S. M., FANG, Y., GUERRETTE, J. C., SCANLON, T. C. & GRISWOLD, K. E. (2015). Genetically enhanced lysozyme evades a pathogen derived inhibitory protein. *ACS Chemical Biology* **10**, 1110–1117.
- DU, H., PURI, S., MCCALL, A., NORRIS, H. L., RUSSO, T. & EDGERTON, M. (2017). Human salivary protein histatin 5 has potent bactericidal activity against ESKAPE pathogens. *Frontiers in Cellular and Infection Microbiology* **7**, 41.
- DU, J., ABDEL-RAZEK, O., SHI, Q., HU, F., DING, G., COONEY, R. N. & WANG, G. (2018). Surfactant protein D attenuates acute lung and kidney injuries in pneumonia-induced sepsis through modulating apoptosis, inflammation and NF- κ B signaling. *Scientific Reports* **8**, 15393.
- DUBOUIX, A., CAMPANAC, C., FAUVEL, J., SIMON, M. F., SALLES, J. P., ROQUES, C., CHAP, H. & MARTY, N. (2003). Bactericidal properties of group IIA secreted phospholipase A2 against *Pseudomonas aeruginosa* clinical isolates. *Journal of Medical Microbiology* **52**, 1039–1045.
- DUPERTHUY, M. (2020). Antimicrobial peptides: virulence and resistance modulation in gram-negative bacteria. *Microorganisms* **8**, 280.
- DUPLANTIER, A. J. & VAN HOEK, M. L. (2013). The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. *Frontiers in Immunology* **4**, 143.
- DÜRR, U. H. N., SUDHEENDRA, U. S. & RAMAMOORTHY, A. (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochimica et Biophysica Acta - Biomembranes* **1758**, 1408–1425.
- DZIARSKI, R. & GUPTA, D. (2018). How innate immunity proteins kill bacteria and why they are not prone to resistance. *Current Genetics* **64**, 125–129.
- DZIARSKI, R., KASHYAP, D. R. & GUPTA, D. (2012). Mammalian peptidoglycan recognition proteins kill bacteria by activating two-component systems and modulate microbiome and inflammation. *Microbial Drug Resistance* **18**, 280–285.
- ECKERT, M., WITTMANN, I., RÖLLINGHOFF, M., GESSNER, A. & SCHNARE, M. (2006). Endotoxin-induced expression of murine bactericidal permeability/increasing protein is mediated exclusively by Toll/IL-1 receptor domain-containing adaptor inducing IFN- β -dependent pathways. *Journal of Immunology* **176**, 522–528.
- EHMANN, D., KOENINGER, L., WENDLER, J., MALEK, N. P., STANGE, E. F., WEHKAMP, J. & JENSEN, B. A. H. (2020). Fragmentation of human neutrophil α -defensin 4 to combat multidrug resistant bacteria. *Frontiers in Microbiology* **11**, 1147.
- EKKELENKAMP, M. B., CANTÓN, R., DíEZ-AGUILAR, M., TUNNEY, M. M., GILPIN, D. F., BERNARDINI, F., DALE, G. E., ELBORN, J. S., BAYJANOV, J. R. & FLUIT, A. (2020). Susceptibility of *Pseudomonas aeruginosa* recovered from cystic fibrosis patients to murepavadin and 13 comparator antibiotics. *Antimicrobial Agents and Chemotherapy* **64**, e01541–e01519.
- ELAD, S., EPSTEIN, J. B., RABER-DURLACHER, J., DONNELLY, P. & STRAHILEVITZ, J. (2012). The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. *Journal of Oral Pathology & Medicine* **41**, 229–234.
- ELADAWY, M., EL-MOWAFY, M., EL-SOKKARY, M. M. A. & BARWA, R. (2020). Effects of lysozyme, proteinase K, and cephalosporins on biofilm formation by clinical isolates of *Pseudomonas aeruginosa*. *Interdisciplinary Perspectives on Infectious Diseases* **2020**, 6156720.
- ELLISON, R. T. & GIEHL, T. J. (1991). Killing of gram-negative bacteria by lactoferrin and lysozyme. *Journal of Clinical Investigation* **88**, 1080–1091.
- EPAUD, R., DELESTRAIN, C., WEAVER, T. E. & AKINBI, H. T. (2019). Bacterial killing is enhanced by exogenous administration of lysozyme in the lungs. *Respiratory Medicine and Research* **76**, 22–27.
- FENG, X., SAMBANTHAMOORTHY, K., PALYS, T. & PARANAVITANA, C. (2013). The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant *Acinetobacter baumannii*. *Peptides* **49**, 131–137.
- FERNÁNDEZ, L., JENSSEN, H., BAINS, M., WIEGAND, I., GOODERHAM, W. J. & HANCOCK, R. E. W. (2012). The two-component system CprRS senses cationic peptides and triggers adaptive resistance in *Pseudomonas aeruginosa* independently of ParRS. *Antimicrobial Agents and Chemotherapy* **56**, 6212–6222.
- FERRARA, A., DOS SANTOS, C. & LUPI, A. (2001). Effect of some fractions of alveolar surfactant (phospholipids and SP-A) on the bactericidal activity of different antimicrobials against some respiratory pathogens. *Clinical Microbiology and Infection* **7**, 114–119.
- FERRATI, S., WU, T., FUENTES, O., BRUNAUGH, A. D., KANAPURAM, S. R. & SMYTH, H. D. C. (2018). Influence of formulation factors on the aerosol

- performance and stability of lysozyme powders: a systematic approach. *AAPS PharmSciTech* **19**, 2755–2766.
- FIALKINA, S., BONDARENKO, V., RABAEV, I., NIKOLAEVA, I. & SEMENOVA, D. (2014). Frequency of occurrence of *ipyC* and *pliC* lysozyme inhibitors genes in clinical *Klebsiella* strains. *Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii* **4**, 3–7.
- FLEITAS, O. & FRANCO, O. L. (2016). Induced bacterial cross-resistance toward host antimicrobial peptides: a worrying phenomenon. *Frontiers in Microbiology* **7**, 381.
- FLOROS, J., THORENOOR, N., TSOTAKOS, N. & PHELPS, D. S. (2021). Human surfactant protein SP-A1 and SP-A2 variants differentially affect the alveolar microenvironment, surfactant structure, regulation and function of the alveolar macrophage, and animal and human survival under various conditions. *Frontiers in Immunology* **12**, 681639.
- FOSCHIATTI, M., CESCUTTI, P., TOSSI, A. & RIZZO, R. (2009). Inhibition of cathelicidin activity by bacterial exopolysaccharides. *Molecular Microbiology* **72**, 1137–1146.
- FRICKER, J. (2002). A natural antibiotic for cystic fibrosis. *Drug Discovery Today* **7**, 159–160.
- GAGLIONE, R., CESARO, A., DELL'OLMO, E., DI GIROLAMO, R., TARTAGLIONE, L., PIZZO, E. & ARCIELLO, A. (2020). Cryptides identified in human apolipoprotein b as new weapons to fight antibiotic resistance in cystic fibrosis disease. *International Journal of Molecular Sciences* **21**, 2049.
- GANZ, T., GABAYAN, V., LIAO, H.-I., LIU, L., OREN, A., GRAF, T. & COLE, A. M. (2003). Increased inflammation in lysozyme M-deficient mice in response to *Mycobacterium avium* and its peptidoglycan. *Blood* **101**, 2388–2392.
- GEITANI, R., AYUB MOUBARECK, C., TOUQUI, L. & KARAM SARKIS, D. (2019). Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant *Staphylococcus aureus* and multidrug-resistant *Pseudomonas aeruginosa*. *BMC Microbiology* **19**, 54.
- GELIUS, E., PERSSON, C., KARLSSON, J. & STEINER, H. (2003). A mammalian peptidoglycan recognition protein with N-acetylmuramoyl-L-alanine amidase activity. *Biochemical and Biophysical Research Communications* **306**, 988–994.
- GHOSH, A., LEE, S., DZIARSKI, R. & CHAKRAVARTI, S. (2009). A novel antimicrobial peptidoglycan recognition protein in the cornea. *Investigative Ophthalmology & Visual Science* **50**, 4185–4191.
- GIACOMETTI, A., CIRIONI, O., DEL PRETE, M. S., PAGGI, A. M., D'ERRICO, M. M. & SCALISE, G. (2000). Combination studies between polycationic peptides and clinically used antibiotics against gram-positive and gram-negative bacteria. *Peptides* **21**, 1155–1160.
- GIACOMETTI, A., CIRIONI, O., GHISELLI, R., MOCCHIGLIANI, F., D'AMATO, G., CIRCO, R., ORLANDO, F., SKERLAVAJ, B., SILVESTRI, C., SABA, V., ZANETTI, M. & SCALISE, G. (2004). Cathelicidin peptide sheep myeloid antimicrobial peptide 29 prevents endotoxin-induced mortality in rat models of septic shock. *American Journal of Respiratory and Critical Care Medicine* **169**, 187–194.
- GIACOMETTI, A., CIRIONI, O., GHISELLI, R., MOCCHIGLIANI, F., D'AMATO, G., SIMONA DEL PRETE, M., ORLANDO, F., KAMYSZ, W., LUKASIAK, J., SABA, V. & SCALISE, G. (2003a). Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. *Gut* **52**, 874–878.
- GIACOMETTI, A., CIRIONI, O., GHISELLI, R., MOCCHIGLIANI, F., VITICCHI, C., ORLANDO, F., D'AMATO, G., DEL PRETE, M. S., KAMYSZ, W., LUKASIAK, J., SABA, V. & SCALISE, G. (2003b). Antidotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock. *Peptides* **24**, 1747–1752.
- GIACOMETTI, A., CIRIONI, O., KAMYSZ, W., D'AMATO, G., SILVESTRI, C., DEL PRETE, M. S., LICCI, A., RIVA, A., LUKASIAK, J. & SCALISE, G. (2005). In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. *Antimicrobial Agents and Chemotherapy* **49**, 1249–1252.
- GIANNONI, E., SAWA, T., ALLEN, L., WIENER-KRONISH, J. & HAWGOOD, S. (2006). Surfactant proteins A and D enhance pulmonary clearance of *Pseudomonas aeruginosa*. *American Journal of Respiratory Cell and Molecular Biology* **34**, 704–710.
- GIBSON, A. L., THOMAS-VIRNIG, C. L., CENTANNI, J. M., SCHLOSSER, S. J., JOHNSTON, C. E., VAN WINKLE, K. F., SZILAGYI, A., HE, L. K., SHANKAR, R. & ALLEN-HOFFMANN, B. L. (2012). Nonviral human beta defensin-3 expression in a bioengineered human skin tissue: a therapeutic alternative for infected wounds. *Wound Repair and Regeneration* **20**, 414–424.
- GIFFORD, J. L., HUNTER, H. N. & VOGEL, H. J. (2005). Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. *Cellular and Molecular Life Sciences* **62**, 2588–2598.
- GILES, F. J., REDMAN, R., YAZJI, S. & BELLM, L. (2002). Iseganon HCl: A novel antimicrobial agent. *Expert Opinion on Investigational Drugs* **11**, 1161–1170.
- GILES, F. J., RODRIGUEZ, R., WEISDORF, D., WINGARD, J. R., MARTIN, P. J., FLEMING, T. R., GOLDBERG, S. L., ANAÏSSIE, E. J., BOLWELL, B. J., CHAO, N. J., SHEA, T. C., BRUNVAND, M. M., VAUGHAN, W., PETERSEN, F., SCHUBERT, M., et al. (2004). A phase III, randomized, double-blind, placebo-controlled, study of iseganon for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. *Leukemia Research* **28**, 559–565.
- GOMES, A. P., MANO, J. F., QUEIROZ, J. A. & GOUVEIA, I. C. (2015). Incorporation of antimicrobial peptides on functionalized cotton gauzes for medical applications. *Carbohydrate Polymers* **127**, 451–461.
- GOODERHAM, W. J., BAINS, M., MCPHEE, J. B., WIEGAND, I. & HANCOCK, R. E. W. (2008). Induction by cationic antimicrobial peptides and involvement in intrinsic polymyxin and antimicrobial peptide resistance, biofilm formation, and swarming motility of PstA in *Pseudomonas aeruginosa*. *Journal of Bacteriology* **190**, 5624–5634.
- GOODERHAM, W. J. & HANCOCK, R. E. W. (2009). Regulation of virulence and antibiotic resistance by two-component regulatory systems in *Pseudomonas aeruginosa*. *FEMS Microbiology Reviews* **33**, 279–294.
- GORR, S. U., FLORY, C. M. & SCHUMACHER, R. J. (2019). In vivo activity and low toxicity of the second-generation antimicrobial peptide DGL13K. *PLoS One* **14**, e0216669.
- GORR, S. U., SOTSKY, J. B., SHELAR, A. P. & DEMUTH, D. R. (2008). Design of bacteria-agglutinating peptides derived from parotid secretory protein, a member of the bactericidal/permeability increasing-like protein family. *Peptides* **29**, 2118–2127.
- GOWDA, R. N., REDFERN, R., FRIKES, J., PINGLAY, S., FOSTER, J. W., LEMA, C., COPE, L. & CHAKRAVARTI, S. (2015). Functions of peptidoglycan recognition proteins (Pglytps) at the ocular surface: bacterial keratitis in gene-targeted mice deficient in Pglytp-2, -3 and -4. *PLoS One* **10**, e0137129.
- GRAF, M. & WILSON, D. N. (2019). Intracellular antimicrobial peptides targeting the protein synthesis machinery. *Advances in Experimental Medicine and Biology* **1117**, 73–89.
- GREIN, F., SCHNEIDER, T. & SAHL, H. G. (2019). Docking on Lipid II—a widespread mechanism for potent bactericidal activities of antibiotic peptides. *Journal of Molecular Biology* **431**, 3520–3530.
- GRISWOLD, K. E., BEMENT, J. L., TENEBACK, C. C., SCANLON, T. C., WARGO, M. J. & LECLAIR, L. W. (2014). Bioengineered lysozyme in combination therapies for *Pseudomonas aeruginosa* lung infections. *Bioengineered* **5**, 143–147.
- GRUDEN, Š. & POKLAR ULRIH, N. (2021). Diverse mechanisms of antimicrobial activities of lactoferrins, lactoferricins, and other lactoferrin-derived peptides. *International Journal of Molecular Sciences* **22**, 11264.
- GUILHELMELLI, F., VILELA, N., ALBUQUERQUE, P., DERENGOWSKI, L., SILVA-PEREIRA, I. & KYAW, C. (2013). Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. *Frontiers in Microbiology* **4**, 353.
- GUNASEKERA, S., MUHAMMAD, T., STRÖMSTEDT, A. A., ROSENGREN, K. J. & GÖRANSSON, U. (2018). Alanine and lysine scans of the LL-37-derived peptide fragment KR-12 reveal key residues for antimicrobial activity. *Chembiochem* **19**, 931–939.
- GUNASEKERA, S., MUHAMMAD, T., STRÖMSTEDT, A. A., ROSENGREN, K. J. & GÖRANSSON, U. (2020). Backbone cyclization and dimerization of LL-37-derived peptides enhance antimicrobial activity and proteolytic stability. *Frontiers in Microbiology* **11**, 168.
- GUO, Y., XUN, M. & HAN, J. (2018). A bovine myeloid antimicrobial peptide (BMAP-28) and its analogs kill pan-drug-resistant *Acinetobacter baumannii* by interacting with outer membrane protein A (OmpA). *Medicine (Baltimore)* **97**, e12832.
- HAIGH, B., HOOD, K., BROADHURST, M., MEDELE, S., CALLAGHAN, M., SMOLENSKI, G., DINES, M. & WHEELER, T. (2008). The bovine salivary proteins BSP30a and BSP30b are independently expressed BPI-like proteins with anti-*Pseudomonas* activity. *Molecular Immunology* **45**, 1944–1951.
- HAN, S. H. & MALLAMPALLI, R. K. (2015). The role of surfactant in lung disease and host defense against pulmonary infections. *Annals of the American Thoracic Society* **12**, 765–774.
- HANEY, E. F., STRAUS, S. K. & HANCOCK, R. E. W. (2019). Reassessing the host defense peptide landscape. *Frontiers in Chemistry* **7**, 1–22.
- HANSEN, F. C., STRÖMDAHL, A. C., MÖRGELIN, M., SCHMIDTCHEN, A. & VAN DER PLAS, M. J. A. (2017). Thrombin-derived host-defense peptides modulate monocyte/macrophage inflammatory responses to gram-negative bacteria. *Frontiers in Immunology* **8**, 1–11.
- HANSMANN, B., SCHRÖDER, J. M. & GERSTEL, U. (2015). Skin-derived C-terminal Filaggrin-2 fragments are *Pseudomonas aeruginosa*-directed antimicrobials targeting bacterial replication. *PLoS Pathogens* **11**, e1005159.
- HARM, S., LOHNER, K., FICHTINGER, U., SCHILDBÖCK, C., ZOTTL, J. & HARTMANN, J. (2019). Blood compatibility—an important but often forgotten aspect of the characterization of antimicrobial peptides for clinical application. *International Journal of Molecular Sciences* **20**, 5426.
- HARRIS, F., DENNISON, S. & PHOENIX, D. (2009). Anionic antimicrobial peptides from eukaryotic organisms. *Current Protein & Peptide Science* **10**, 585–606.
- HASHEMI, A., BAHROLOUMI, Z., KHAKSAR, Y., SAFFARZADEH, N., NEAMATZADE, H. & FEROUGHI, E. (2015). Mouth-rinses for the prevention of chemotherapy induced oral mucositis in children: a systematic review. *Iranian Journal of Pediatric Hematology and Oncology* **5**, 106–112.
- HAUKLAND, H. H., ULVATNE, H., SANDVIK, K. & VORLAND, L. H. (2001). The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. *FEBS Letters* **508**, 389–393.

- HEESTERBEEK, D. A. C., MUTS, R. M., VAN HENSBERGEN, V. P., DE SAINT AULAIRE, P., WENNEKES, T., BARDOEL, B. W., VAN SORGE, N. M. & ROOIJAKKERS, S. H. M. (2021). Outer membrane permeabilization by the membrane attack complex sensitizes gram-negative bacteria to antimicrobial proteins in serum and phagocytes. *PLoS Pathogens* **17**, 1–22.
- HILPERT, K., ELLIOTT, M. R., VOLKMER-ENGERT, R., HENKLEIN, P., DONINI, O., ZHOU, Q., WINKLER, D. F. H. & HANCOCK, R. E. W. (2006). Sequence requirements and an optimization strategy for short antimicrobial peptides. *Chemistry & Biology* **13**, 1101–1107.
- HIRT, H. & GORR, S. U. (2013). Antimicrobial peptide GL13K is effective in reducing biofilms of *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* **57**, 4903–4910.
- HOOVER, D. M., WU, Z., TUCKER, K., LU, W. & LUBKOWSKI, J. (2003). Antimicrobial characterization of human β -defensin 3 derivatives. *Antimicrobial Agents and Chemotherapy* **47**, 2804–2809.
- HORCAJADA, J. P., MONTERO, M., OLIVER, A., SORLÍ, L., LUQUE, S., GÓMEZ-ZORRILLA, S., BENITO, N. & GRAU, S. (2019). Epidemiology and treatment of multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* infections. *Clinical Microbiology Reviews* **32**, e00031-19.
- HSIEH, P. F., LIU, J. Y., PAN, Y. J., WU, M. C., LIN, T. L., HUANG, Y. T. & WANG, J. T. (2013). *Klebsiella pneumoniae* peptidoglycan-associated lipoprotein and murein lipoprotein contribute to serum resistance, antiphagocytosis, and proinflammatory cytokine stimulation. *Journal of Infectious Diseases* **208**, 1580–1589.
- HU, Q., ZUO, P., SHAO, B., YANG, S., XU, G., LAN, F., LU, X., XIONG, W., XU, Y. & XIONG, S. (2010). Administration of nonviral gene vector encoding rat β -defensin-2 ameliorates chronic *Pseudomonas aeruginosa* lung infection in rats. *The Journal of Gene Medicine* **12**, 276–286.
- HUANG, L. C., JEAN, D., PROSKE, R. J., REINS, R. Y. & McDERMOTT, A. M. (2007a). Ocular surface expression and in vitro activity of antimicrobial peptides. *Current Eye Research* **32**, 595–609.
- HUANG, L. C., REDFERN, R. L., NARAYANAN, S., REINS, R. Y. & McDERMOTT, A. M. (2007b). In vitro activity of human β -defensin 2 against *Pseudomonas aeruginosa* in the presence of tear fluid. *Antimicrobial Agents and Chemotherapy* **51**, 3853–3860.
- HUANG, L. C., REINS, R. Y., GALLO, R. L. & McDERMOTT, A. M. (2007c). Cathelicidin-deficient (Cnlp^{-/-}) mice show increased susceptibility to *Pseudomonas aeruginosa* keratitis. *Investigative Ophthalmology & Visual Science* **48**, 4498–4508.
- HUERTAS, N. D. J., MONROY, Z. J. R., MEDINA, R. F. & CASTAÑEDA, J. E. G. (2017). Antimicrobial activity of truncated and polyvalent peptides derived from the FKRRQWQWRMKKGLA sequence against *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 25923. *Molecules* **22**, 987.
- HUKIĆ, M., SELJMO, D., RAMOVIĆ, A., IBRIŠIMOVIĆ, M. A., DOGAN, S., HUKIĆ, J. & BOJIC, E. F. (2018). The effect of lysozyme on reducing biofilms by *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Gardnerella vaginalis*: an in vitro examination. *Microbial Drug Resistance* **24**, 353–358.
- HUNTER, H. N., ROSS DEMCOE, A., JENSEN, H., GUTTEBERG, T. J. & VOGEL, H. J. (2005). Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. *Antimicrobial Agents and Chemotherapy* **49**, 3387–3395.
- IB 367 (1999). IB 367. *Drugs in R & D* **1**, 174–175. <https://doi.org/10.2165/00126839-199901020-00015>.
- IBRAHIM, H. R., THOMAS, U. & PELLEGRINI, A. (2001). A helix-loop-helix peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. *Journal of Biological Chemistry* **276**, 43767–43774.
- ISAACSON, R. E. (2003). MBI-226. Micrologix/Fujisawa. *Current Opinion in Investigational Drugs* **4**, 999–1003.
- JABBOUR, J. F., SHARARA, S. L. & KANJ, S. S. (2020). Treatment of multidrug-resistant gram-negative skin and soft tissue infections. *Current Opinion in Infectious Diseases* **33**, 146–154.
- JAKEL, A., QASEEM, A. S., KISHORE, U. & SIM, R. B. (2013). Ligands and receptors of lung surfactant proteins SP-A and SP-D. *Frontiers in Bioscience* **18**, 1129–1140.
- JAŚKIEWICZ, M., NEUBAUER, D., KAZOR, K., BARTOSZEWSKA, S. & KAMYSZ, W. (2019). Antimicrobial activity of selected antimicrobial peptides against planktonic culture and biofilm of *Acinetobacter baumannii*. *Probiotics and Antimicrobial Proteins* **11**, 317–324.
- JIANG, S., DESLOUCHES, B., CHEN, C., DI, M. E. & PETER DI, Y. (2019). Antibacterial properties and efficacy of a novel SPLUNC1-derived antimicrobial peptide, α 4-short, in a murine model of respiratory infection. *MBio* **10**, e00226-19.
- JUAN, C., TORRENS, G., BARCELÓ, I. M. & OLIVER, A. (2018). Interplay between peptidoglycan biology and virulence in gram-negative pathogens. *Microbiology and Molecular Biology Reviews* **82**, e00033-18.
- JUAN, C., TORRENS, G., GONZÁLEZ-NICOLAU, M. & OLIVER, A. (2017). Diversity and regulation of intrinsic β -lactamases from non-fermenting and other gram-negative opportunistic pathogens. *FEMS Microbiology Reviews* **41**, 781–815.
- KÁDÁR, B., KOCSIS, B., KRISTOF, K., TÓTH, Á. & SZABÓ, D. (2015). Effect of antimicrobial peptides on colistin-susceptible and colistin-resistant strains of *Klebsiella pneumoniae* and *Enterobacter asburiae*. *Acta Microbiologica et Immunologica Hungarica* **62**, 501–508.
- KALLE, M., PAPAREDDY, P., KASETTY, G., VAN DER PLAS, M. J., MÖRGELIN, M., MALMSTEN, M. & SCHMIDTCHEN, A. (2014). A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive *Pseudomonas aeruginosa* infection. *PLoS One* **9**, e102577.
- KAMOSHIDA, G., AKAJI, T., TAKEMOTO, N., SUZUKI, Y., SATO, Y., KAI, D., HIBINO, T., YAMAGUCHI, D., KIKUCHI-UEDA, T., NISHIDA, S., UNNO, Y., TANSHO-NAGAKAWA, S., UBAGAI, T., MIYOSHI-AKIYAMA, T., ODA, M., et al. (2020). Lipopolysaccharide-deficient *Acinetobacter baumannii* due to colistin resistance is killed by neutrophil-produced lysozyme. *Frontiers in Microbiology* **11**, 573.
- KASHYAP, D. R., ROMPCA, A., GABALLA, A., HELMANN, J. D., CHAN, J., CHANG, C. J., HOZO, I., GUPTA, D. & DZIARSKI, R. (2014). Peptidoglycan recognition proteins kill bacteria by inducing oxidative, thiol, and metal stress. *PLoS Pathogens* **10**, e1004280.
- KAWASAKI, T., KAWASAKI, C., SATA, T., KOBAYASHI, M. & SUZUKI, F. (2015). Depressed production of beta-defensins from mouse splenic dendritic cells following thermal injury and its influence on susceptibility to infection. *Journal of Anesthesiology* **29**, 78–86.
- KETKO, A. & DONN, S. (2014). Surfactant-associated proteins: structure, function and clinical implications. *Current Pediatric Reviews* **10**, 162–167.
- KIM, E. Y., RAJASEKARAN, G. & SHIN, S. Y. (2017). LL-37-derived short antimicrobial peptide KR-12-a5 and its D-amino acid substituted analogs with cell selectivity, anti-biofilm activity, synergistic effect with conventional antibiotics, and anti-inflammatory activity. *European Journal of Medicinal Chemistry* **136**, 428–441.
- KINTSES, B., MÉHI, O., ARI, E., SZÁMEL, M., GYÖRKEI, Á., JANGIR, P. K., NAGY, I., PÁL, F., FEKETE, G., TENGÖLICS, R., NYERGES, Á., LIKÓ, I., BÁLINT, A., MOLNÁR, T., BÁLINT, B., et al. (2019). Phylogenetic barriers to horizontal transfer of antimicrobial peptide resistance genes in the human gut microbiota. *Nature Microbiology* **4**, 447–458.
- KLEIN, S., LORENZO, C., HOFFMANN, S., WALTHER, J. M., STORBECK, S., PIEKARSKI, T., TINDALL, B. J., WRAY, V., NIMTZ, M. & MOSER, J. (2009). Adaptation of *Pseudomonas aeruginosa* to various conditions includes tRNA-dependent formation of ananyl-phosphatidylglycerol. *Molecular Microbiology* **71**, 551–565.
- KOLLEF, M., PITTET, D., GARCÍA, M. S., CHASTRE, J., FAGON, J. Y., BONTEN, M., HYZY, R., FLEMING, T. R., FUCHS, H., BELLM, L., MERCAT, A., MAÑEZ, R., MARTÍNEZ, A., EGGIMANN, P., DAGUERRE, M., et al. (2006). A randomized double-blind trial of ivermectin in prevention of ventilator-associated pneumonia. *American Journal of Respiratory and Critical Care Medicine* **173**, 91–97.
- KOO, H. B. & SEO, J. (2019). Antimicrobial peptides under clinical investigation. *Peptide Science* **111**, e24122.
- KOŚCIUCZUK, E. M., LISOWSKI, P., JARCZAK, J., STRZAŁKOWSKA, N., JÓZWIK, A., HORBAŃCZUK, J., KRZYŻEWSKI, J., ZWIERZCHOWSKI, L. & BAGNICKA, E. (2012). Cathelicidins: family of antimicrobial peptides. A review. *Molecular Biology Reports* **39**, 10957–10970.
- KOVACH, M. A., BALLINGER, M. N., NEWSTEAD, M. W., ZENG, X., BHAN, U., YU, F., MOORE, B. B., GALLO, R. L. & STANDIFORD, T. J. (2012). Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in gram-negative bacterial pneumonia. *Journal of Immunology* **189**, 304–311.
- KRISHNAKUMARI, V., BINNY, T. M., ADICHERLA, H. & NAGARAJ, R. (2020). *Escherichia coli* lipopolysaccharide modulates biological activities of human- β -defensin analogues but not non-ribosomally synthesized peptides. *ACS Omega* **5**, 6366–6375.
- KRISHNAKUMARI, V., SHARADADEVI, A., SINGH, S. & NAGARAJ, R. (2003). Single disulfide and linear analogues corresponding to the carboxy-terminal segment of bovine β -defensin-2: effects of introducing the β -hairpin nucleating sequence D-ProGly on antibacterial activity and biophysical properties. *Biochemistry* **42**, 9307–9315.
- KUANG, Z., HAO, Y., HWANG, S., ZHANG, S., KIM, E., AKINBI, H. T., SCHURR, M. J., IRVIN, R. T., HASSETT, D. J. & LAU, G. W. (2011a). The *Pseudomonas aeruginosa* flagellum confers resistance to pulmonary surfactant protein-A by impacting the production of exoproteases through quorum-sensing. *Molecular Microbiology* **79**, 1220–1235.
- KUANG, Z., HAO, Y., WALLING, B. E., JEFFRIES, J. L., OHMAN, D. E. & LAU, G. W. (2011b). *Pseudomonas aeruginosa* Elastase provides an escape from phagocytosis by degrading the pulmonary surfactant protein-A. *PLoS One* **6**, e27091.
- KUMAR, P., KIZHAKKEDATHU, J. N. & STRAUS, S. K. (2018). Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. *Biomolecules* **8**, 4.
- KURODA, K., OKUMURA, K., ISOGAI, H. & ISOGAI, E. (2015). The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. *Frontiers in Oncology* **5**, 144.
- KUZMENKO, A. I., WU, H. & McCORMACK, F. X. (2006). Pulmonary collectins selectively permeabilize model bacterial membranes containing rough lipopolysaccharide. *Biochemistry* **45**, 2679–2685.

- KUZMENKO, A. I., WU, H., WAN, S. & MCCORMACK, F. X. (2005). Surfactant protein A is a principal and oxidation-sensitive microbial permeabilizing factor in the alveolar lining fluid. *Journal of Biological Chemistry* **280**, 25913–25919.
- LAM, J. S., TAYLOR, V. L., ISLAM, S. T., HAO, Y. & KOČIŇCOVÁ, D. (2011). Genetic and functional diversity of *Pseudomonas aeruginosa* lipopolysaccharide. *Frontiers in Microbiology* **2**, 118.
- LARRICK, J., HIRATA, M., SHIMOMOURA, Y., YOSHIDA, M., ZHENG, H., ZHONG, J. & WRIGHT, S. (1994). Rabbit CAP18 derived peptides inhibit gram negative and gram positive bacteria. *Progress in Clinical and Biological Research* **388**, 125–135.
- LATENDORF, T., GERSTEL, U., WU, Z., BARTELS, J., BECKER, A., THOLEY, A. & SCHRÖDER, J. M. (2019). Cationic intrinsically disordered antimicrobial peptides (CIDAMPs) represent a new paradigm of innate defense with a potential for novel anti-Infectives. *Scientific Reports* **9**, 3331.
- LAZARIDIS, T., HE, Y. & PRIETO, L. (2013). Membrane interactions and pore formation by the antimicrobial peptide protegrin. *Biophysical Journal* **104**, 633–642.
- LAZZARO, B. P., ZASLOFF, M. & ROLFF, J. (2020). Antimicrobial peptides: application informed by evolution. *Science* **368**, eaau5480.
- LEE, E. K., KIM, Y. C., NAN, Y. H. & SHIN, S. Y. (2011). Cell selectivity, mechanism of action and LPS-neutralizing activity of bovine myeloid antimicrobial peptide-18 (BMAP-18) and its analogs. *Peptides* **32**, 1123–1130.
- LEE, J., GEDDES, K., STREUTKER, C., PHILPOTT, D. J. & GIRARDIN, S. E. (2012). Role of mouse peptidoglycan recognition protein PGLYRP2 in the innate immune response to *Salmonella enterica* serovar typhimurium infection in vivo. *Infection and Immunity* **80**, 2645–2654.
- LEE, K. M., LEE, K., GO, J., PARK, I. H., SHIN, J. S., CHOI, J. Y., KIM, H. J. & YOON, S. S. (2017). A genetic screen reveals novel targets to render *Pseudomonas aeruginosa* sensitive to lysozyme and cell wall-targeting antibiotics. *Frontiers in Cellular and Infection Microbiology* **7**, 59.
- LEE, T.-H. N., HALL, K. & AGUILAR, M.-I. (2016). Antimicrobial peptide structure and mechanism of action: a focus on the role of membrane structure. *Current Topics in Medicinal Chemistry* **16**, 25–39.
- LETSIOU, E., HTWE, Y. M. & DUDEK, S. M. (2021). Secretory phospholipase A2 enzymes in acute lung injury. *Cell Biochemistry and Biophysics* **79**, 609–617.
- LEVINE, A. M., KURAK, K. E., BRUNO, M. D., STARK, J. M., WHITSETT, J. A. & KORFHAGEN, T. R. (1998). Surfactant protein-A-deficient mice are susceptible to *Pseudomonas aeruginosa* infection. *American Journal of Respiratory Cell and Molecular Biology* **19**, 700–708.
- LEVY, O., SISSON, R. B., KENYON, J., EICHENWALD, E., MACONE, A. B. & GOLDMANN, D. (2000). Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo. *Infection and Immunity* **68**, 5120–5125.
- LEWIS, A., DU PLESSIS, L. H. & WENTZEL, J. F. (2019). Antimicrobial peptides: the Achilles' heel of antibiotic resistance? *Probiotics and Antimicrobial Proteins* **11**, 370–381.
- LI, J., XIE, D., LI, A. & YUE, J. (2013). Oral topical decontamination for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. *Journal of Hospital Infection* **84**, 283–293.
- LIM, C. H., PUTHIA, M., BUTRYM, M., TAY, H. M., LEE, M. Z. Y., HOU, H. W. & SCHMIDTCHEN, A. (2017). Thrombin-derived host defence peptide modulates neutrophil rolling and migration in vitro and functional response in vivo. *Scientific Reports* **7**, 1–12.
- LIMOLI, D. H., ROCKEL, A. B., HOST, K. M., JHA, A., KOPP, B. T., HOLLIS, T. & WOZNIAK, D. J. (2014). Cationic antimicrobial peptides promote microbial mutagenesis and pathoadaptation in chronic infections. *PLoS Pathogens* **10**, e1004083.
- LIN, L., NONEJUIE, P., MUNGUA, J., HOLLANDS, A., OLSON, J., DAM, Q., KUMARASWAMY, M., RIVERA, H., CORRIDEN, R., ROHDE, M., HENSLER, M. E., BURKART, M. D., POGLIANO, J., SAKOULAS, G. & NIZET, V. (2015a). Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens. *eBioMedicine* **2**, 690–698.
- LIN, M. F., TSAI, P. W., CHEN, J. Y., LIN, Y. Y. & LAN, C. Y. (2015b). OmpA binding mediates the effect of antimicrobial peptide LL-37 on *Acinetobacter baumannii*. *PLoS One* **10**, e0141107.
- LINDSAY, S., OATES, A. & BOURDILLON, K. (2017). The detrimental impact of extracellular bacterial proteases on wound healing. *International Wound Journal* **14**, 1237–1247.
- LIU, Y., BARTLETT, J. A., DI, M. E., BOMBERGER, J. M., CHAN, Y. R., GAKHAR, L., MALLAMPALLI, R. K., MCCRAY, P. B. & DI, Y. P. (2013a). SPLUNC1/BPIFA1 contributes to pulmonary host defense against *Klebsiella pneumoniae* respiratory infection. *The American Journal of Pathology* **182**, 1519–1531.
- LIU, Y., DI, M. E., CHU, H. W., LIU, X., WANG, L., WENZEL, S. & DI, Y. P. (2013b). Increased susceptibility to pulmonary *Pseudomonas* infection in Splunc1 knockout mice. *Journal of Immunology* **191**, 4259–4268.
- LIU, Y., SUN, Y., XU, Y., FENG, H., FU, S., TANG, J., LIU, W., SUN, D., JIANG, H. & XU, S. (2013c). Preparation and evaluation of lysozyme-loaded nanoparticles coated with poly- γ -glutamic acid and chitosan. *International Journal of Biological Macromolecules* **59**, 201–207.
- LOBET, E., CAMPOS, M. A., GIMÉNEZ, P., MORANTA, D. & BENGOCHEA, J. A. (2011). Analysis of the networks controlling the antimicrobial-peptide-dependent induction of *Klebsiella pneumoniae* virulence factors. *Infection and Immunity* **79**, 3718–3732.
- LOBET, E., MARCH, C., GIMÉNEZ, P. & BENGOCHEA, J. A. (2009). *Klebsiella pneumoniae* OmpA confers resistance to antimicrobial peptides. *Antimicrobial Agents and Chemotherapy* **53**, 298–302.
- LOBET, E., TOMÁS, J. M. & BENGOCHEA, J. A. (2008). Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. *Microbiology* **154**, 3877–3886.
- LOCKWOOD, N. A., HASEMAN, J. R., TIRRELL, M. V. & MAYO, K. H. (2004). Acylation of SC4 dodecapeptide increases bactericidal potency against gram-positive bacteria, including drug-resistant strains. *Biochemical Journal* **378**, 93–103.
- LUTHER, A., URFER, M., ZAHN, M., MÜLLER, M., WANG, S. Y., MONDAL, M., VITALE, A., HARTMANN, J. B., SHARPE, T., MONTE, F. L., KOCHERLA, H., CLINE, E., PESSI, G., RATH, P., MODARESI, S. M., et al. (2019). Chimeric peptidomimetic antibiotics against gram-negative bacteria. *Nature* **576**, 452–458.
- MAISETTA, G., DI LUCA, M., ESIN, S., FLORIO, W., BRANCATISANO, F. L., BOTTAI, D., CAMPA, M. & BATONI, G. (2008). Evaluation of the inhibitory effects of human serum components on bactericidal activity of human beta defensin 3. *Peptides* **29**, 1–6.
- MALIN, J. J. & DE LEEUW, E. (2019). Therapeutic compounds targeting Lipid II for antibacterial purposes. *Infection and Drug Resistance* **12**, 2613–2625.
- MALLOY, J. L., VELDHUIZEN, R. A. W., THIBODEAUX, B. A., O'CALLAGHAN, R. J. & WRIGHT, J. R. (2005). *Pseudomonas aeruginosa* protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions. *American Journal of Physiology-Lung Cellular and Molecular Physiology* **288**, L409–L418.
- MANNION, B. A., WEISS, J. & ELSBACH, P. (1990). Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on *Escherichia coli*. *Journal of Clinical Investigation* **85**, 853–860.
- MARDIROSIAN, M., BARRIÈRE, Q., TIMCHENKO, T., MÜLLER, C., PACOR, S., MERGAERT, P., SCOCCHI, M. & WILSON, D. N. (2018). Fragments of the nonlytic proline-rich antimicrobial peptide Bac5 kill *Escherichia coli* cells by inhibiting protein synthesis. *Antimicrobial Agents and Chemotherapy* **62**, e00534-18.
- MARDIROSIAN, M., POMPILIO, A., CROCETTA, V., DE NICOLA, S., GUIDA, F., DEGASPERI, M., GENNARO, R., DI BONAVENTURA, G. & SCOCCHI, M. (2016). In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections. *Amino Acids* **48**, 2253–2260.
- MARDIROSIAN, M., POMPILIO, A., DEGASPERI, M., RUNTI, G., PACOR, S., DI BONAVENTURA, G. & SCOCCHI, M. (2017). D-BMAP18 antimicrobial peptide is active in vitro, resists to pulmonary proteases but loses its activity in a murine model of *Pseudomonas aeruginosa* lung infection. *Frontiers in Chemistry* **5**, 40.
- MARDIROSIAN, M., SOLA, R., BECKERT, B., COLLIS, D. W. P., DI STASI, A., ARMAS, F., HILPERT, K., WILSON, D. N. & SCOCCHI, M. (2019). Proline-rich peptides with improved antimicrobial activity against *E. coli*, *K. pneumoniae*, and *A. baumannii*. *ChemMedChem* **14**, 2025–2033.
- MARKART, P., FAUST, N., GRAF, T., NA, C.-L., WEAVER, T. E. & AKINBI, H. T. (2004a). Comparison of the microbicidal and muramidase activities of mouse lysozyme M and P. *Biochemical Journal* **380**, 385–392.
- MARKART, P., KORFHAGEN, T. R., WEAVER, T. E. & AKINBI, H. T. (2004b). Mouse lysozyme M is important in pulmonary host defense against *Klebsiella pneumoniae* infection. *American Journal of Respiratory and Critical Care Medicine* **169**, 454–458.
- MARTINEZ, J. G., WALDON, M., HUANG, Q., ALVAREZ, S., OREN, A., SANDOVAL, N., DU, M., ZHOU, F., ZENZ, A., LOHNER, K., DESHARNAIS, R. & PORTER, E. (2009). Membrane-targeted synergistic activity of docosahexaenoic acid and lysozyme against *Pseudomonas aeruginosa*. *Biochemical Journal* **419**, 193–200.
- MARTIN-LOECHES, I., DALE, G. E. & TORRES, A. (2018). Murepavadin: a new antibiotic class in the pipeline. *Expert Review of Anti-Infective Therapy* **16**, 259–268.
- MAST, M., PINET, E. & PAGÈS, J. M. (2020). Complex response of the CpxAR two-component system to β -lactams on antibiotic resistance and envelope homeostasis in *Enterobacteriaceae*. *Antimicrobial Agents and Chemotherapy* **64**, 1–14.
- MATOS DE OPITZ, C. L. & SASS, P. (2020). Tackling antimicrobial resistance by exploring new mechanisms of antibiotic action. *Future Microbiology* **15**, 703–708.
- MC HUGH, B. J., WANG, R., LI, H. N., BEAUMONT, P. E., KELLS, R., STEVENS, H., YOUNG, L., ROSSI, A. G., GRAY, R. D., DORIN, J. R., FINDLAY, E. L. G., BROUGH, D. & DAVIDSON, D. J. (2019). Cathelicidin is a “fire alarm”, generating protective NLRP3-dependent airway epithelial cell inflammatory responses during infection with *Pseudomonas aeruginosa*. *PLoS Pathogens* **15**, e1007694.
- MCLAUGHLIN, M. I. & VAN DER DONK, W. A. (2020). The fellowship of the rings: macrocyclic antibiotic peptides reveal an anti-gram-negative target. *Biochemistry* **59**, 343–345.
- MELGERS, M. J., TEAGUE, J., WARN, P., HANSEN, J., BERNARDINI, F., WACH, A., OBRECHT, D., DALE, G. E. & MOUTONA, J. W. (2019). Pharmacokinetics and pharmacodynamics of murepavadin in neutropenic mouse models. *Antimicrobial Agents and Chemotherapy* **63**, e016999-18.

- MELO, M., DUGOURD, D. & CASTANHO, M. (2006). Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. *Recent Patents on Anti-Infective Drug Discovery* **1**, 201–207.
- MELO, M. N. & CASTANHO, M. A. R. B. (2007). Omiganan interaction with bacterial membranes and cell wall models. Assigning a biological role to saturation. *Biochimica et Biophysica Acta* **1768**, 1277–1290.
- MERCER, D. K., TORRES, M. D. T., DUAY, S. S., LOVIE, E., SIMPSON, L., VON KÖCKRITZ-BLICKWEDE, M., DE LA FUENTE-NUNEZ, C., O'NEIL, D. A. & ANGELES-BOZA, A. M. (2020). Antimicrobial susceptibility testing of antimicrobial peptides to better predict efficacy. *Frontiers in Cellular and Infection Microbiology* **10**, 326.
- MERZA, M., RAHMAN, M., ZHANG, S., HWAIZ, R., REGNER, S., SCHMIDTCHEN, A. & THORLACIUS, H. (2014). Human thrombin-derived host defense peptides inhibit neutrophil recruitment and tissue injury in severe acute pancreatitis. *American Journal of Physiology-Gastrointestinal and Liver Physiology* **307**, G914–G921.
- MESSIKA, J., LA COMBE, B. & RICARD, J.-D. (2018). Oropharyngeal colonization: epidemiology, treatment and ventilator-associated pneumonia prevention. *Annals of Translational Medicine* **6**, 426–426.
- MICHALEK, M., GELHAUS, C., HECHT, O., PODSCHUN, R., SCHRÖDER, J. M., LEIPPE, M. & GRÖTZINGER, J. (2009). The human antimicrobial protein psoriasin acts by permeabilization of bacterial membranes. *Developmental & Comparative Immunology* **33**, 740–746.
- MIKEROV, A. N., HAQUE, R., GAN, X., GUO, X., PHELPS, D. S. & FLOROS, J. (2008). Ablation of SP-A has a negative impact on the susceptibility of mice to *Klebsiella pneumoniae* infection after ozone exposure: sex differences. *Respiratory Research* **9**, 77.
- MILLS, G., DUMIGAN, A., KIDD, T., HOBLEY, L. & BENGOCHEA, J. A. (2017). Identification and characterization of two *Klebsiella pneumoniae* *lpxL* lipid A late acyltransferases and their role in virulence. *Infection and Immunity* **85**, e00068-17.
- MIN, C., OHTA, K., KAJIYA, M., ZHU, T., SHARMA, K., SHIN, J., MAWARDI, H., HOWAIT, M., HIRSCHFELD, J., BAHAMAM, L., ICHIMONJI, I., GANTA, S., AMIJI, M. & KAWAI, T. (2012). The antimicrobial activity of the appetite peptide hormone ghrelin. *Peptides* **36**, 151–156.
- MIN, H. J., YUN, H., JI, S., RAJASEKARAN, G., KIM, J. I., KIM, J. S., SHIN, S. Y. & LEE, C. W. (2017). Rattusin structure reveals a novel defensin scaffold formed by intermolecular disulfide exchanges. *Scientific Reports* **7**, 1–13.
- MISHRA, A. K., CHOI, J., MOON, E. & BAEK, K. H. (2018). Tryptophan-rich and proline-rich antimicrobial peptides. *Molecules* **23**, 815.
- MISHRA, B., REILING, S., ZARENA, D. & WANG, G. (2017). Host defense antimicrobial peptides as antibiotics: design and application strategies. *Current Opinion in Chemical Biology* **38**, 87–96.
- MISHRA, B. & WANG, G. (2017a). Individual and combined effects of engineered peptides and antibiotics on *Pseudomonas aeruginosa* biofilms. *Pharmaceuticals* **10**, 58.
- MISHRA, B. & WANG, G. (2017b). Titanium surfaces immobilized with the major antimicrobial fragment FK-16 of human cathelicidin LL-37 are potent against multiple antibiotic-resistant bacteria. *Biofouling* **33**, 544–555.
- MOHAMMED, I., SAID, D. G., NUBILE, M., MASTROPASQUA, L. & DUA, H. S. (2019). Cathelicidin-derived synthetic peptide improves therapeutic potential of vancomycin against *Pseudomonas aeruginosa*. *Frontiers in Microbiology* **10**, 2190.
- MOORE, P. J., SESMA, J., ALEXIS, N. E. & TARRAN, R. (2019). Tobacco exposure inhibits P/LUNC1-dependent antimicrobial activity. *Respiratory Research* **20**, 94.
- MORANTA, D., REGUEIRO, V., MARCH, C., LLOBET, E., MARGARETO, J., LARRATE, E., GARMENDIA, J. & BENGOCHEA, J. A. (2010). *Klebsiella pneumoniae* capsule polysaccharide impedes the expression of β -defensins by airway epithelial cells. *Infection and Immunity* **78**, 1135–1146.
- MORICI, P., FLORIO, W., RIZZATO, C., GHELARDI, E., TAVANTI, A., ROSSOLINI, G. M. & LUPETTI, A. (2017). Synergistic activity of synthetic N-terminal peptide of human lactoferrin in combination with various antibiotics against carbapenem-resistant *Klebsiella pneumoniae* strains. *European Journal of Clinical Microbiology & Infectious Diseases* **36**, 1739–1748.
- MORRONI, G., SIMONETTI, O., BRENCIANI, A., BRESCINI, L., KAMYSZ, W., KAMYSZ, E., NEUBAUER, D., CAFFARINI, M., ORCIANI, M., GIOVANETTI, E., OFFIDANI, A., GIACOMETTI, A. & CIRIONI, O. (2019). In vitro activity of Protegrin-1, alone and in combination with clinically useful antibiotics, against *Acinetobacter baumannii* strains isolated from surgical wounds. *Medical Microbiology and Immunology* **208**, 877–883.
- MOSCA, D. A., HURST, M. A., SO, W., VIAJAR, B. S. C., FUJII, C. A. & FALLA, T. J. (2000). IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. *Antimicrobial Agents and Chemotherapy* **44**, 1803–1808.
- MOSKOWITZ, S. M., ERNST, R. K. & MILLER, S. I. (2004). PmrAB, a two-component regulatory system of *Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to Lipid A. *Journal of Bacteriology* **186**, 575–579.
- MULANI, M. S., KAMBLE, E. E., KUMKAR, S. N., TAWRE, M. S. & PARDESI, K. R. (2019). Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. *Frontiers in Microbiology* **10**, 539.
- MUN, J. J., TAM, C., KOWBEL, D., HAWGOOD, S., BARNETT, M. J., EVANS, D. J. & FLEISZIG, S. M. J. (2009). Clearance of *Pseudomonas aeruginosa* from a healthy ocular surface involves surfactant protein D and is compromised by bacterial elastase in a murine null-infection model. *Infection and Immunity* **77**, 2392–2398.
- MURAKAMI, M., SATO, H., MIKI, Y., YAMAMOTO, K. & TAKETOMI, Y. (2015). A new era of secreted phospholipase A2. *Journal of Lipid Research* **56**, 1248–1261.
- MUSCEDERE, J., DODEK, P., KEENAN, S., FOWLER, R., COOK, D. & HEYLAND, D. (2008). Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. *Journal of Critical Care* **23**, 126–137.
- NAPIER, B. A., BURD, E. M., SATOLA, S. W., CAGLE, S. M., RAY, S. M., MCGANN, P., POHL, J., LESH, E. P. & WEISS, D. S. (2013). Clinical use of colistin induces cross-resistance to host antimicrobials in *Acinetobacter baumannii*. *MBio* **4**, e00021–e00013.
- NASH, J. A., BALLARD, T. N. S., WEAVER, T. E. & AKINBI, H. T. (2006). The peptidoglycan-degrading property of lysozyme is not required for bactericidal activity in vivo. *Journal of Immunology* **177**, 519–526.
- NAYAK, A., DODAGATTA-MARRI, E., TSOLAKI, A. G. & KISHORE, U. (2012). An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. *Frontiers in Immunology* **3**, 131.
- NEVALAINEN, T. J., GRAHAM, G. G. & SCOTT, K. F. (2008). Antibacterial actions of secreted phospholipases A2. *Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids* **1781**, 1–9.
- NIBBERING, P. H., RAVENSBERGEN, E., WELLING, M. M., VAN BERKEL, L. A., VAN BERKEL, P. H. C., PAUWELS, E. K. J. & NUIJENS, J. H. (2001). Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. *Infection and Immunity* **69**, 1469–1476.
- NICHOLS, D. P., JIANG, D., HAPPOLDT, C., BERMAN, R. & CHU, H. W. (2015). Therapeutic effects of α 1-antitrypsin on *Pseudomonas aeruginosa* infection in ENaC transgenic mice. *PLoS One* **10**, e0141232.
- NIETO-ORELLANA, A., COGHLAN, D., ROTHERY, M., FALCONE, F. H., BOSQUILLON, C., CHILDERHOUSE, N., MANTOVANI, G. & STOLNIK, S. (2018). Dry-powder formulations of non-covalent protein complexes with linear or miktoarm copolymers for pulmonary delivery. *International Journal of Pharmaceutics* **540**, 78–88.
- NIGRO, E., COLAVITA, I., SARNATARO, D., SCUDIERO, O., DANIELE, A., SALVATORE, F. & PESSI, A. (2017). Host defense peptide-derived privileged scaffolds for anti-infective drug discovery. *Journal of Peptide Science* **23**, 303–310.
- NORDSTRÖM, R., NYSTRÖM, L., ANDRÉN, O. C. J., MALKOCH, M., UMERKA, A., DAVOUDI, M., SCHMIDTCHEN, A. & MALMSTEN, M. (2018). Membrane interactions of microgels as carriers of antimicrobial peptides. *Journal of Colloid and Interface Science* **513**, 141–150.
- NURI, R., SHPRUNG, T. & SHAI, Y. (2015). Defensive remodeling: how bacterial surface proteomics and biofilm formation promote resistance to antimicrobial peptides. *Biochimica et Biophysica Acta* **1848**, 3089–3100.
- OHTA, K., KAJIYA, M., ZHU, T., NISHI, H., MAWARDI, H., SHIN, J., ELBADAWI, L., KAMATA, N., KOMATSUZAWA, H. & KAWAI, T. (2011). Additive effects of orexin B and vasoactive intestinal polypeptide on LL-37-mediated antimicrobial activities. *Journal of Neuroimmunology* **233**, 37–45.
- OLIVA, R., DEL VECCHIO, P., GRIMALDI, A., NOTOMISTA, E., CAFARO, V., PANE, K., SCHUABB, V., WINTER, R. & PETRACONE, L. (2019). Membrane disintegration by the antimicrobial peptide (P)GKY20: lipid segregation and domain formation. *Physical Chemistry Chemical Physics* **21**, 3989–3998.
- Oo, T. Z., COLE, N., GARTHWAITE, L., WILLCOX, M. D. P. & ZHU, H. (2010). Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. *Journal of Antimicrobial Chemotherapy* **65**, 1243–1251.
- OPPEDIJK, S. F., MARTIN, N. I. & BREUKINK, E. (2016). Hit 'em where it hurts: the growing and structurally diverse family of peptides that target lipid-II. *Biochimica et Biophysica Acta - Biomembranes* **1858**, 947–957.
- OPPENHEIM, F., XU, T., McMILLIAN, F., LEVITZ, S., DIAMOND, R., OFFNER, G. & TROXLER, R. (1988). Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on *Candida albicans*. *Journal of Biological Chemistry* **263**, 7472–7477.
- OVERHAGE, J., CAMPISANO, A., BAINS, M., TORFS, E. C. W., REHM, B. H. A. & HANCOCK, R. E. W. (2008). Human host defense peptide LL-37 prevents bacterial biofilm formation. *Infection and Immunity* **76**, 4176–4182.
- PACHÓN-IBÁÑEZ, M. E., SMANI, Y., PACHÓN, J. & SÁNCHEZ-CÉSPEDES, J. (2017). Perspectives for clinical use of engineered human host defense antimicrobial peptides. *FEMS Microbiology Reviews* **41**, 323–342.
- PADILLA, E., LLOBET, E., DOMÉNECH-SÁNCHEZ, A., MARTÍNEZ-MARTÍNEZ, L., BENGOCHEA, J. A. & ALBERTÍ, S. (2010). *Klebsiella pneumoniae* AcrAB efflux pump contributes to antimicrobial resistance and virulence. *Antimicrobial Agents and Chemotherapy* **54**, 177–183.
- PANE, K., CAFARO, V., AVITABILE, A., TORRES, M. D. T., VOLLARO, A., DE GREGORIO, E., CATANIA, M. R., DI MARO, A., BOSSO, A., GALLO, G., ZANFARDINO, A., VARCAMONTI, M., PIZZO, E., DI DONATO, A., LU, T. K., et al. (2018). Identification of novel cryptic multifunctional antimicrobial peptides from

- the human stomach enabled by a computational-experimental platform. *ACS Synthetic Biology* **7**, 2105–2115.
- PANE, K., DURANTE, L., CRESCENZI, O., CAFARO, V., PIZZO, E., VARCAMONTI, M., ZANFARDINO, A., IZZO, V., DI DONATO, A. & NOTOMISTA, E. (2017). Antimicrobial potency of cationic antimicrobial peptides can be predicted from their amino acid composition: application to the detection of “cryptic” antimicrobial peptides. *Journal of Theoretical Biology* **419**, 254–265.
- PANE, K., SGAMBATI, V., ZANFARDINO, A., SMALDONE, G., CAFARO, V., ANGRISANO, T., PEDONE, E., DI GAETANO, S., CAPASSO, D., HANEY, E. F., IZZO, V., VARCAMONTI, M., NOTOMISTA, E., HANCOCK, R. E. W., DI DONATO, A., et al. (2016). A new cryptic cationic antimicrobial peptide from human apolipoprotein E with antibacterial activity and immunomodulatory effects on human cells. *FEBS Journal* **283**, 2115–2131.
- PANTELEEV, P. V., BOLOSOV, I. A., KALASHNIKOV, A., KOKRYAKOV, V. N., SHAMOVA, O. V., EMELIANOVA, A. A., BALANDIN, S. V. & OVCHINNIKOVA, T. V. (2018). Combined antibacterial effects of goat cathelicidins with different mechanisms of action. *Frontiers in Microbiology* **9**, 2983.
- PAPAREDDY, P., KALLE, M., BHONGIR, R. K., MÖRGELEIN, M., MALMSTEN, M. & SCHMIDTCHEN, A. (2014). Antimicrobial effects of helix D-derived peptides of human antithrombin III. *Journal of Biological Chemistry* **289**, 29790–29800.
- PAPAREDDY, P., KALLE, M., KASETTY, G., MÖRGELEIN, M., RYDENGÅRD, V., ALBIGER, B., LUNDQVIST, K., MALMSTEN, M. & SCHMIDTCHEN, A. (2010b). C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. *Journal of Biological Chemistry* **285**, 28387–28398.
- PAPAREDDY, P., KALLE, M., SØRENSEN, O. E., LUNDQVIST, K., MÖRGELEIN, M., MALMSTEN, M. & SCHMIDTCHEN, A. (2012). Tissue factor pathway inhibitor 2 is found in skin and its C-terminal region encodes for antibacterial activity. *PLoS One* **7**, e52772.
- PAPAREDDY, P., KALLE, M., SØRENSEN, O. E., MALMSTEN, M., MÖRGELEIN, M. & SCHMIDTCHEN, A. (2013). The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. *PLoS Pathogens* **9**, e1003803.
- PAPAREDDY, P., RYDENGÅRD, V., PASUPULETI, M., WALSE, B., MÖRGELEIN, M., CHALUPKA, A., MALMSTEN, M. & SCHMIDTCHEN, A. (2010a). Proteolysis of human thrombin generates novel host defense peptides. *PLoS Pathogens* **6**, e1000857.
- PARDUCHO, K. R., BEADELL, B., YBARRA, T. K., BUSH, M., ESCALERA, E., TREJOS, A. T., CHIENG, A., MENDEZ, M., ANDERSON, C., PARK, H., WANG, Y., LU, W. & PORTER, E. (2020). The antimicrobial peptide human Beta-defensin 2 inhibits biofilm production of *Pseudomonas aeruginosa* without compromising metabolic activity. *Frontiers in Immunology* **11**, 805.
- PARK, P. W., PIER, G. B., HINKES, M. T. & BERNFIELD, M. (2001). Exploitation of syndecan-1 shedding by *Pseudomonas aeruginosa* enhances virulence. *Nature* **411**, 98–102.
- PARK, S., KIM, J. I., LEE, I., BAE, J. Y., HWANG, M. W., KIM, D., JANG, S. I., KIM, H., PARK, M. S., KWON, H. J., SONG, J. W., CHO, Y. S., CHUN, W. & PARK, M. S. (2014). Inhibition of *Pseudomonas aeruginosa* with a recombinant RNA-based viral vector expressing human β -defensin 4. *BMC Microbiology* **14**, 237.
- PASUPULETI, M., DAVOUDI, M., MALMSTEN, M. & SCHMIDTCHEN, A. (2009a). Antimicrobial activity of a C-terminal peptide from human extracellular superoxide dismutase. *BMC Research Notes* **2**, 136.
- PASUPULETI, M., ROUPE, M., RYDENGÅRD, V., SUREWICZ, K., SUREWICZ, W. K., CHALUPKA, A., MALMSTEN, M., SØRENSEN, O. E. & SCHMIDTCHEN, A. (2009b). Antimicrobial activity of human prion protein is mediated by its N-terminal region. *PLoS One* **4**, e7358.
- PASUPULETI, M., SCHMIDTCHEN, A. & MALMSTEN, M. (2012). Antimicrobial peptides: key components of the innate immune system. *Critical Reviews in Biotechnology* **32**, 143–171.
- PEEL, E., CHENG, Y., DJORDJEVIC, J. T., FOX, S., SORRELL, T. C. & BELOV, K. (2016). Cathelicidins in the Tasmanian devil (*Sarcophilus harrisii*). *Scientific Reports* **6**, 35019.
- PERNET, E., GUILLEMOT, L., BURGEL, P. R., MARTIN, C., LAMBEAU, G., SERMET-GAUDELUS, I., SANDS, D., LEDUC, D., MORAND, P. C., JEAMMET, L., CHIGNARD, M., WU, Y. & TOUQUI, L. (2014). *Pseudomonas aeruginosa* eradicates *Staphylococcus aureus* by manipulating the host immunity. *Nature Communications* **5**, 5105.
- PETROVA, J., PETRUK, G., HUBER, R. G., MCBURNIE, E. W., VAN DER PLAS, M. J. A., BOND, P. J., PUTHIA, M. & SCHMIDTCHEN, A. (2020). Thrombin-derived C-terminal fragments aggregate and scavenge bacteria and their proinflammatory products. *Journal of Biological Chemistry* **295**, 3417–3430.
- POLYPHOR (2019). Polyphor closes Phase III Prism Stud. murepavadin Intraven. Formul. Eval. Furth. Prod. Improv. options. Electronic file available at <https://www.polyphor.com/news/corporate-news-details/?newsid=1800485> Accessed 4.12.2021
- POMPILIO, A., CROCCETTA, V., SCOCCHI, M., POMPONIO, S., DI VINCENZO, V., MARDIROSSIAN, M., GHERARDI, G., FISCARELLI, E., DICUNZO, G., GENNARO, R. & DI BONAVENTURA, G. (2012). Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed -helical peptides against *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Stenotrophomonas maltophilia*. *BMC Microbiology* **12**, 145.
- POMPILIO, A., SCOCCHI, M., POMPONIO, S., GUIDA, F., DI PRIMIO, A., FISCARELLI, E., GENNARO, R. & DI BONAVENTURA, G. (2011). Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. *Peptides* **32**, 1807–1814.
- PORRO, G. A., LEE, J. H., DE AZAVEDO, J., CRANDALL, I., WHITEHEAD, T., TULLIS, E., GANZ, T., LIU, M., SLUTSKY, A. S. & ZHANG, H. (2001). Direct and indirect bacterial killing functions of neutrophil defensins in lung explants. *American Journal of Physiology-Lung Cellular and Molecular Physiology* **281**, 1240–1247.
- POULAKOU, G., LAGOU, S., KARAGEORGOPOULOS, D. E. & DIMOPOULOS, G. (2018). New treatments of multidrug-resistant gram-negative ventilator-associated pneumonia. *Annals of Translational Medicine* **6**, 423–423.
- PROVENZANI, A., HOSPODAR, A. R., MEYER, A. L., LEONARDI VINCI, D., HWANG, E. Y., BUTRUS, C. M. & POLIDORI, P. (2020). Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents. *International Journal of Clinical Pharmacy* **42**, 1016–1025.
- QIN, G. T., LOPEZ, A., SANTOS, C., MCDERMOTT, A. M. & CAI, C. Z. (2015). Antimicrobial peptide LL-37 on surfaces presenting carboxylate anions. *Biomaterials Science* **3**, 771–778.
- RAGLAND, S. A. & CRISS, A. K. (2017). From bacterial killing to immune modulation: recent insights into the functions of lysozyme. *PLoS Pathogens* **13**, e1006512.
- RAHEEM, N. & STRAUS, S. K. (2019). Mechanisms of action for antimicrobial peptides with antibacterial and antibiofilm functions. *Frontiers in Microbiology* **10**, 1–14.
- RAJASEKARAN, G., KIM, E. Y. & SHIN, S. Y. (2017). LL-37-derived membrane-active FK-13 analogs possessing cell selectivity, anti-biofilm activity and synergy with chloramphenicol and anti-inflammatory activity. *Biochimica et Biophysica Acta - Biomembranes* **1859**, 722–733.
- REN, H., WU, J., COLLETTA, A., MEYERHOFF, M. E. & XI, C. (2016). Efficient eradication of mature *Pseudomonas aeruginosa* biofilm via controlled delivery of nitric oxide combined with antimicrobial peptide and antibiotics. *Frontiers in Microbiology* **7**, 1260.
- REZZOAGLI, C., ARCHETTI, M., MIGNOT, I., BAUMGARTNER, M. & KÜMMERLI, R. (2020). Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in *Pseudomonas aeruginosa*. *PLoS Biology* **18**, e3000805.
- RIEG, S., HUTH, A., KALBACHER, H. & KERN, W. V. (2009). Resistance against antimicrobial peptides is independent of *Escherichia coli* AcrAB, *Pseudomonas aeruginosa* MexAB and *Staphylococcus aureus* NorA efflux pumps. *International Journal of Antimicrobial Agents* **33**, 174–176.
- RODRÍGUEZ-ROJAS, A., MAKAROVA, O., MÜLLER, U. & ROLFF, J. (2015). Cationic peptides facilitate iron-induced mutagenesis in bacteria. *PLoS Genetics* **11**, e1005546.
- ROMANO, K. P., WARRIER, T., POULSEN, B. E., NGUYEN, P. H., LOFTIS, A. R., SAEBI, A., PENTELUTE, B. L. & HUNG, D. T. (2019). Mutations in *pmrB* confer cross-resistance between the LptD inhibitor POL7080 and colistin in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* **63**, e00511-19.
- ROUTSIAS, J. G., KARAGOUNIS, P., PARVULESKU, G., LEGAKIS, N. J. & TSARRIS, A. (2010). In vitro bactericidal activity of human β -defensin 2 against nosocomial strains. *Peptides* **31**, 1654–1660.
- ROYET, J., GUPTA, D. & DZIARSKI, R. (2011). Peptidoglycan recognition proteins: modulators of the microbiome and inflammation. *Nature Reviews Immunology* **11**, 837–851.
- ROZEK, A., FRIEDRICH, C. L. & HANCOCK, R. E. W. (2000). Structure of the bovine antimicrobial peptide indolicidin bound to dodecylphosphocholine and sodium dodecyl sulfate micelles. *Biochemistry* **39**, 15765–15774.
- RUBINCHIK, E., DUGOURD, D., ALGARA, T., PASETKA, C. & FRIEDLAND, H. D. (2009). Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. *International Journal of Antimicrobial Agents* **34**, 457–461.
- RUDEN, S., RIEDER, A., CHIS STER, I., SCHWARTZ, T., MIKUT, R. & HILPERT, K. (2019). Synergy pattern of short cationic antimicrobial peptides against multidrug-resistant *Pseudomonas aeruginosa*. *Frontiers in Microbiology* **10**, 2740.
- RUNTI, G., BENINCASA, M., GIUFFRIDA, G., DEVECOVI, G., VENTURI, V., GENNARO, R. & SCOCCHI, M. (2017). The mechanism of killing by the proline-rich peptide Bac7(1-35) against clinical strains of *Pseudomonas aeruginosa* differs from that against other gram-negative bacteria. *Antimicrobial Agents and Chemotherapy* **61**, e01660-e01616.
- SADER, H. S., DALE, G. E., RHOMBERG, P. R. & FLAMM, R. K. (2018a). Antimicrobial activity of murepavadin tested against clinical isolates of *Pseudomonas aeruginosa* from the United States, Europe, and China. *Antimicrobial Agents and Chemotherapy* **62**, e00311-18.
- SADER, H. S., FEDLER, K. A., RENNIE, R. P., STEVENS, S. & JONES, R. N. (2004). Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: Spectrum of antimicrobial activity and measurements of bactericidal activity. *Antimicrobial Agents and Chemotherapy* **48**, 3112–3118.
- SADER, H. S., FLAMM, R. K., DALE, G. E., RHOMBERG, P. R. & CASTANHEIRA, M. (2018b). Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR *Pseudomonas aeruginosa*. *Journal of Antimicrobial Chemotherapy* **73**, 2400–2404.
- SAHA, S., JING, X., PARK, S. Y., WANG, S., LI, X., GUPTA, D. & DZIARSKI, R. (2010). Peptidoglycan recognition proteins protect mice from experimental colitis by

- promoting normal gut flora and preventing induction of interferon- γ . *Cell Host and Microbe* **8**, 147–162.
- SAHA, S., QI, J., WANG, S., WANG, M., LI, X., KIM, Y.-G., NÚÑEZ, G., GUPTA, D. & DZIARSKI, R. (2009). PGLYRP-2 and Nod2 are both required for peptidoglycan-induced arthritis and local inflammation. *Cell Host and Microbe* **5**, 137–150.
- SAHLY, H., SCHUBERT, S., HARDER, J., KLEINE, M., SANDVANG, D., ULLMANN, U., SCHRÖDER, J. M. & PODSCHUN, R. (2006). Activity of human β -defensins 2 and 3 against ESBP-producing *Klebsiella* strains. *Journal of Antimicrobial Chemotherapy* **57**, 562–565.
- SAIMAN, L., TABIBI, S., STARNER, T. D., SAN GABRIEL, P., WINOKUR, P. L., JIA, H. P., MCCRAY, J. & TACK, B. F. (2001). Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. *Antimicrobial Agents and Chemotherapy* **45**, 2838–2844.
- SAITO, H., SAKAKIBARA, Y., SAKATA, A., KURASHIGE, R., MURAKAMI, D., KAGESHIMA, H., SAITO, A. & MIYAZAKI, Y. (2019). Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and Methicillin-resistant *Staphylococcus aureus*. *PLoS One* **14**, e0217504.
- SÁNCHEZ-GÓMEZ, S., FERRER-ESPADA, R., STEWART, P. S., PITTS, B., LOHNER, K. & MARTÍNEZ DE TEJADA, G. (2015). Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against *Pseudomonas aeruginosa* planktonic cultures and biofilms. *BMC Microbiology* **15**, 137.
- SANG, Y., ORTEGA, M. T., BLECHA, F., PRAKASH, O. & MELGAREJO, T. (2005). Molecular cloning and characterization of three β -defensins from canine testes. *Infection and Immunity* **73**, 2611–2620.
- SARAVANAN, R., HOLDBROOK, D. A., PETRLOVA, J., SINGH, S., BERGLUND, N. A., CHOONG, Y. K., KJELLSTRÖM, S., BOND, P. J., MALMSTEN, M. & SCHMIDTCHEN, A. (2018). Structural basis for endotoxin neutralisation and anti-inflammatory activity of thrombin-derived C-terminal peptides. *Nature Communications* **9**, 2762.
- SAUNDERS, D. P., EPSTEIN, J. B., ELAD, S., ALLEMANO, J., BOSSI, P., VAN DE WETERING, M. D., RAO, N. G., POTTING, C., CHENG, K. K., FREIDANK, A., BRENNAN, M. T., BOWEN, J., DENNIS, K. & LALLA, R. V. (2015). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. *Support Care Cancer* **21**, 3191–3207.
- SAWA, T., KURAHASHI, K., OHARA, M., GROPPER, M. A., DOSHI, V., LARRICK, J. W. & WIENER-KRONISH, J. P. (1998). Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against *Pseudomonas aeruginosa* in a mouse model. *Antimicrobial Agents and Chemotherapy* **42**, 3269–3275.
- SAYEED, S., NISTICO, L., ST CROIX, C. & DI, P. P. (2013). Multifunctional role of human SPLUNC1 in *Pseudomonas aeruginosa* infection. *Infection and Immunity* **81**, 285–291.
- SCHNEIDER, M. R., VAN DEN BELT, M., TJEERDSMA-VAN BOKHOVEN, J. L. M., SCHNEIDER, V. A. F., ORDONEZ, S. R., VAN DIJK, A., VELDHIJZEN, E. J. A. & HAAGSMAN, H. P. (2019). Cathelicidins PMP-36, LL-37 and CATH-2 are similar peptides with different modes of action. *Scientific Reports* **9**, 4780.
- SCHMIDTCHEN, A., FRICK, I. M., ANDERSSON, E., TAPPER, H. & BJÖRCK, L. (2002). Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. *Molecular Microbiology* **46**, 157–168.
- SCHMIDTCHEN, A., FRICK, I. M. & BJÖRCK, L. (2001). Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial α -defensin. *Molecular Microbiology* **39**, 708–713.
- SCUDIERO, O., GALDIERO, S., NIGRO, E., DEL VECCHIO, L., DI NOTO, R., CANTISANI, M., COLAVITA, I., GALDIERO, M., CASSIMAN, J. J., DANIELE, A., PEDONE, C. & SALVATORE, F. (2013). Chimeric beta-defensin analogs, including the novel 3NI analog, display salt-resistant antimicrobial activity and lack toxicity in human epithelial cell lines. *Antimicrobial Agents and Chemotherapy* **57**, 1701–1708.
- SCUDIERO, O., NIGRO, E., CANTISANI, M., COLAVITA, I., LEONE, M., MERCURIO, F. A., GALDIERO, M., PESSI, A., DANIELE, A., SALVATORE, F. & GALDIERO, S. (2015). Design and activity of a cyclic mini- β -defensin analog: a novel antimicrobial tool. *International Journal of Nanomedicine* **10**, 6523–6539.
- SEPTIMUS, E. J. & SCHWEIZER, M. L. (2016). Decolonization in prevention of health care-associated infections. *Clinical Microbiology Reviews* **29**, 201–221.
- SHAMOVA, O., ORLOV, D., STEGEMANN, C., CZIHAL, P., HOFFMANN, R., BROGDEN, K., KOLODKIN, N., SAKUTA, G., TOSSI, A., SAHL, H. G., KOKRYAKOV, V. & LEHRER, R. I. (2009). ChBac3.4: a novel proline-rich antimicrobial peptide from goat leukocytes. *International Journal of Peptide Research and Therapeutics* **15**, 107–119.
- SHAMOVA, O., ORLOV, D., ZHARKOVA, M., BALANDIN, S., YAMSCHIKOVA, E., KNAPPE, D., HOFFMANN, R., KOKRYAKOV, V. & OVCHINNIKOVA, T. (2016). Minibactenecins ChBac7.N α and ChBac7. N β - antimicrobial peptides from leukocytes of the goat *Capra hircus*. *Acta Naturae* **8**, 136–146.
- SHANG, Z., CHAN, S. Y., SONG, Q., LI, P. & HUANG, W. (2020). The strategies of pathogen-oriented therapy on circumventing antimicrobial resistance. *Research* **2020**, 2016201.
- SHANKARAMMA, S. C., MOEHLE, K., JAMES, S., VRIJBOED, J. W., OBRECHT, D. & ROBINSON, J. A. (2003). A family of macrocyclic antibiotics with a mixed peptide-peptoid β -hairpin backbone conformation. *Chemical Communications* **3**, 1842–1843.
- SHEFFIELD, C. L., CRIPPEN, T. L., POOLE, T. L. & BEIER, R. C. (2012). Destruction of single-species biofilms of *Escherichia coli* or *Klebsiella pneumoniae* subsp. *Pneumoniae* by dextranase, lactoferrin, and lysozyme. *International Microbiology* **15**, 185–189.
- SHEN, Z., FANG, L., ZHAO, L. & LEI, H. (2014). β -Defensin 2 ameliorates lung injury caused by *Pseudomonas* infection and regulates proinflammatory and anti-inflammatory cytokines in rat. *International Journal of Molecular Sciences* **15**, 13372–13387.
- SHEN, Z., ZHOU, Y., QU, L. & LEI, H. (2017). ATP serves an anti-inflammatory role by enhancing β -defensin-2 response in acute pneumonia of rat. *Biomedical Reports* **6**, 649–653.
- SILHAVY, T. J., KAHNE, D. & WALKER, S. (2010). The bacterial cell envelope. *Cold Spring Harbor Perspectives in Biology* **2**, a000414.
- SIMONETTI, O., CIRIONI, O., GHISELLI, R., ORLANDO, F., SILVESTRI, C., MAZZOCATO, S., KAMYSZ, W., KAMYSZ, E., PROVINCIALI, M., GIACOMETTI, A., GUERRIERI, M. & OFFIDANI, A. (2014). In vitro activity and in vivo animal model efficacy of IB-367 alone and in combination with imipenem and colistin against gram-negative bacteria. *Peptides* **55**, 17–22.
- SINHA, S., HARIODH, M. K., DEWANGAN, R. P., NG, W. J., GHOSH, J. K. & BHATTACHARJYA, S. (2018). Cell-selective pore forming antimicrobial peptides of the prodomain of human furin: a conserved aromatic/cationic sequence mapping, membrane disruption, and atomic-resolution structure and dynamics. *ACS Omega* **3**, 14650–14664.
- SOLA, R., MARDIROSIAN, M., BECKERT, B., DE LUNA, L. S., PRICKETT, D., TOSSI, A., WILSON, D. N. & SCOCCHI, M. (2020). Characterization of cetacean proline-rich antimicrobial peptides displaying activity against ESKAPE pathogens. *International Journal of Molecular Sciences* **21**, 7367.
- SPENCER, J. J., PITTS, R. E., PEARSON, R. A. & KING, L. B. (2018). The effects of antimicrobial peptides WAM-1 and LL-37 on multidrug-resistant *Acinetobacter baumannii*. *Pathogens and Disease* **76**, fty007. <https://doi.org/10.1093/femsdp/fty007>.
- SRINIVAS, N., JETTER, P., UEBERBACHER, B. J., WERNEBURG, M., ZERBE, K., STEINMANN, J., VAN DER MEIJDEN, B., BERNARDINI, F., LEDERER, A., DIAS, R. L. A., MISSON, P. E., HENZE, H., ZUMBRUNN, J., GOMBERT, F. O., OBRECHT, D., et al. (2010). Peptidomimetic antibiotics target outer-membrane biogenesis in *Pseudomonas aeruginosa*. *Science* **327**, 1010–1013.
- STAROSTA, V. & GRIESE, M. (2006). Oxidative damage to surfactant protein D in pulmonary diseases. *Free Radical Research* **40**, 419–425.
- STEINSTRASSER, L., KLEIN, R. D., AMINLARI, A., FAN, M. H., KHILANANI, V., REMICK, D. G., SU, G. L. & WANG, S. C. (2001). Protegrin-1 enhances bacterial killing in thermally injured skin. *Critical Care Medicine* **29**, 1431–1437.
- STRØM, M. B., REKDAL, Ø. & SVENDSEN, J. S. (2002). The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. *Journal of Peptide Science* **8**, 36–43.
- SU, Y., WANG, H., MISHRA, B., LAKSHMAIAH NARAYANA, J., JIANG, J., REILLY, D. A., HOLLINS, R. R., CARLSON, M. A., WANG, G. & XIE, J. (2019). Nanofiber dressings topically delivering molecularly engineered human cathelicidin peptides for the treatment of biofilms in chronic wounds. *Molecular Pharmaceutics* **16**, 2011–2020.
- SUPP, D. M., GARDNER, J., KLINGENBERG, J. M. & NEELY, A. N. (2009). Antibiotic resistance in clinical isolates of *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* does not impact sensitivity to human beta defensin 4. *Burns* **35**, 949–955.
- SUTHERLAND, R. E., BARRY, S. S., OLSEN, J. S., SALANTES, D. B., CAUGHEY, G. H. & WALTERS, P. J. (2014). Dipeptidyl peptidase i controls survival from *Klebsiella pneumoniae* lung infection by processing surfactant protein D. *Biochemical and Biophysical Research Communications* **450**, 818–823.
- TACCONELLI, E. & PEZZANI, M. D. (2019). Public health burden of antimicrobial resistance in Europe. *Lancet Infectious Diseases* **19**, 4–6.
- TAGGART, C. C., GREENE, C. M., SMITH, S. G., LEVINE, R. L., MCCRAY, P. B., O'NEILL, S. & McELVANEY, N. G. (2003). Inactivation of human β -Defensins 2 and 3 by elastolytic cathepsins. *Journal of Immunology* **171**, 931–937.
- TAI, K. P., KAMDAR, K., YAMAKI, J., LE, V. V., TRAN, D., TRAN, P., SELSTED, M. E., OUELLETTE, A. J. & WONG-BERINGER, A. (2015). Microbicidal effects of α - and θ -defensins against antibiotic-resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *Innate Immunity* **21**, 17–29.
- TAM, C., MUN, J. J., EVANS, D. J. & FLEISZIG, S. M. J. (2012). Cytokeratins mediate epithelial innate defense through their antimicrobial properties. *Journal of Clinical Investigation* **122**, 3665–3677.
- TAN, R. M., KUANG, Z., HAO, Y., LEE, F., LEE, T., LEE, R. J. & LAU, G. W. (2015). Type IV pilus glycosylation mediates resistance of *Pseudomonas aeruginosa* to opsonic activities of the pulmonary surfactant protein A. *Infection and Immunity* **83**, 1339–1346.

- TAYLOR, K., ROLFE, M., RENOLDS, N., KILANOWSKI, F., PATHANIA, U., CLARKE, D., YANG, D., OPPENHEIM, J., SAMUEL, K., HOWIE, S., BARRAN, P., MACMILLAN, D., CAMPOPIANO, D. & DORIN, J. (2009). Defensin-related peptide 1 (Defb1) is allelic to Defb8 and chemoattracts immature DC and CD4+ T cells independently of CCR6. *European Journal of Immunology* **39**, 1353–1360.
- TENEBACK, C. C., SCANLON, T. C., WARGO, M. J., BEMENT, J. L., GRISWOLD, K. E. & LECLAIR, L. W. (2013). Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid *Pseudomonas aeruginosa* lung infection. *Antimicrobial Agents and Chemotherapy* **57**, 5559–5564.
- THACKER, S., MORAN, A., LIONAKIS, M., MASTRANGELO, M. A. A., HALDER, T., DEL PILAR HUBY, M., WU, Y. & TWEARDY, D. J. (2014). Restoration of lung surfactant protein D by IL-6 protects against secondary pneumonia following hemorrhagic shock. *Journal of Infection* **68**, 231–241.
- THENNARASU, S. & NAGARAJ, R. (1999). Synthetic peptides corresponding to the β-hairpin loop of rabbit defensin NP-2 show antimicrobial activity. *Biochemical and Biophysical Research Communications* **254**, 281–283.
- THÉOLIER, J., FLISS, I., JEAN, J. & HAMMAMI, R. (2014). MilkAMP: a comprehensive database of antimicrobial peptides of dairy origin. *Dairy Science and Technology* **94**, 181–193.
- THEPRUNGSIRIKUL, J., SKOPELJA-GARDNER, S. & RIGBY, W. F. C. (2021). Killing three birds with one BPI: bactericidal, opsonic, and anti-inflammatory functions. *Journal of Translational Autoimmunity* **4**, 100105.
- THEURETZBACHER, U., OUTTERSON, K., ENGEL, A. & KARLÉN, A. (2020). The global preclinical antibacterial pipeline. *Nature Reviews Microbiology* **18**, 275–285.
- THI, M. T. T., WIBOWO, D. & REHM, B. H. A. (2020). *Pseudomonas aeruginosa* biofilms. *International Journal of Molecular Sciences* **21**, 8671.
- THOMAS-VIRNIG, C. L. & ALLEN-HOFFMANN, B. L. (2012). A bioengineered human skin tissue for the treatment of infected wounds. *Advances in Wound Care* **1**, 88–94.
- THOMAS-VIRNIG, C. L., CENTANNI, J. M., JOHNSTON, C. E., HE, L. K., SCHLOSSER, S. J., VAN WINKLE, K. F., CHEN, R., GIBSON, A. L., SZILAGYI, A., LI, L., SHANKAR, R. & ALLEN-HOFFMANN, B. L. (2009). Inhibition of multidrug-resistant *Acinetobacter baumannii* by nonviral expression of hCAP-18 in a bioengineered human skin tissue. *Molecular Therapy* **17**, 562–569.
- THORENOOR, N., UMSTEAD, T. M., ZHANG, X., PHELPS, D. S. & FLOROS, J. (2018). Survival of surfactant protein-A1 and SP-A2 transgenic mice after *Klebsiella pneumoniae* infection, exhibits sex-, gene-, and variant specific differences; treatment with surfactant protein improves survival. *Frontiers in Immunology* **9**, 2424.
- TIPTON, K. A., CHIN, C. Y., FAROKHYFAR, M., WEISS, D. S. & RATHERA, P. N. (2018). Role of capsule in resistance to disinfectants, host antimicrobials, and desiccation in *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy* **62**, e01188-18.
- TOHIDNEZHAD, M., VAROGA, D., PODSCHUN, R., WRUCK, C. J., SEEKAMP, A., BRANDENBURG, L. O., PUFER, T. & LIPPROSS, S. (2011). Thrombocytes are effectors of the innate immune system releasing human beta defensin-3. *Injury* **42**, 682–686.
- TORRENS, G., BARCELÓ, I. M., PÉREZ-GALLEGO, M., ESCOBAR-SALOM, M., TURGRACIA, S., MUNAR-BESTARD, M., DEL MAR GONZÁLEZ-NICOLAU, M., CABRERA-VENEGAS, Y. J., RIGO-RUMBOS, E. N., CABOT, G., LÓPEZ-CAUSAPÉ, C., ROJO-MOLINERO, E., OLIVER, A. & JUAN, C. (2019a). Profiling the susceptibility of *Pseudomonas aeruginosa* strains from acute and chronic infections to cell-wall-targeting immune proteins. *Scientific Reports* **9**, 3575.
- TORRENS, G., ESCOBAR-SALOM, M., OLIVER, A. & JUAN, C. (2020). Activity of mammalian peptidoglycan-targeting immunity against *Pseudomonas aeruginosa*. *Journal of Medical Microbiology* **69**, 492–504.
- TORRENS, G., PÉREZ-GALLEGO, M., MOYA, B., MUNAR-BESTARD, M., ZAMORANO, L., CABOT, G., BLÁZQUEZ, J., AYALA, J. A., OLIVER, A. & JUAN, C. (2017). Targeting the permeability barrier and peptidoglycan recycling pathways to disarm *Pseudomonas aeruginosa* against the innate immune system. *PLoS One* **12**, 1–24.
- TORRENS, G., SÁNCHEZ-DIENER, I., JORDANA-LLUCH, E., BARCELÓ, I. M., ZAMORANO, L., JUAN, C. & OLIVER, A. (2019b). In vivo validation of peptidoglycan recycling as a target to disable AmpC-mediated resistance and reduce virulence enhancing the cell-wall-targeting immunity. *Journal of Infectious Diseases* **220**, 1729–1737.
- TORRES, A. M., BANSAL, P., KOH, J. M. S., PAGÈS, G., WU, M. J. & KUCHEL, P. W. (2014). Structure and antimicrobial activity of platypus “intermediate” defensin-like peptide. *FEBS Letters* **588**, 1821–1826.
- TRAVIS, S. M., ANDERSON, N. N., FORSYTH, W. R., ESPIRITU, C., CONWAY, B. D., GREENBERG, E. P., MCCRAY, P. B., LEHRER, R. I., WELSH, M. J. & TACK, B. F. (2000). Bactericidal activity of mammalian cathelicidin-derived peptides. *Infection and Immunity* **68**, 2748–2755.
- TROTTI, A., GARDEN, A., WARDE, P., SYMONDS, P., LANGER, C., REDMAN, R., PAJAK, T. F., FLEMING, T. R., HENKE, M., BOURHIS, J., ROSENTHAL, D. I., JUNOR, E., CMELAK, A., SHEEHAN, F., PULLIAM, J., et al. (2004). A multinational, randomized phase iii trial of iseganan hcl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. *International Journal of Radiation Oncology*Biophysics*Physics* **58**, 674–681.
- TSOU, Y. A., CHEN, C. M., LIN, T. C., HU, F. W., TAI, C. J., CHEN, H. C., YEH, T. H., HARN, H. J., TSAI, M. H. & JAN, C. I. (2013). Decreased SPLUNC1 expression is associated with *Pseudomonas* infection in surgically treated chronic rhinosinusitis patients who may require repeated sinus surgery. *Laryngoscope* **123**, 845–851.
- TÜMMLER, B. (2019). Emerging therapies against infections with *Pseudomonas aeruginosa*. *F1000Research* **8**, F1000 Faculty Rev-1371.
- ULLOA, E. R., DILLON, N., TSUNEMOTO, H., POGLIANO, J., SAKOULAS, G. & NIZET, V. (2019). Avibactam sensitizes carbapenem-resistant NDM-1-producing *Klebsiella pneumoniae* to innate immune clearance. *Journal of Infectious Diseases* **220**, 484–493.
- UPERT, G., LUTHER, A., OBRECHT, D. & ERMERT, P. (2021). Emerging peptide antibiotics with therapeutic potential. *Medicine in Drug Discovery* **9**, 100078.
- VAN DER DOES, A. M., HENSBERGEN, P. J., BOGAARDS, S. J., CANSOY, M., DEELDER, A. M., VAN LEEUWEN, H. C., DRIJFHOUT, J. W., VAN DISSEL, J. T. & NIBBERING, P. H. (2012). The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. *Journal of Immunology* **188**, 5012–5019.
- VAN DER KRAAN, M. I. A., GROENINK, J., NAZMI, K., VEERMAN, E. C. I., BOLSCHEER, J. G. M. & NIEUW AMERONGEN, A. V. (2004). Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. *Peptides* **25**, 177–183.
- VAN DER PLAS, M. J. A., BHONGIR, R. K. V., KJELLSTRÖM, S., SILLER, H., KASETTY, G., MÖRGELIN, M. & SCHMIDTCHEN, A. (2016). *Pseudomonas aeruginosa* elastase cleaves a C-terminal peptide from human thrombin that inhibits host inflammatory responses. *Nature Communications* **7**, 11567.
- VAN DER VELDEN, W. J. F. M., VAN IERSEL, T. M. P., BLIJLEVENS, N. M. A. & DONNELLY, J. P. (2009). Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). *BMC Medicine* **7**, 44.
- VARNEY, K. M., BONVIN, A. M. J. J., PAZGIER, M., MALIN, J., YU, W., ATEH, E., OASHI, T., LU, W., HUANG, J., DIEPEVEEN-DE BUIN, M., BRYANT, J., BREUKINK, E., MACKERELL, A. D. & DE LEEUW, E. P. H. (2013). Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II. *PLoS Pathogens* **9**, e1003732.
- VEGA CHAPARRO, S. C., VALENCIA SALGUERO, J. T., MARTÍNEZ BAQUERO, D. A. & ROSAS PÉREZ, J. E. (2018). Effect of polyvalence on the antibacterial activity of a synthetic peptide derived from bovine lactoferrin against healthcare-associated infectious pathogens. *BioMed Research International* **2018**, 5252891.
- VEGA-BAUTISTA, A., DE LA GARZA, M., CARRERO, J. C., CAMPOS-RODRÍGUEZ, R., GODÍNEZ-VICTORIA, M. & DRAGO-SERRANO, M. E. (2019). The impact of lactoferrin on the growth of intestinal inhabitant bacteria. *International Journal of Molecular Sciences* **20**, 4707.
- VELEBA, M., HIGGINS, P. G., GONZALEZ, G., SEIFERT, H. & SCHNEIDERS, T. (2012). Characterization of RarA, a novel AraC family multidrug resistance regulator in *Klebsiella pneumoniae*. *Antimicrobial Agents and Chemotherapy* **56**, 4450–4458.
- VIEIRA, F., KUNG, J. W. & BHATTI, F. (2017). Structure, genetics and function of the pulmonary associated surfactant proteins A and D: the extra-pulmonary role of these C type lectins. *Annals of Anatomy* **211**, 184201.
- VITALE, A., PESSI, G., URFER, M., LOCHER, H. H., ZERBE, K., OBRECHT, D., ROBINSON, J. A. & EBERL, L. (2020). Identification of genes required for resistance to peptidomimetic antibiotics by transposon sequencing. *Frontiers in Microbiology* **11**, 1681.
- WACH, A., DEMBOWSKY, K. & DALE, G. E. (2018). Pharmacokinetics and safety of intravenous murepavadin infusion in healthy adult subjects administered single and multiple ascending doses. *Antimicrobial Agents and Chemotherapy* **62**, e02355-17.
- WAKABAYASHI, H., TAKASE, M. & TOMITA, M. (2005). Lactoferrin derived from milk protein lactoferrin. *Current Pharmaceutical Design* **9**, 1277–1287.
- WALTON, W. G., AHMAD, S., LITTLE, M. S., KIM, C. S. K., TYRRELL, J., LIN, Q., DI, Y. P., TARRAN, R. & REDINBO, M. R. (2016). Structural features essential to the antimicrobial functions of human SPLUNC1. *Biochemistry* **55**, 2979–2991.
- WANG, A., ZENG, H., LIU, D., SU, Y., CHENG, T., CHEN, F., WANG, J., WANG, C., ZHAO, G., WANG, S., CHEN, Y., GONG, Y., CHEN, S., XU, Y., HU, M., et al. (2018). A simplified derivative of human defensin 5 with potent and efficient activity against multidrug-resistant *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy* **62**, e01504–e01517.
- WANG, G., EPAND, R. F., MISHRA, B., LUSHNIKOVA, T., THOMAS, V. C., BAYLES, K. W. & EPAND, R. M. (2012). Decoding the functional roles of cationic side chains of the major antimicrobial region of human cathelicidin LL-37. *Antimicrobial Agents and Chemotherapy* **56**, 845–856.
- WANG, G., HANKE, M. L., MISHRA, B., LUSHNIKOVA, T., HEIM, C. E., THOMAS, V. C., BAYLES, K. W. & KIELIAN, T. (2014). Transformation of human cathelicidin LL-37 into selective, stable, and potent antimicrobial compounds. *ACS Chemical Biology* **9**, 1997–2002.

- WANG, G., NARAYANA, J. L., MISHRA, B., ZHANG, Y., WANG, F., WANG, C., ZARENA, D., LUSHNIKOVA, T. & WANG, X. (2019). Design of antimicrobial peptides: progress made with human cathelicidin LL-37. *Advances in Experimental Medicine and Biology* **1117**, 215–240.
- WANG, H., DONG, B. & LOU, L. (2011a). HNP-3 enhanced the antimicrobial activity of CIP by promoting ATP efflux from *P. aeruginosa* cells. *Molecular Biology Reports* **38**, 2673–2678.
- WANG, J., WONG, E. S. W., WHITLEY, J. C., LI, J., STRINGER, J. M., SHORT, K. R., RENFREE, M. B., BELOV, K. & COCKS, B. G. (2011b). Ancient antimicrobial peptides kill antibiotic-resistant pathogens: Australian mammals provide new options. *PLoS One* **6**, e24030.
- WANG, P., WANG, X., YANG, X., LIU, Z., WU, M. & LI, G. (2013). Budesonide suppresses pulmonary antibacterial host defense by down-regulating cathelicidin-related antimicrobial peptide in allergic inflammation mice and in lung epithelial cells. *BMC Immunology* **14**, 7.
- WANG, Y., LI, S., JIN, M., HAN, Q., LIU, S., CHEN, X. & HAN, Y. (2020). Enhancing the thermo-stability and anti-bacterium activity of lysozyme by immobilization on chitosan nanoparticles. *International Journal of Molecular Sciences* **21**, 1635.
- WANG, Y., WALTER, G., HERTING, E., AGERBERTH, B. & JOHANSSON, J. (2004). Antibacterial activities of the cathelicidins prophenin (residues 62 to 79) and LL-37 in the presence of a lung surfactant preparation. *Antimicrobial Agents and Chemotherapy* **48**, 2097–2100.
- WEI, Y., HAN, M., WEN, W. & LI, H. (2016). Differential short palate, lung, and nasal epithelial clone 1 suppression in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps: implications for pathogenesis and treatment. *Current Opinion in Allergy and Clinical Immunology* **16**, 31–38.
- WEITZ, A., SPOTNITZ, R., COLLINS, J., OVADIA, S. & IOVINE, N. M. (2013). Log reduction of multidrug-resistant gram-negative bacteria by the neutrophil-derived recombinant bactericidal/permeability-increasing protein. *International Journal of Antimicrobial Agents* **42**, 571–574.
- WELLING, M. M., HIEMSTRA, P. S., VAN DEN BARSELAAR, M. T., PAULUSMA-ANNEMA, A., NIBBERING, P. H., PAUWELS, E. K. J. & CALAME, W. (1998). Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. *Journal of Clinical Investigation* **102**, 1583–1590.
- WITTMANN, I., SCHÖNEFELD, M., AICHELE, D., GROER, G., GESSNER, A. & SCHNARE, M. (2008). Murine bactericidal/permeability-increasing protein inhibits the endotoxic activity of lipopolysaccharide and gram-negative bacteria. *Journal of Immunology* **180**, 7546–7552.
- WOLF, A. J. & UNDERHILL, D. M. (2018). Peptidoglycan recognition by the innate immune system. *Nature Reviews Immunology* **18**, 243–254.
- WOMMACK, A. J., ZIAREK, J. J., TOMARAS, J., CHILEVERU, H. R., ZHANG, Y., WAGNER, G. & NOLAN, E. M. (2014). Discovery and characterization of a disulfide-locked C2-symmetric defensin peptide. *Journal of the American Chemical Society* **136**, 13494–13497.
- WU, H., LIU, L., LIN, M., LIU, L., HE, C., ZHENG, D. & HUANG, W. (2016). Importance of the residue 190 on bactericidal activity of the bactericidal/permeability-increasing protein 5. *Oncotarget* **7**, 43088–43094.
- WU, M. & HANCOCK, R. E. W. (1999). Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. *Journal of Biological Chemistry* **274**, 29–35.
- WU, M., MCCLELLAN, S. A., BARRETT, R. P., ZHANG, Y. & HAZLETT, L. D. (2009). β -defensins 2 and 3 together promote resistance to *Pseudomonas aeruginosa* keratitis. *Journal of Immunology* **183**, 8054–8060.
- WU, T., WU, C., FU, S., WANG, L., YUAN, C., CHEN, S. & HU, Y. (2017a). Integration of lysozyme into chitosan nanoparticles for improving antibacterial activity. *Carbohydrate Polymers* **155**, 192–200.
- WU, X., LI, Z., LI, X., TIAN, Y., FAN, Y., YU, C., ZHOU, B., LIU, Y., XIANG, R. & YANG, L. (2017b). Synergistic effects of antimicrobial peptide DP7 combined with antibiotics against multidrug-resistant bacteria. *Drug Design, Development and Therapy* **11**, 939–946.
- WU, Y., RAYMOND, B., GOOSSENS, P. L., NJAMKEPO, E., GUISSO, N., PAYA, M. & TOUQUET, L. (2010). Type-IIA secreted phospholipase A2 is an endogenous antibiotic-like protein of the host. *Biochimie* **92**, 583–587.
- WYRES, K. L., WICK, R. R., GORRIE, C., JENNEY, A., FOLLADOR, R., THOMSON, N. R. & HOLT, K. E. (2016). Identification of *Klebsiella* capsule synthesis loci from whole genome data. *Microbial Genomics* **2**, e000102.
- XIE, F., ZAN, Y., ZHANG, X., ZHANG, H., JIN, M., ZHANG, W., ZHANG, Y. & LIU, S. (2020). Differential abilities of mammalian cathelicidins to inhibit bacterial biofilm formation and promote multifaceted immune functions of neutrophils. *International Journal of Molecular Sciences* **21**, 1871.
- XU, G., XIANG, W., HU, Q., ZUO, P., SHAO, B., LAN, F., LU, X., XU, Y. & XIANG, S. (2010). Lactoferrin-derived peptides and Lactoferricin chimera inhibit virulence factor production and biofilm formation in *Pseudomonas aeruginosa*. *Journal of Applied Microbiology* **109**, 1311–1318.
- XU, M., WANG, Z. & LOCKSLEY, R. M. (2004). Innate immune responses in peptidoglycan recognition protein L-deficient mice. *Molecular and Cellular Biology* **24**, 7949–7957.
- ZANFARDINO, A., BOSSO, A., GALLO, G., PISTORIO, V., DI NAPOLI, M., GAGLIONE, R., DELL'OLMO, E., VARCAMONTI, M., NOTOMISTA, E., ARCIELLO, A. & PIZZO, E. (2018). Human apolipoprotein E as a reservoir of cryptic bioactive peptides: the case of ApoE 133-167. *Journal of Peptide Science* **24**, 1–10.
- ZELECHOWSKA, P., AGIER, J. & BRZEZIŃSKA-BIAŁSZCZYK, E. (2016). Endogenous antimicrobial factors in the treatment of infectious diseases. *Central European Journal of Immunology* **41**, 419–425.
- ZERBE, K., MOEHLE, K. & ROBINSON, J. A. (2017). Protein epitope mimetics: from new antibiotics to spramolecular synthetic vaccines. *Accounts of Chemical Research* **50**, 1323–1331.
- ZHANG, R., WU, F., WU, L., TIAN, Y., ZHOU, B., ZHANG, X., HUANG, R., YU, C., HE, G. & YANG, L. (2018). Novel self-assembled micelles based on cholesterol-modified antimicrobial peptide (DP7) for safe and effective systemic administration in animal models of bacterial infection. *Antimicrobial Agents and Chemotherapy* **62**, e00368–e00318.
- ZHANG, S., CHEN, Y., POTVIN, E., SANSCHAGRIN, F., LEVESQUE, R. C., MCCORMACK, F. X. & LAU, G. W. (2005). Comparative signature-tagged mutagenesis identifies *Pseudomonas* factors conferring resistance to the pulmonary collectin SP-A. *PLoS Pathogens* **1**, e31.
- ZHARKOVA, M. S., ORLOV, D. S., GOLUBEVA, O. Y., CHAKCHIR, O. B., ELISEEV, I. E., GRINGHUK, T. M. & SHAMOVA, O. V. (2019). Application of antimicrobial peptides of the innate immune system in combination with conventional antibiotics—a novel way to combat antibiotic resistance? *Frontiers in Cellular and Infection Microbiology* **9**, 128.
- ZHENG, J., HUANG, Y., ISLAM, D., WEN, X. Y., WU, S., STREUTKER, C., LUO, A., LI, M., KHANG, J., HAN, B., ZHONG, N., LI, Y., YU, K. & ZHANG, H. (2018). Dual effects of human neutrophil peptides in a mouse model of pneumonia and ventilator-induced lung injury. *Respiratory Research* **19**, 1–11.
- ZHOU, L., LIU, S. P., CHEN, L. Y., LI, J., ONG, L. B., GUO, L., WOHLAND, T., TANG, C. C., LAKSHMINARAYANAN, R., MAVINAHALLI, J., VERMA, C. & BEUERMAN, R. W. (2011). The structural parameters for antimicrobial activity, human epithelial cell cytotoxicity and killing mechanism of synthetic monomer and dimer analogues derived from hBD3 C-terminal region. *Amino Acids* **40**, 123–133.
- ZHOU, Y., SHI, Y., YANG, L., SUN, Y., HAN, Y., ZHAO, Z., WANG, Y., LIU, Y., MA, Y., ZHANG, T., REN, T., DALE, T. P., FORSYTH, N. R., JIN, F., QU, J., et al. (2020). Genetically engineered distal airway stem cell transplantation protects mice from pulmonary infection. *EMBO Molecular Medicine* **12**, e10233.
- ZIELKE, R. A., LE VAN, A., BAARDA, B. I., HERRERA, M. F., ACOSTA, C. J., JERSE, A. E. & SIKORA, A. E. (2018). Slic is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during *Neisseria gonorrhoeae* infection. *PLoS Pathogens* **14**, e1007081.
- ZWEYTICK, D., PABST, G., ABUJA, P. M., JILEK, A., BLONDELLE, S. E., ANDRÁ, J., JERALA, R., MONREAL, D., MARTINEZ DE TEJADA, G. & LOHNER, K. (2006). Influence of N-acylation of a peptide derived from human lactoferricin on membrane selectivity. *Biochimica et Biophysica Acta - Biomembranes* **1758**, 1426–1435.

(Received 18 May 2021; revised 12 December 2021; accepted 15 December 2021; published online 18 January 2022)